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Age-related macular degeneration (AMD) is the most common cause of visual loss amongst 
the elderly in developed countries. AMD is a complex disease with a highly variable 
phenotype, which makes generating reliable disease models difficult. In addition, lack of 
knowledge of the underlying pathological mechanisms makes development of an effective 
treatment difficult. To address the lack of knowledge of the molecular mechanisms affected 
in AMD a robust cell-based model system is needed. Late-onset retinal degeneration (L-ORD) 
is a rare autosomal dominant disorder caused by a p.S163R, p.P188T, or p.G216C missense 
mutation in the C1q and tumor necrosis factor-related protein 5 (C1QTNF5) gene. L-ORD has 
a very similar phenotype to AMD, including sub-RPE deposit formation, the hallmark of AMD. 
Studying L-ORD could therefore potentially reveal common molecular pathways affected in 
macular degenerations. Here, I used CRISPR/Cas9 gene editing to correct the p.S163R 
mutation in C1QTNF5 in patient-derived induced pluripotent stem cells (iPSCs) and generated 
C1QTNF5 null iPSCs. The iPSC lines were differentiated into retinal pigment epithelium (RPE), 
the cell type that highly expresses C1QTNF5 and is severely affected in macular 
degenerations. RNA sequencing of L-ORD and control iPSC-RPE revealed that the 
extracellular matrix, complement system, lipid and general cell metabolism, and oxidative 
stress pathways are affected in L-ORD. C1QTNF5S163R in L-ORD iPSC-RPE was found to form 
less high molecular weight multimeric structures compared to its isogenic gene-corrected 
control. In addition, L-ORD iPSC-RPE were also found to phagocytose and possibly adhere 
differently compared to their isogenic controls. Both oxidative stress and the complement 
system play an important role in the pathology of macular degenerations. RPE were found to 
undergo regulated necrosis in response to oxidative stress and L-ORD iPSC-RPE were found 
to be more sensitive to UV light-induced oxidative stress. In addition, the terminal 
complement system complex C5b-9 was found to bind more frequently to L-ORD iPSC-RPE 
and colocalises with APOE in sub-RPE drusen-like deposits after human serum exposure. 
Together, the results in this thesis reveal that L-ORD iPSC-RPE have a molecular phenotype 
that could explain part of the clinical presentation of this disease and possibly of AMD. 
Further study of the affected molecular mechanisms could potentially lead to therapies for 






Age-related macular degeneration (AMD) is the most common cause of visual loss amongst 
the elderly in developed countries. AMD is a complex disease with a highly variable clinical 
presentation which inevitably leads to difficulty when studying this disease. AMD always 
leads to the degeneration of the macula, the most light-sensitive part of the retina and is 
responsible for sharp central vision. Lack of knowledge of this disease is one of the main 
reasons why there is currently no effective treatment. Related diseases with similar 
characteristics to AMD, are caused by one mutation. Unlike AMD, these are much easier to 
study and could potentially provide more information about shared macular degeneration-
causing mechanisms. One of these diseases is late-onset retinal degeneration (L-ORD), which 
is a rare disorder caused by a mutation in the gene C1QTNF5. L-ORD has a noticeably similar 
clinical presentation to AMD, and therefore the mutation in C1QTNF5 is likely to affect the 
same molecular mechanisms involved in causing AMD. Here, I used gene editing to correct 
the C1QTNF5 mutation in patient-derived stem cells. These stem cells were then converted 
into retinal pigment epithelial (RPE) cells, the type of eye cells most affected in macular 
degenerations. Comparison of gene-corrected RPE and uncorrected RPE from patients 
revealed some key differences. The protein encoded by the C1QTNF5 gene was found to have 
a different shape caused by the mutation, which likely affects its function. Moreover, RPE 
from patients had greater sensitivity to light-induced stress and increased accumulation of 
immune system proteins compared to the gene-corrected cells. Together, the results in this 
thesis reveal some of the molecular mechanisms affected in L-ORD that could explain part of 
the clinical presentation of this disease and possibly also of AMD. Further study of the 
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Chapter 1 Introduction 
 
1.1 The retina 
The retina is the light-sensitive tissue in the back of the eye, and it consists of retinal neurons, 
retinal glial cells, and the retinal pigment epithelium (RPE). Six types of retinal neurons form 
the neural retina: rod and cone photoreceptors, horizontal cells, bipolar cells, amacrine cells, 
and retinal ganglion cells (RGCs). The retinal macroglia are the Müller glia and retinal 
astrocytes and the retina also contains retinal microglia. Together, these cell types capture, 
process, and transfer light signals to the brain. 
The retina has multiple different regions. Light is focused by the lens on the centre of the 
retina, termed the macula lutea. In the centre of the macula is the fovea, a small pit structure 
of about 1.5 mm in diameter that contains the highest density of cone photoreceptor cells 
and is therefore responsible for central, high-resolution, colour vision. The region of the 
retina towards the nose is called the optic disc, or the blind spot, and contains no 
photoreceptor cells. Here, the RGCs form the optic nerve that extents from the eye to the 
brain. 
The retina has a multi-layered structure and light can pass though most of the layers1,2. The 
retina has ten distinct layers (Fig. 1.1). Anterior, adjacent to the vitreous body, is the inner 
limiting membrane (ILM) which serves as a basement membrane. Adjacent to the ILM is the 
nerve fibre layer (NFL), which contains the axonal fibres of the RGCs that run bundled 
together radially towards the optic disc, where they leave the eye into the optic nerve. 
Adjacent to the NFL is the ganglion cell layer (GCL) where the cell bodies of the RGCs are 
located. The dendritic processes of the RGCs extend into the adjacent inner plexiform layer 
(IPL), where they synapse with the processes of the bipolar and amacrine cells. The next layer, 
the inner nuclear layer (INL), is the location of the cell bodies of the bipolar, horizontal, and 
amacrine cells. Adjacent is the outer plexiform layer (OPL) where again mostly synaptic 
connections take place, but this time between photoreceptor cells and bipolar and horizontal 
cells. The cell bodies of the photoreceptor cells are located in the adjacent outer nuclear layer 
(ONL). The external limiting membrane (ELM) separates the photoreceptor cell bodies from 
the disposable light-sensitive photoreceptor outer segments (POS), which have their own 
2 
 
layer. Here, the used POS are shed from the photoreceptors. RPE, in the final layer, 
phagocytose the POS. 
 
 
Figure 1.1 | The layers and cell types of the retina. The layers of the retina, and the position of the 
retinal cells within these layers, under normal physiological conditions. ILM = inner limiting membrane; 
NFL = nerve fibre layer; GCL = ganglion cell layer; IPL = inner plexiform layer; INL = inner nuclear layer; 
OPL = outer plexiform layer; ONL = outer nuclear layer; ELM = external limiting membrane; POS = 
photoreceptor outer segments; RPE = retinal pigment epithelium; asterisk (*) = blood vessel. 
Reproduced from Rathnasamy et al. (2019)3. 
 
Retinal neurons have a variety of functions4. They are relatively very small but numerous. The 
rod photoreceptor is the second most numerous neuronal type in the human body after 
cerebellar granule cells4. Rod photoreceptors are specialised for dim light vision and 
outnumber cone photoreceptors about 20-fold4. Rod photoreceptors contain the light-
sensitive pigment rhodopsin in the POS, whereas each cone photoreceptors contains a 
different cone opsin. Each cone opsin absorbs a different spectrum of light, forming the basis 
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for colour vision. Photoreceptors can absorb photons from light with their light-sensitive 
pigment situated in the POS and converts this into a biochemical signal. Photo-oxidative 
damage causes inactivation of POS and are therefore shed from the photoreceptors. Because 
of continuous photo-oxidative damage, POS are constantly shed and new POS are constantly 
regrown, a process that is light-dependent5. Shed POS are phagocytosed by RPE.  
Before POS are shed, the light-induced biochemical signal in the POS is transduced back 
through the layers of the retina, via horizontal, bipolar and amacrine cells, to the RGCs. 
Horizontal cells provide direct inhibitory feedback to the photoreceptors, by adjusting the 
output, and therefore can adjust the brightness locally in the image4. Rod photoreceptors are 
connected to rod bipolar cells, whereas cone photoreceptors are connected to 11 different 
types of cone bipolar cells6. Each different bipolar cell extracts different information from the 
photoreceptor output to transmit to the inner retina4. There are around 30 types of amacrine 
cells that modulate the output of bipolar cells4. Amacrine cells receive input from bipolar cells 
and feed this signal back to the bipolar cells, forward to the RGCs, and lateral to other 
amacrine cells. Amacrine cells help RGCs to detect motion, vertically integrate signals to allow 
for signal crossover, and regulate the output of other retinal neurons4. There are around 20 
types of RGCs, each transducing different signals obtained from the input of different bipolar 
and amacrine cells4. RGCs extent through the optic nerve to the various visual centres in the 
brain. About 20-30% of the human cerebral cortex is devoted to vision7. Here, the processing 
of light signals continues. 
The retinal glial cells have a supportive function in the retina. Retinal astrocytes and Müller 
glia are the macroglia of the retina8. Macroglia provide metabolic and functional support, 
protect from oxidative stress, and maintain a homeostatic environment for retinal neurons. 
In addition, macroglia are also involved in regulating local blood flow. Müller glia are long 
radially oriented cells that span the entire width of the retina (Fig. 1.1). Müller glia are 
typically the first glial cells to detect and respond to retinal injury because of their radially 
distribution in the retina9. Retinal astrocytes are mainly located in the NFL of the retina (Fig. 
1.1)10. Retinal microglia are the immune cells of the retina3,11,12. Under normal physiological 
conditions microglia are in a resting state and can be found in the inner layers of the retina, 
but not beyond the OPL (Fig. 1.1). In this state, microglia survey their microenvironment and 
release neuroprotective and anti-inflammatory factors13. Microglia become activated in the 
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event of an injury or in disease, resulting in a change of morphology and migration to the site 
of injury14,15. 
The retina has a dual vascular supply. The retinal vasculature supplies the inner layers of the 
retina, whilst the choroid supplies the outer layers of the retina. The retina, and specifically 
the macula, is considered the most metabolic active tissue in the body16. The choroid has 
fenestrated capillaries, allowing for leakage of proteins and other molecules from circulation 
into the Bruch’s membrane. The Bruch’s membrane is a layer of extracellular matrix (ECM) 
and separates the RPE from the endothelium of the choroid. Large macromolecules cannot 
pass through the Bruch’s membrane. The RPE forms a barrier with its tight junctions between 
the fluid of the choroid and the rest of the retina. 
 
1.2 Retinal pigment epithelium 
The most posterior layer of the retina is the RPE. The RPE is a pigmented monolayer that has 
several important roles to fulfil to ensure correct functioning of the retina17. The apical and 
basal sides of the RPE faces the photoreceptors and Bruch’s membrane of the choroid 
respectively. RPE have tight junctions that form a narrow barrier between the subretinal 
space and the choriocapillaris17,18. This forms the blood-retina barrier and is of importance 
for the immune privilege of the eye and for the highly selective transport between the 
choroid and the retina. 
One important function of RPE is to absorb light focused on the retina by the lens17. The 
retina has a high blood perfusion, creating an oxygen-rich environment. Light focussed on 
the macula lutea thus enables photo-oxidation, leading to the production of radical oxygen 
species (ROS) and subsequent oxidative damage. RPE therefore have melanosomes, a 
lysosome-related organelle, which produce and store melanin pigments19. Scattered light is 
filtered and absorbed by the melanin in melanosomes of the RPE to improve the image 
quality and to limit oxidative damage. 
RPE also participate in the visual cycle together with the photoreceptors17,20. Photoreceptors 
catch light in the visual pigments situated in the POS with the molecule 11-cis retinal bound 
to the protein opsin, forming photopsin. 11-cis retinal forms all-trans retinal after photon 
absorption. Photoreceptors are unable to re-isomerise all-trans retinal back to 11-cis retinal. 
All-trans retinal is transported to the cytoplasm by ATP Binding Cassette Subfamily A Member 
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4 (ABCA4) and reduced by all-trans retinol dehydrogenase (RDH12) to all-trans retinol, also 
known as vitamin A. All-trans retinol is transported through the subretinal space via 
interstitial retinal binding protein (IRBP) to the RPE for re-isomerisation to 11-cis retinal. In 
RPE, lecithin retinol acyltransferase (LRAT) esterifies all-trans retinol to phosphatidylcholine 
to form all-trans retinyl esters. Retinoid isomerase and retinoid isomerohydrolase RPE-
specific 65 KDa protein (RPE65) isomerise all-trans retinyl esters to 11-cis retinol. Finally, 11-
cis retinol is converted to 11-cis retinal by 11-cis retinol dehydrogenase (RDH5), a process 
accelerated by cellular retinaldehyde-binding protein (CRALBP). 11-cis retinal is then released 
from CRALBP and transported back to the photoreceptors via IRBP. 
RPE are also important for photoreceptor maintenance17. RPE secrete growth factors that 
promote photoreceptor survival21 and phagocytose POS to maintain photoreceptor 
excitability22,23. RPE have microvilli on their apical surface that physically associate with POS 
and use these microvilli to phagocytose POS as they are shed. Two RPE receptors are mainly 
involved in the phagocytosis of POS: αVβ5 integrin and MER proto-oncogene tyrosine kinase 
(MERTK)23-25. αVβ5 integrin is necessary for the binding of RPE microvilli to the POS. Bound 
αVβ5 integrin activates two intracellular signalling cascades that causes phosphorylation and 
activation of Rac1 GTPase and MERTK23. Rac1 GTPase is required for the recruitment of F-
actin for the formation of phagocytic cups and MERTK is in part required for the contraction 
of the phagocytic cup during phagocytosis26. Mutations in MERTK were found to be the cause 
of recessive retinitis pigmentosa27,28, a form of hereditary retinal degeneration. Mutated 
orthologue Mertk was also found to be the cause of retinal degeneration in Royal College of 
Surgeons (RCS) rats27, an important model system for hereditary retinal degeneration. 
Activation of MERTK also results into an intracellular signalling cascade leading to increased 
levels of free Ca2+ which is necessary for regulating phagocytic activity17. In addition to the 
αVβ5/MERTK pathway, CD36 can bind to oxidised phospholipids on POS and facilitate 
increased phagocytic capacity of RPE, possibly to prevent oxidative damage24,29. After 
phagocytosis by RPE, POS components are either marked for degradation or recycled for 
transport back to the photoreceptors. 
RPE also secretes a variety of growth factors, vital for the adjacent endothelium and 
photoreceptors17,21,30, as well as complement components for a local immune response31. 
Some important factors that RPE secrete to adjacent cells include ATP, fas-ligand (fas-L), 
fibroblast growth factors, transforming growth factor-β (TGF-β), insulin-like growth factor-1 
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(IGF-1), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), 
lens epithelium-derived growth factor (LEDGF), ciliary neurotrophic factor (CNTF), members 
of the interleukin family, pigment epithelium-derived factor (PEDF), tissue inhibitor of matrix 
metalloprotease 3 (TIMP3), complement factor H (CFH), and C-C motif chemokine ligand 2 
(CCL2)17,30,32. 
Some critical functions of the RPE are regulated by intracellular free Ca2+ concentration 
changes33,34. Bestrophin-1 (BEST1) is an important regulator of intracellular Ca2+ homeostasis 
in RPE and functions as both a Ca2+-activated anion channel and a regulator of intracellular 
Ca2+ signalling35,36. BEST1 is predominantly expressed in the RPE and is an integral membrane 
protein localised to the basolateral plasma membrane37. It functions as a Ca2+-activated anion 
channel in the ER, where it regulates the levels of the Ca2+ stores38. In addition, BEST1 can 
also function as a regulator for Ca2+ channel activity39. Ion channels like BEST1 were found to 
regulate RPE phagocytosis of POS40. Ca2+ is also important for regulation of VEGF secretion 
by RPE41. There are over 200 mutations found in the gene BEST1, causing at least five clinically 
distinct forms of retinal degeneration, of which Best vitelliform macular dystrophy is the most 
common42,43. 
The RPE maintains ion homeostasis in the subretinal space17. Photo-activation of the 
photoreceptors and the activity of retinal neurons causes changes in the subretinal space44. 
The RPE provides a fast compensation for these changes. In particular, K+ concentrations in 
the subretinal space can change rapidly because of photoreceptor activity. In the dark, there 
is an influx of K+ into the POS from the subretinal space, which is compensated by an efflux 
of K+ from the photoreceptor inner segments (PIS) into the subretinal space. When light 
strikes the photoreceptors, the ion channels on the POS closes and the efflux of K+ from the 
PIS decreases. This leads to decrease of K+ concentrations in the subretinal space and 
subsequent depolarisation of the RPE apical membrane. Depolarisation of the RPE apical 
membrane induces transport of K+ from the RPE to the subretinal space. This compensation 
of K+ concentration is required to maintain photoreceptor and retinal neuron excitability. 
The RPE plays an important role in the pathology of many retinal degenerations when 
compromised. The most common form of retinal degeneration is age-related macular 




1.3 Age-related macular degeneration 
AMD is the most common cause of visual loss in the elderly in developed countries45-47. It is 
estimated that 8.7% of all blindness worldwide is caused by AMD and this is expected to 
increase to 196 million people affected in 2020, and 288 million in 204048. AMD is a major 
public health problem costing annually at least $30 billion in the United States alone49 and 
has a significant impact on the quality of life, making a person with AMD less active50 with a 
higher risk of depression51 and anxiety52. 
AMD is a complex multifactorial chronic disease that typically occurs after the sixth decade 
of life53 and has a highly variable phenotype which makes generating reliable disease models 
difficult. In addition, lack of knowledge of the underlying pathological mechanisms makes 
development of a treatment difficult54. Risk factors for AMD include age, ethnicity, smoking, 
light exposure, hypertension, high body mass index, cataract surgery, and genetic 
predisposition55. AMD has a strong genetic component, as a number of susceptibility variants 
of loci are implicated to contribute to AMD56,57. This wide range of risk factors lead to a 
diverse disease phenotype. 
About 52 single nucleotide polymorphisms (SNPs) have been found at 34 loci that have been 
associated with late stage AMD in a large genome-wide association study57. The most 
important susceptibility loci for AMD are in a cluster on chromosome 1 which includes CFH 
and CFHRs and on chromosome 10 near age-related maculopathy susceptibility 2 (ARMS2) 
and high-temperature requirement A serine peptidase 1 (HTRA1)58. Loci conferring moderate 
risk to AMD are on chromosome 6 near C2 and CFB and on chromosome 19 near C358. It is 
still unclear what the underlying molecular mechanisms are that are affected by ARMS2 and 
HTRA1 in AMD. Nonetheless, ARMS2 has been associated with an increase in systemic 
complement system activation in AMD59. HTRA1 encodes for a serine protease that is thought 
to play a role in the processing of amyloid β precursor protein (APP)60, the precursor for 
amyloid β (Aβ), a component of sub-RPE deposits found in AMD61,62. CFH, CFHRs, CFB, C2, 
and C3 are components of the complement system, which is thought to play a major role in 
the pathology of AMD (see Chapter 5). 
AMD can be characterised by sub-RPE deposit formation63, accumulation of lipofuscin in RPE 
(see Chapter 4), RPE senescence64, detachment of RPE from the Bruch’s membrane and 
subsequent cell death65, chronic oxidative injury (see Chapter 4), chronic complement system 
activation (see Chapter 5), and chronic inflammation in the retina. Transcriptome analysis of 
8 
 
patients with AMD revealed the involvement of inflammatory genes in the onset and 
progression of AMD66. 
AMD can be classified as early, intermediate, and late stage disease, based on clinical 
presentation67. One of the earliest manifestations of AMD is deposit formation between the 
RPE and the Bruch’s membrane, termed drusen68. Medium (63–125 μm) to large (≥125 μm) 
soft drusen can be found in early and intermediate stage AMD and these stages have little to 
no vision loss. Soft drusen are pale yellow deposits visible upon fundoscopic examination and 
are located between the basal lamina of the RPE and the Bruch’s membrane. The amount 
and size of soft drusen are associated with an increased risk of AMD69. In early AMD, also 
pigmentary changes can be observed in the macula, such as hyperpigmentation or 
hypopigmentation67. Intermediate AMD is defined by the extensive presence of medium-
sized drusen67. 
There are two variants of late stage AMD: exudative “wet” or neovascular AMD (nvAMD) and 
“dry” or geographic atrophy AMD (gaAMD). nvAMD is responsible for around 85% of the legal 
blindness caused by AMD70. In nvAMD, choroidal neovascularisation (CNV) leads to 
neovascular tuft growth through the Bruch’s membrane into the sub-RPE space or between 
the RPE and the neural retina. Vessels produced in nvAMD haemorrhage or leak fluid more 
often, leading to rapid loss of vision. In contrast, vision loss in gaAMD is more gradual. In 
gaAMD, geographic atrophy causes loss of the choroid, RPE, and neural retina. Areas with 
confluent drusen are typically where geographic atrophy develops. 
nvAMD can be treated with VEGF inhibitors which slows down loss in visual acuity71. 
Continued loss of visual acuity with anti-VEGF therapy is attributed to retinal thinning, an 
increase in geographic atrophy, and an increase in lesion size. Anti-VEGF therapy requires 
multiple injections per year for at least five years. About one fifth of the patients treated with 
anti-VEGF therapy develop gaAMD within two years of treatment72. There is still no 
treatment for gaAMD. Anti-VEGF therapy is therefore not a good treatment for AMD. 
Drusen are considered to be a hallmark of AMD63. Whilst it is believed that drusen are 
associated with pathological processes, it is still not understood how these deposits develop 
and what role they have in the pathology. The content of drusen has been analysed with 
immunohistochemistry and proteomics73. Drusen have been found to contain cholesterol74, 
and over 129 different proteins73 including, TIMP375, vitronectin76, inflammatory proteins of 
the complement system (see Chapter 5), the Alzheimer’s Aβ, apolipoprotein E (APOE)77, 
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clusterin, and immunoglobulins. The proportion of inflammatory proteins found in drusen 
suggest a role for local inflammation in the biogenesis of drusen63. 
Cellular senescence is thought to play a causative role in age-related diseases and aging in 
general78. Similarly, RPE senescence has been suggested to play a role in the aetiology of 
AMD64. Senescence of RPE can be induced by oxidative stress79. However, the precise 
mechanisms on how RPE senescence contributes to AMD pathology on a molecular level 
have not been uncovered yet. 
To address the lack of knowledge of the molecular mechanisms affected in AMD a robust 
model system is needed. There are a number of very rare diseases that resemble AMD but 
are caused by a single mutation. It is thought that studying these diseases would lead to a 
better understanding of AMD and could potentially function as models for AMD. There is 
especially not much know about the early stages of AMD when drusen are formed. Late-
onset retinal degeneration (L-ORD), Malattia Leventinese (ML) / Doyne honeycomb retinal 
dystrophy (DHRD), and Sorsby's fundus dystrophy (SFD) are diseases causing macular 
degeneration that closely resemble the early stages of AMD and form sub-RPE drusen-like 
deposits. Therefore, these diseases could potentially form model systems of early stage 
AMD. 
 
1.4 Late-onset retinal degeneration 
L-ORD is a rare autosomal dominant disorder caused by a mutation in the complement 
component 1q (C1q) and tumor necrosis factor (TNF)-related protein 5 (C1QTNF5) gene, also 
known as CTRP580 (see Chapter 3). The founder mutation in C1QTNF5 is thought to originate 
from the south-east of Scotland81. Patients often have increased difficulty with dark 
adaptation in their fourth decade of life and progresses to sudden loss of central vision in 
their sixth decade of life. Eventually the progressive symptoms lead to total loss of vision. 
L-ORD has a very similar clinical and pathological phenotype compared to AMD and has 
therefore been suggested as a model for AMD81. Given its rarity and similarity to AMD, L-ORD 
is often misdiagnosed as AMD81. L-ORD can be characterised by bilateral loss of vision, 
delayed dark adaptation, fundus drusen-like yellow spots, midperipheral pigmentation, CNV, 
chorioretinal atrophy, and long anteriorly inserted lens zonules (LAZ)81. 
10 
 
There are three stages recognised in L-ORD progression81. Stage one (age 0-40) is often 
asymptomatic with normal visual acuity. However, LAZ may be found on pupil dilatation 
tests82. LAZ are characterised by zonular fibres that extend more central than usual on the 
anterior lens capsule and can be already found in the third decade of life in patients with L-
ORD83. Stage two (age 40-60) is characterised with increased difficulty adapting to dark84. 
Patients still have normal visual acuity, but fundus examination reveals yellow dots and 
pigmentary changes. Stage three (age 60 and older) is characterised by CNV, resulting in 
sudden central vision loss. CNV areas rapidly increase and leave retinal scarring and atrophy. 
Early stage three mostly resembles AMD but the same visual changes in AMD typically occur 
later than in L-ORD81. 
High doses of vitamin A have led to some improvements in dark adaptation in patients with 
early stage L-ORD83,84. However, vitamin A treatment does not affect disease progression and 
only has a short- to medium-term beneficial effect81. Anti-VEGF treatment has not been 
tested yet on patients with L-ORD to treat the CNV. There is therefore no effective treatment 
yet for this disease. 
 
1.5 Malattia Leventinese / Doyne honeycomb retinal dystrophy and Sorsby's fundus 
dystrophy 
ML/DHRD and SFD are rare hereditary macular degenerations with many phenotypical 
similarities compared to early stage AMD and L-ORD but also have distinct differences. 
Nonetheless, common molecular pathways are likely to be affected amongst these diseases. 
A p.R345W mutation in epidermal growth factor (EGF)-containing fibrillin-like extracellular 
matrix protein 1 (EFEMP1), also known as fibulin-3, causes ML and DHRD85. ML/DHRD is also 
known as autosomal dominant radial drusen. ML and DHRD are both autosomal dominant 
diseases. EFEMP1 is located on chromosome 2 (2p16.1) and encodes for a 55 kDa protein 
that is normally secreted into the ECM. EFEMP1 is most commonly expressed in the RPE and 
the lung85,86. 
EFEMP1 is a member of the fibulin family of glycoproteins. Fibulins are secreted into the ECM 
and are involved in basement membrane formation and stabilisation87,88. EFEMP1 belongs to 
the short fibulins subgroup. Short fibulins are involved in the formation and homeostasis of 
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elastic tissue. EFEMP1 is therefore thought to be a component of the elastic fiber/microfibril 
system89. EFEMP1 can bind to TIMP390 and CFH91. 
Short fibulins are proteolysed by matrix metalloproteinases (MMPs). Specifically, the a 
disintegrin and metalloproteinase domain (ADAM) family of proteins and the ADAM with 
thrombospondin motifs (ADAMTS) family of proteins are thought to be involved in specific 
short fibulin proteolysis89. Interestingly, a homozygous p.C1079R missense mutation in 
ADAMTS18 was shown to cause early-onset retinal dystrophy92. 
The p.R345W mutation was found to cause misfolding of EFEMP1 and therefore reduced 
secretion and thus retention of this protein in the RPE93. In addition, EFEMP1 is also found 
between the RPE and drusen in both ML and AMD93. This aberrant accumulation of EFEMP1 
is thought to be the cause of drusen formation in ML, DHRD and AMD. Moreover, mice with 
a EFEMP1R345W/ R345W knock-in mutation were found to develop basal deposits resembling 
those found in AMD94,95. Furthermore, deposits formed by EFEMP1R345W RPE in vitro were 
shown to induce a complement response by these cells31. Complement factors produced by 
RPE were shown to contribute to the deposit formation. Drusen found in ML and DHRD often 
closely resemble those found in AMD, but also have some distinct differences96. Mutations 
in fibulin-597,98 and fibulin-6/hemicentin 199 (HMCN1) are also implicated to be involved in 
AMD. In addition, mutation p.Q5345R in HMCN1 leads to dominant macular dystrophy100,101. 
Sorsby's fundus dystrophy (SFD) is a rare autosomal dominant disorder102. SFD is 
characterised by bilateral deposition of yellow drusen-like material and extensive CNV 
occurring between the third and fifth decades of life. SFD closely resembles stage 2 L-ORD 
but has an earlier onset81 and is caused by mutations in the TIMP3 gene103-105. In addition, a 
rare mutation in TIMP3 has also been associated with AMD57. TIMP3 is located on 
chromosome 22 (22q12.3) and encodes for a 24 kDa glycosylated protein that binds to 
EFEMP190. TIMP3 mRNA is expressed in the RPE106 and the protein localises to the ECM 
component of Bruch’s membrane107. 
The TIMP family of proteins inhibit MMPs to regulate ECM renewal. The ECM is constantly 
remodelled in healthy tissue. Synthesis and degradation of ECM components are in a dynamic 
equilibrium. MMPs degrade specific components in the ECM and are tightly regulated108. The 
N-terminal domain of TIMPs is responsible for MMP inhibition. Of all the TIMPs, TIMP3 
inhibits the most MMPs, including multiple ADAMs and ADAMTSs109. 
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Multiple different mutations in TIMP3 can lead to SFD, especially missense mutations in exon 
5 of TIMP3. This leads to a cysteine transition in TIMP3 that causes SFD, such as p.S156C110, 
p.G166C111, p.G167C112, p.Y168C103, p.S170C113, p.Y172C114, p.S181C103, and p.Y191C115. It was 
found that most of these mutated proteins had normal TIMP3 characteristics and localisation 
to the ECM, but also form dimers unlike the wildtype TIMP3105,116. Each of these mutations 
are thought to lead to an unpaired cysteine at a different site in the protein. The unpaired 
cysteine at different locations could potentially explain the different TIMP3 dimers found to 
predominate for each mutation105. Unpaired cysteines can create additional intermolecular 
disulphide bonds. In addition, mutations near the C-terminus could also interfere with the 
TIMP3 binding site to EFEMP1, which is located here90.  
TIMP3 is found to inhibit angiogenesis and neovascularisation117-119. It inhibits angiogenesis 
by blocking VEGF from binding to the VEGF receptor 2120. It is therefore likely that TIMP3 
mutations lead to a loss of function causing the extensive CNV in SFD. Treatment of patients 
with anti-VEGF has therefore been proposed121. Furthermore, delayed dark adaptation in SFD 
was found to be reversible with vitamin A treatment112. 
 
1.6 Aims of this study 
There is a lack of knowledge of the molecular mechanisms affected in AMD, especially in the 
early stages of AMD. Formation of the sub-RPE drusen, the hallmark of AMD, is not well 
understood. Rare hereditary sub-RPE drusen-like deposit-forming macular degenerations, 
such as L-ORD, ML/DHRD, and SFD, closely resemble early stage AMD. Shared molecular 
pathways could be affected between these diseases that lead to the sub-RPE deposit 
formation. Studying these rare hereditary macular degenerations could therefore possibly 
provide valuable knowledge about shared early-disease mechanisms. Knowledge of early-
disease mechanisms could lead to the development of treatment before the onset of severe 
disease symptoms and could possibly prevent disease progression. 
Studying hereditary macular degenerations provides the advantage of a single mutation 
leading to the disease phenotype, whereas in AMD a combination of multiple genetic and 
environmental risk factors leads to the disease phenotype. Hereditary macular 
degenerations therefore allow for the generation of patient-specific induced pluripotent 
stem cells (iPSCs) bearing the gene mutation of interest. Gene editing can subsequently be 
13 
 
used to correct the mutation, generating isogenic pairs, where only the mutation of interest 
is the difference. This allows precise studying of the effect of a single mutation. Furthermore, 
these cells allow for the investigation of two cellular processes commonly affected in macular 
degenerations: oxidative stress and the complement system. 
In order to study the molecular mechanisms affected in L-ORD, iPSCs had previously been 
generated from patients. These iPSCs were used in this work to achieve the following aims: 
• Gene-correction of L-ORD iPSC lines using CRISPR/Cas9 gene editing. In addition, 
generation of C1QTNF5 knockout (KO) iPSC line using the same gene editing tools. 
• Generation of RPE to study the C1QTNF5 protein function and what effects the L-
ORD mutation has on the protein. 
• Investigation of the effects of oxidative stress on RPE and how this contributes to the 
macular degeneration phenotype, all using the generated L-ORD iPSC RPE and RPE 
cell lines. 
• Investigate how the complement system contributes to the macular degeneration 
phenotype using L-ORD iPSC RPE.  
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2.1.1 Induced pluripotent stem cells 
Stem cells are self-renewing cells that can differentiate into more specialised cells. Stem cells 
found in the inner cell mass of developing embryos are said to be pluripotent. Pluripotent 
cells have the ability to differentiate into the different cell types that comprise the endoderm, 
mesoderm, and ectoderm germ layers. Embryonic stem cells (ESCs) can be isolated and 
maintained in in vitro culture122. Moreover, it has been found that human somatic cells can 
be reprogrammed to pluripotent stem cells through the addition of four transcription factors: 
Oct-3/4, SOX2, KLF4, and c-Myc123 or Oct-3/4, SOX2, NANOG, and LIN28124. These induced 
pluripotent stem cells (iPSCs) have the same ability to self-renew and differentiate into the 
three germ layers as ESCs. The ability of pluripotent stem cells to become most cell types and 
their ability to self-renew provides for a virtually unlimited supply of a cell type of choice. 
Both ESCs and iPSCs are now routinely used for fundamental cell research, disease modelling, 
and drug development. 
iPSCs hold several important advantages over ESCs. Most significantly, iPSCs do not require 
the need for embryos but can be generated from most cell types taken directly from patients. 
This allows for the generation of patient-specific stem cells that have the same genotype as 
the patient and could therefore be transplanted back to the patient without risking immune 
rejection. This is an important consideration for regenerative medicine. Patient-derived iPSCs 
could be used to correct a genetic defect via gene editing, differentiated to the affected cell 
type, and then transplanted back to the patient to restore the affected tissue. In addition, 
gene correction of patient-derived iPSCs and their comparison with uncorrected iPSCs allows 
for the study of the effect of a single gene mutation with an otherwise identical genetic 
background. Furthermore, the study of isogenic iPSC pairs allows for more precise disease 




2.1.2 CRISPR/Cas9 gene editing 
Gene editing tools can be used to introduce or correct SNPs. In addition, these tools can also 
be used to introduce short sequences or delete parts of a sequence. This allows for the 
introduction of one of the macular degeneration-causing mutations into wildtype (wt) iPSC 
lines and the correction of the mutation in patient-derived iPSC lines. Moreover, KO lines can 
be generated with these gene editing tools to investigate the function of the protein of 
interest. 
Clustered regularly interspaced short palindromic repeats (CRISPR), in association with the 
nuclease CRISPR-associated protein (Cas), is an RNA-guided nuclease system that is used for 
gene editing125,126. In this system the nuclease Cas is guided by a specific RNA guide to a 
specific locus where it can introduce a double-stranded break (DSB). The DSB is subsequently 
repaired by one of two endogenous DNA repair mechanisms: homology directed repair (HDR) 
or non-homologous end joining (NHEJ) (Fig. 2.1). NHEJ occurs in the absence of a repair 
template. This process is highly error-prone and therefore introduces insertion or deletion 
(indel) mutations. In contrast, by providing a repair template HDR can fully repair the DSB. 
 
 
Figure 2.1 | Cas9 creates a DSB that can be resolved by HDR or NHEJ. Cas9 is directed to the locus of 
interest by the gRNA where it will create a DSB. Endogenous DNA repair mechanisms HDR or NHEJ can 
repair the break. Only HDR uses a template to repair the break and normally this is the other allele. 
For gene editing purposes a template can be added instead, with the edit of interest. NHEJ typically 
causes indel mutations resulting in a premature stop codon. DSB = double-stranded break; HDR = 




The CRISPR/Cas systems originated as an acquired defence system in bacteria and archaea128-
131. This multistep process is executed by cas genes and non-coding RNA. Small invading 
foreign DNA fragments are recognised as non-self and subsequently incorporated into the 
host CRISPR loci between repetitive elements. These incorporated foreign DNA fragments, 
now termed protospacers, are then transcribed and processed into CRISPR RNA (crRNA) used 
for targeting foreign DNA. Downstream of a protospacer is a conserved 5’-NGG sequence, 
termed protospacer adjacent motif (PAM). In the Type II CRISPR system, targeting crRNA 
anneals to trans-activating crRNA (tracrRNA) to form guide RNA (gRNA). gRNA forms a 
ribonuclear protein (RNP) with Cas9 and can bind and neutralise complementary invading 
viral and plasmid DNA. After the gRNA binds to a 20-base pair (bp) target sequence, Cas9 
induces a DSB ~3 bp upstream of the PAM. The resulting DNA fragments can again be 
incorporated into the CRISPR loci. 
The CRISPR/Cas systems have been repurposed and modified to allow efficient gene editing 
in a variety of species125. For biotechnology purposes, targeting crRNA and tracrRNA can be 
fused together to form a chimeric single-guide RNA (sgRNA)132 and, to improve specificity of 
gene editing, a D10A nickase mutant of Cas9 (Cas9n) was generated that introduces nicks in 
the DNA instead of DSBs133. By using a pair of offset sgRNAs complementary to opposite 
strands of the target site, site-specific DSBs can be generated with Cas9n. Off-target 
individual single strand DNA nicks would be repaired by the endogenous base excision repair 
(BER) system. A CRISPR/Cas system can be leveraged into editing a specific locus if a repair 
template is provided for HDR. Plasmids or single-stranded oligodeoxy-nucleotides (ssODNs) 
containing homology arms flanking the insertion sequence can be used as HDR templates. 
Recent advances in stem cell technologies combined with advances in gene editing tools 
provides an unprecedented opportunity to develop new experimental models to study 
macular degeneration. However, background genetic variation among different patient-
derived iPSC lines leads to confounding results, presenting a challenge to disease modelling. 
Generation of isogenic pairs, using CRISPR/Cas9, allows for the study of the effect of a single 
gene mutation, since the only difference between the parental line and the gene-corrected 
line is the mutation. Therefore, correcting the C1QTNF5S163R mutation in L-ORD patient-
derived stem cells should provide a basis for modelling L-ORD and likely macular 




2.1.3 Aims and objectives 
In order to study the function of C1QTNF5 and the effect of the C1QTNF5S163R mutation on 
the protein, the following was carried out in this chapter: 
1. The C1QTNF5S163R mutation in patient-derived iPSCs was gene-corrected by using 
CRISPR/Cas9 gene editing to generate an isogenic pair for disease modelling 
2. A biallelic KO of the C1QTNF5 gene was generated in an iPSC line by using 
CRISPR/Cas9 gene editing to study the function of C1QTNF5 
3. The gene editing strategies used were investigated if they resulted in off-target 




2.2 Materials and methods 
 
2.2.1 Cell culture 
iPSCs were cultured in Essential 8 medium (Gibco, Loughborough, UK) on 6-well plates coated 
with growth factor-reduced matrigel (Corning, New York, NY) by Dr Burr (The University of 
Edinburgh) and Almar Neiteler. L-ORD case iPSC lines LORD3 and LORD4 were previously 
generated from male patient-derived fibroblasts through episomal reprogramming by Dr 
Borooah (The University of Edinburgh) with Dr Burr (The University of Edinburgh) (PhD thesis, 
Dr Borooah, The University of Edinburgh). The control wt iPSC line used, CS02iCTR-NTn1, was 
previously generated from peripheral blood mononuclear cells from a wt male through 
episomal reprogramming (Cedars-Sinai, Los Angeles, CA). 
HEK 293T cells were cultured in DMEM/F-12 (Gibco) supplemented with 10% foetal calf 
serum (FCS; Gibco) and 2 mM L-glutamine (Gibco). 
 
2.2.2 Pluripotency staining 
The iPSC lines were washed with PBS and fixed with 4% paraformaldehyde (PFA) for 10 
minutes. After another two washes with PBS the cells were permeabilised with 0.1% TritonX-
100 (Sigma-Aldrich, Dorset, UK) for 10 minutes and subsequently blocked with 3% normal 
goat serum for 1 hour. The fixed cells were incubated with the primary antibody overnight at 
4 °C. The cells were washed twice with PBS and subsequently incubated with a secondary 
Alexa Fluor®-conjugated antibody for 30 minutes and counterstained with 300 nM DAPI 
(Biotium, Fremont, CA) for 10 minutes. After another three washes with PBS, the cells were 
mounted in Fluorsave mounting medium (Merck Millipore, Nottingham, UK) and imaged with 
a Leica DM IRB fluorescence microscope (Leica Microsystems, Milton Keynes, UK). The 
antibodies and concentrations used are listed in Table S8. 
 
2.2.3 Karyotyping 
The iPSC lines were arrested in metaphase and labelled with a 10 μM bromodeoxyuridine 
(BrdU; Sigma-Aldrich) and 10 μg/ml colcemid (Sigma-Aldrich) solution for 15 hours. The cells 
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were then enlarged with a hypotonic 0.56% potassium chloride (Sigma-Aldrich) and 0.4% 
sodium citrate solution (Fisher Scientific UK Ltd., Loughborough, UK) for 25 minutes to 
facilitate the spreading of metaphase chromosomes. The cells were then fixed in a methanol 
and glacial acetic acid fixative solution and send for karyotyping (TDL Genetics, London, UK). 
 
2.2.4 Designing CRISPR/Cas9(n) constructs and cloning 
Targeting crRNA pairs to use in conjunction with Cas9n to target the C1QTNF5S163R mutation 
site were designed as 20-bp sequences directly upstream of a 5’-NGG PAM sequence 
according to specifications previously described127,133. In short, the pairs were designed to 
generate 5’ overhangs and at least one of the pairs nicks within 22 bp of the HDR insertion 
site. The targeting crRNA pair offset gap for use with Cas9n was designed to be between 0-
20 bp and pairs nick in opposite strands.  
The L-ORD C1QTNF5S163R mutation itself is part of a 5’-NGG PAM. Therefore, another 
targeting crRNA was designed by Dr Selvaraj (The University of Edinburgh) to specifically 
target this site to use in conjunction with wt Cas9. 
To generate a C1QTNF5 KO iPSC line, Dr Selvaraj (The University of Edinburgh) designed a 
targeting crRNA pair that, in conjunction with wt Cas9, creates a deletion in exon one and 
thereby creating an in-frame stop codon. 
Targeting crRNA pairs to use in conjunction with Cas9n to edit C1QTNF5 were ligated into a 
plasmid containing Cas9n, pSpCas9n(BB)-2A-Puro (PX462) V2.0 (Addgene, Middlesex, UK). 
The targeting crRNA pairs for C1QTNF5 repair and C1QTNF5 KO were ligated into a plasmid 
containing wt Cas9, pSpCas9(BB)-2A-Puro (PX459) V2.0 (Addgene). Both plasmids already 
contain the tracrRNA. Targeting crRNAs and repair templates were ordered as ssODNs (IDT, 
Leuven, Belgium), see Table S1. After annealing, the targeting crRNA ODNs were ligated into 
the pSpCas9n vector cut open with BbsI (Thermo Scientific, Paisley, UK), upstream of the 
tracrRNA, for co-expression of Cas9 or Cas9n with sgRNA. The ligation mix was treated with 
PlasmidSafe Exonuclease (Epicentre, Madison, WI) to remove any linear DNA from the mix. 
pSpCas9 vectors with correction and KO crRNAs were obtained from Dr Selvaraj (The 
University of Edinburgh), see Table S2. All plasmids were cloned in One Shot® TOP10 




The C1QTNF5 targeting crRNA for L-ORD repair was also ordered for an Alt-R CRISPR/Cas9 
system (IDT) transfection. For this system, crRNA, tracrRNA and Cas9 protein were ordered 
separately. Targeting crRNA and tracrRNA oligomers were resuspended to 200 µM in TE 
buffer, mixed together in equimolar concentrations, and annealed together at 95 °C for 2 
minutes to generate the gRNA duplex. To 200 pmol gRNA, 137.25 pmol of Cas9 protein was 
added and incubated for 10-20 minutes to generate the RNP for transfection. For RNA 
sequences used in the RNP complex see Table S3. 
The HDR templates were designed as ssODNs with homology arms of at least 70 nucleotides 
(nt) on either side127. One or both PAM sequences were mutated in the repair template to 
prevent sequential editing and therefore lowering the chance of NHEJ events. For HDR 
template sequences see Table S4. 
 
2.2.5 Transfection 
The pSpCas9(n)-sgRNA constructs were first tested on HEK 293T cells. HEK 293T cells were 
seeded in a 12-well plate well (2*105 cells/well) a day prior to transfection. Cells were 
transfected once 80-90% confluent with Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol. The pSpCas9(n)-sgRNA constructs were co-transfected with 
pmaxGFP (Lonza Ltd., Basel, Switzerland) to check transfection efficiency. Transfection 
efficiency was observed with a fluorescence microscope (Carl Zeiss Ltd., Cambridge, UK) the 
day after transfection. 
iPSCs were transfected once 80-90% confluent. Cells were washed with PBS and dissociated 
to single cells with Accutase (Stemcell Technologies, Vancouver, Canada). The single cell 
suspension was washed again with PBS and the cells were counted. 8*105 cells were 
nucleofected using a P3 Primary Cell 4D-Nucleofector X Kit (Lonza Ltd.) in combination with 
a 4D-Nucleofector™ Core Unit and X Unit (Lonza Ltd.) with program CA-137 according to the 
manufacturer’s protocol. 2 µg per pSpCas9(n)-sgRNA or 9 µl of RNP complex and 2.5 µl of 
200 µM HDR template were used for nucleofection. In all nucleofections 1 µg 
pEGFP/Puromycin was co-transfected for selection. Nucleofected cells were seeded in a 
Matrigel-coated 6-well plate well in E8 medium supplemented with 10 µM ROCK-inhibitor Y-
27632 (Stemcell Technologies). Transfection efficiency was observed with a fluorescence 
microscope (Carl Zeiss Ltd.) the day after transfection. Nucleofected cells were selected with 
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10 µM puromycin (Gibco) for 24 hours. The cells were allowed to recover from selection and 
were passaged at very low density (5*103 and 1*104) as single cells onto a Matrigel-coated 
10 cm dish in E8 with ROCK-inhibitor. Single colonies were picked and transferred to a 
Matrigel-coated 96-well plate. Duplicate plates were made for maintenance and restriction 
fragment length polymorphism (RFLP) screening. Nucleofection of pSpCas9 constructs for 
gene correction, selection, and the maintenance of single cell-derived clones was performed 
in collaboration with James Cooper (The University of Edinburgh). 
 
2.2.6 PCR 
Plasmids ligated with targeting crRNAs were validated using GoTaq Flexi polymerase 
(Promega, Southampton, UK). The PCR program had an initial denaturation step at 95 ˚C for 
2 minutes. After the initial denaturation step the program continued with 21 cycles of 
denaturation at 95 ˚C for 15 seconds, annealing at 57.5 ˚C for 30 seconds, and extension at 
73 ˚C for 30 seconds. The final extension was at 73 ˚C for 5 minutes. PCR products were run 
on a 2% agarose gel. PCR primers were designed with the primer design tool Primer3134-136 
and are listed in Table S6. 
The C1QTNF5 mutation region was PCR amplified using Q5® High-Fidelity DNA Polymerase 
(New England Biolabs, Ipswich, MA). The PCR program had an initial denaturation step at 98 
˚C for 30 seconds. After the initial denaturation step the program continued with 34 cycles 
of denaturation at 98 ˚C for 10 seconds, annealing at 66 ˚C for 30 seconds, and extension at 
72 ˚C for 30 seconds. The final extension was at 72 ˚C for 2 minutes. PCR products were run 
on a 2% agarose gel. PCR of the C1QTNF5 mutation region was performed in collaboration 
with James Cooper (The University of Edinburgh). 
The C1QTNF5 KO region was PCR amplified using the QIAGEN Multiplex PCR Kit (Qiagen, 
Manchester, UK). The PCR program had an initial denaturation step at 95 ˚C for 15 minutes. 
After the initial denaturation step the program continued with 34 cycles of denaturation at 
94 ̊ C for 30 seconds, annealing at 55 ̊ C for 30 seconds, and extension at 72 ̊ C for 30 seconds. 




2.2.7 Restriction fragment length polymorphism screening and Sanger sequencing 
For restriction fragment length polymorphism (RFLP) screening and Sanger sequencing, 
genomic DNA (gDNA) was isolated from transfected cells, using a Wizard® Genomic DNA 
Purification Kit (Promega), according to the manufacturer’s instructions. Isolated gDNA was 
used for PCR amplification of the mutation region. PCR products were purified using the 
ChargeSwitch PCR Clean-Up Kit (Invitrogen), according to the manufacturer’s instructions. 
Purified PCR products were normalised to 200 ng and used to generate heteroduplexes by 
denaturing and slowly reannealing the DNA strands127,137. The slow annealing program had 
an initial denaturation step at 95 ˚C for 5 minutes. After the initial denaturation step the 
program continued by reannealing slowly by lowering the temperature 2 ˚C/second to 85 ˚C. 
After 1 minutes at 85 ˚C the program lowered the temperature 0.1 ˚C/second to 25 ˚C 
followed by 30 seconds at 25 ˚C. The formed heteroduplexes were then digested with T7 
Endonuclease I (New England Biolabs) at 37 ˚C for 15 minutes. Digested products were run 
on a 2% agarose gel. 
PCR products of the mutation region were also used for restriction digestion. The L-ORD 
C1QTNF5S163R mutation site generates a BstNI restriction site. To 15 µl of PCR product 2 µl of 
NEBuffer 3.1 (New England Biolabs), 2 µl of dH2O, and 1 µl of BstNI (New England Biolabs) 
was added. This was incubated at 60 °C for 1 hour. Digested products were run on a 2% 
agarose gel. Restriction digestions were performed in collaboration with James Cooper (The 
University of Edinburgh). 
Purified PCR products were also sent for Sanger sequencing (Source Bioscience, Nottingham, 
UK). 
 
2.2.8 Off-target screening 
Top five possible off-target sites for each targeting crRNA were selected through the Sanger 
Find Off-Targets by Sequence tool138 and are listed in Table S5. Primers for each possible off-
target site were designed with the primer design tool Primer3134-136 and are listed in Table S6. 
Each possible off-target site was PCR amplified as described above in each edited line (see 
section 2.2.6). PCR products were purified using the ChargeSwitch PCR Clean-Up Kit, 
according to the manufacturer’s instructions. Purified PCR products were sent for Sanger 




2.2.9 C1QTNF5 variant effect prediction 
The Ensembl Variant Effect Predictor tool139 was used to predict the effects of the p.S163R 
and the p.A154T missense mutations on the structure and function of C1QTNF5. The 
algorithms SIFT and PolyPhen were used. 





2.3.1 iPSC lines have normal stem cell characteristics 
Several different iPSC lines were used in this study and were tested for their stem cell 
qualities. All iPSC lines used grew as typical iPSC colonies (Fig. 2.2a). The iPSC lines were 
immunostained for known pluripotency markers NANOG, Oct-3/4, and TRA-1-60. All three 
pluripotency markers were found to be expressed in the iPSC lines (Fig. 2.2b). The karyotype 
was analysed for the iPSC lines to check for possible chromosomal abnormalities that can be 
introduced by iPSC propagation and by freezing and thawing of the cells. Karyotyping of the 
lines revealed no chromosomal abnormalities (Fig. 2.2c). Gene correction was performed on 
the L-ORD case iPSC lines LORD3 and LORD4 (see sections 2.3.5, 2.3.6, and 2.3.7), harbouring 
the heterozygous C1QTNF5S163R mutation causative for L-ORD, and were named LORD3C and 
LORD4C respectively. The wt control iPSC line CS02iCTR-NTn1 was used to create a biallelic 










Figure 2.2 | The iPSC lines used had normal iPSC characteristics. The iPSC lines grew in normal iPSC 
colonies (a), expressed the pluripotency markers NANOG, Oct3/4, and TRA-1-60 (b), and had a normal 




2.3.2 Design and construction of C1QTNF5S163R gene correction plasmids 
To target the C1QTNF5S163R mutation site, gRNA pairs were designed that in conjunction with 
Cas9n can generate a DSB near the mutation site (Fig. 2.3a). When transfected in conjunction 
with an HDR template, the C1QTNF5S163R mutation can be corrected. A separate HDR 
template was designed for each gRNA pair to introduce a silent mutation in the PAM sites of 
their respective gRNA pair to prevent subsequent editing. The gRNA pairs here could also be 
used to introduce the C1QTNF5S163R mutation in a wt iPSC line. Both gRNAs of a pair were 
cloned in a plasmid containing Cas9n for co-expression. 
In addition, a gRNA was designed to target only the C1QTNF5S163R mutation (gRNA 
Correction). The C1QTNF5S163R mutation itself generates a PAM sequence and therefore this 
was leveraged to design this gRNA that can only target the L-ORD allele (Fig. 2.3b). This gRNA 
was cloned in a plasmid containing Cas9 for co-expression after transfection. As an 
alternative, gRNA Correction was also used in conjunction with tracrRNA and Cas9 to form 





Figure 2.3 | Strategies used for targeting the C1QTNF5 mutation site. The C1QTNF5S163R mutation site 
(asterisk) was targeted with gRNA pairs (1 and 2, 3 and 4, 5 and 6) in conjunction with Cas9n to 
generate a DSB (a). An HDR template was designed per gRNA pair to introduce or correct the 
C1QTNF5S163R mutation and to create a silent mutation in one or both PAM sites of the gRNAs to 
prevent sequential editing. The C1QTNF5S163R mutation (red, asterisk) also generates a PAM site (b). 
Thus, a gRNA designed with this PAM would only target the C1QTNF5S163R mutation. A wt HDR 
template with 95 bp homology arms was used to repair the mutation (G>C) in a scarless-fashion. The 
C1QTNF5S163R mutation also generates an extra BstNI restriction site (5’-CCWGG-3’). This allows for the 
screening for successfully edited clones. PAM = protospacer adjacent motif; HDR = homology directed 
repair; wt = wildtype. 
 
gRNA1 and gRNA2 were cloned into a plasmid containing Cas9n for co-expression. gRNA 
Correction was previously cloned into a plasmid containing wildtype Cas9 and validated by 
Dr Selvaraj (The University of Edinburgh). Successful cloning of gRNA1 and gRNA2 was 
determined by PCR amplification of the plasmid with the forward primer annealing to the 
gRNA insert and the reverse primer annealing to the plasmid backbone. PCR amplification 
only worked when the gRNA-specific primer was able to anneal to its respective gRNA insert 





Figure 2.4 | gRNA1 and gRNA2 were successfully cloned into plasmids containing Cas9n. gRNA1 and 
gRNA2 were cloned into plasmids containing Cas9n. Forward primers specifically designed to anneal 
to gRNA1 or gRNA2 were used to test correct insertion of the gRNA into the Cas9n plasmids in 
conjunction with a reverse primer annealing to the plasmid backbone. The Cas9n plasmid with gRNA1, 
gRNA2, or empty were PCR amplified with the gRNA1-specific forward primer (left) or the gRNA2-
specific forward primer (right) and only showed a PCR band of 177 bp or 167 bp respectively when 
their specific insert was successfully cloned into the plasmid. 
 
2.3.3 Gene correction gRNA specificity test transfection of HEK 293T cells 
HEK 293T cells were transfected with gRNA1, gRNA2, both gRNA1 and gRNA2, or gRNA 
Correction plasmids, in order to determine if the gRNAs are able to target the site of interest, 
and to assess the cutting efficiency of Cas9 in the site of interest. The C1QTNF5 mutation 
locus was subsequently PCR amplified from isolated gDNA. The PCR products were subjected 
to a denaturing and slow reannealing process that allows for the formation of heteroduplex 
double-stranded DNA (dsDNA). The T7 endonuclease specifically recognises and cleaves the 
resulting mismatched dsDNA. Plasmids containing gRNA1 and gRNA2 also contain Cas9n and 
therefore on their own would not generate a DSB but a nick in the DNA. Therefore, gRNA1 
and gRNA2 were each co-transfected with a plasmid containing Cas9. The plasmid containing 
gRNA Correction already has Cas9 in it. 
Transfection of HEK 293T cells with gRNA1 or gRNA2 in combination with Cas9 causes a DSB 
near the mutation site in C1QTNF5. The DSB is then repaired by endogenous NHEJ, resulting 
in random indel mutations. Transfection with gRNA1 and Cas9 resulted in an undigested PCR 
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product band at 300 bp and bands underneath indicating NHEJ events have taken place which 
were digested by T7 (Fig. 2.5). Therefore, gRNA1 targets the correct locus. The specificity of 
gRNA2 on its own with Cas9 could not be shown (Fig. 2.5). However, gRNA1 and gRNA2 
combined also showed NHEJ multiple bands (Fig. 2.5), indicating that both gRNAs bind to the 
right site in C1QTNF5 and efficiently cause DSBs with Cas9n. Transfection with the plasmid 
containing gRNA Correction did not generate any NHEJ bands (Fig. 2.5), indicating that gRNA 
Correction with Cas9 cannot target the wt HEK 293T cell line. This is expected as gRNA 
Correction has a PAM site that can only recognise the L-ORD mutant allele which is absent in 
the wt HEK 293T cell line (Fig. 2.3b). 
 
 
Figure 2.5 | T7 endonuclease assay test on HEK 293T transfected with gRNA constructs. HEK 293T 
cells were transfected with gRNA1 with wt Cas9 plasmid, gRNA2 with wt Cas9 plasmid, gRNA1 and 2, 
or gRNA correction. gRNA1 in combination with Cas9 would generate 245 and 56 bp bands. gRNA2 in 
combination with Cas9 would generate 193 and 108 bp bands. gRNA1 and gRNA2 together would 
generate 194, 56 and 52 bp bands. The undigested PCR product is 301 bp. 
 
2.3.4 Gene correction gRNA specificity test transfection of L-ORD iPSCs 
gRNA Correction could not be tested on the wt HEK 293T cell line because it lacks the required 
PAM site for the gRNA to bind to. This gRNA was therefore tested on the case iPSC line LORD4 
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in combination with the HDR template. In a T7 assay the untransfected case cells show the 
predicted digestion bands (Fig. 2.6a), since it is a heterozygous mutation. The transfected 
case cells also show these bands when not selected for transfection, indicating that there are 
still mutant cells in the population (Fig. 2.6a). However, this assay was not sensitive enough 
to determine if there was a subpopulation of successfully edited cells (Fig. 2.6a).  
Another method to check successful editing is through restriction digestion. The 
C1QTNF5S163R mutation in the L-ORD case generates a BstNI restriction site (Fig. 2.3b). The 
untransfected case cells show the predicted digestion bands, because two restriction sites 
are already in the amplicon (Fig. 2.6b). Case cells would show these bands in addition to extra 
fragments due to the extra restriction site caused by the C1QTNF5S163R mutation. Correction 
of the C1QTNF5S163R mutation should make these extra bands fainter compared to the case, 
but unfortunately this is not clear (Fig. 2.6b). Nonetheless, since this gRNA is expected to be 







Figure 2.6 | RFLP assays L-ORD case iPSCs transfected with C1QTNF5 correction RNP and HDR 
template on population level. LORD4 case iPSCs were transfected with C1QTNF5 correction RNP with 
HDR template and selected with puromycin for successful transfection. Control iPSCs (CS02iCTR-
NTn1), LORD4, and transfected LORD4 without puromycin selection were used as controls. The 
C1QTNF5 mutation region was PCR amplified and subsequently digested with T7 endonuclease (a) or 
BstNI restriction enzyme (b). In the T7 assay the wt control iPSCs would generate no extra bands, 
untransfected LORD4 iPSCs would generate 209 and 92 bp digestion bands, LORD4 corrected and 
selected would still generate fainter 209 and 92 bp bands, and LORD4 corrected and not selected 
would still generate the 209 and 92 bp bands in the T7 assay (a). In the BstNI assay the wt control iPSCs 
would generate 249, 45 and 7 bp bands, untransfected LORD4 iPSCs would generate the same bands 
in addition to 206 and 43 bp bands, LORD4 corrected and selected would still generate the additional 
206 and 43 bp bands but fainter, and LORD4 corrected and not selected would also still generate the 
additional 206 and 43 bp bands (b). The undigested PCR product is 301 bp for both assays. 
 
2.3.5 Gene correction of LORD4 using the RNP method 
LORD4 was transfected with gRNA Correction using the RNP method. gRNA Correction was 
chosen because it should only edit the L-ORD allele and not the wt allele (Fig. 2.3b). This was 




From the transfected and puromycin-selected LORD4 population of cells, 240 single cell-
derived clones were screened and one C1QTNF5 corrected clone (clone 3-41) was found via 
BstNI restriction digestion (Fig. 2.7a). Sanger sequencing of clone 3-41 confirms that this 
clone has C1QTNF5 successfully gene-corrected (Fig. 2.7b). Although the C1QTNF5S163R 
mutation was corrected, it seemed that the gene editing introduced a new C1QTNF5A154T 
mutation (Fig. 2.7c). 
 
 
Figure 2.7 | BstNI restriction digestion on 240 case iPSC single cell-derived LORD4 clones transfected 
with C1QTNF5 correction RNP and wt HDR template and Sanger sequencing. LORD4 iPSCs were 
transfected with C1QTNF5 correction RNP and 240 single cell-derived clones were screened by PCR 
and subsequent BstNI restriction digestion after selection with puromycin (not all shown) (a). The wt 
control iPSCs were expected to generate 249, 45 and 7 bp bands whereas LORD4 case iPSCs were 
expected to generate additional 206 and 43 bp digestion bands. One out of 240 clones showed the 
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expected loss of the 206 bp band for a successful correction of the L-ORD allele (clone 3-41; red box). 
Sanger sequencing of the antisense strand of LORD4 showed a double peak; a G for the wt allele, and 
a C for the L-ORD allele (arrow) (b). In contrast, clone 3-41 showed a single G peak, indicating successful 
gene correction. However, gene editing introduced a new C>T (p.A154T) mutation upstream in the 
corrected allele (right arrows) (c). The left arrows indicate the L-ORD mutation site. 
 
2.3.6 Gene correction of LORD4 using the plasmid method 
LORD4 was corrected again because of the introduced C1QTNF5A154T mutation (Fig. 2.7c). The 
gRNA Correction in the Cas9 plasmid was used, because the RNP method used previously was 
very inefficient. 192 single cell-derived clones were screened and 36 clones seemed to be 
successfully edited (Fig. 2.8). 
 
Figure 2.8 | BstNI restriction digestion on 192 case iPSC single cell-derived LORD4 clones transfected 
with C1QTNF5 correction plasmid and wt HDR template and Sanger sequencing. LORD4 iPSCs were 
transfected with C1QTNF5 correction plasmid and 192 single cell-derived clones were screened by PCR 
and subsequent BstNI restriction digestion after selection with puromycin (not all shown) (a). The wt 
control iPSCs were expected to generate 249, 45 and 7 bp bands whereas LORD4 case iPSCs were 
expected to generate additional 206 and 43 bp digestion bands. 36 out of 192 clones showed the 
expected loss of the 206 bp band for a successful correction of the L-ORD allele (red boxes). Sanger 
sequencing of the antisense strand of LORD4 showed a double peak; a G for the wt allele, and a C for 





2.3.7 Gene correction of LORD3 using the plasmid method 
For the correction of LORD3 the gRNA Correction in the Cas9 plasmid was used again. 192 




Figure 2.9 | BstNI restriction digestion on 192 case iPSC single cell-derived LORD3 clones transfected 
with C1QTNF5 correction plasmid and wt HDR template and Sanger sequencing. LORD3 iPSCs were 
transfected with C1QTNF5 correction plasmid and 192 single cell-derived clones were screened by PCR 
and subsequent BstNI restriction digestion after selection with puromycin (not all shown) (a). The wt 
control iPSCs were expected to generate 249, 45 and 7 bp bands whereas LORD3 case iPSCs were 
expected to generate additional 206 and 43 bp digestion bands. 35 out of 192 clones showed the 
expected loss of the 206 bp band for a successful correction of the L-ORD allele (red boxes). Sanger 
sequencing of the antisense strand of LORD3 showed a double peak; a G for the wt allele, and a C for 





2.3.8 Checking gene-corrected LORD3 and LORD4 clones for off-target activity 
Even though gRNA Correction was designed to only target the L-ORD allele, and the gRNA did 
not cause any editing activity in wt HEK 293T cells, edited iPSC clones were checked for off-
allele editing. To check if the gRNA is specific for the L-ORD allele, multiple edited clones were 
sequenced. Loss of the BstNI restriction site is either due to HDR-mediated correction of the 
L-ORD allele or due to NHEJ-mediated generation of indels in the L-ORD allele. It is possible 
that, if the wt allele is targeted, indels are introduced in the wt allele. Even in clones that lost 
the BstNI restriction site due to indels generated by NHEJ, the wt trace could be observed in 
the background (Fig. S1a). This suggests that NHEJ only occurred in the L-ORD allele and that 
the wt allele was spared. Therefore, only the L-ORD allele was found to be targeted and 
edited with gRNA Correction. 
The CRISPR/Cas9 system is highly efficient is generating DSBs. However, the downside of such 
high activity is that there is an increased propensity for off-target activity at sites highly 
homologous to the gRNA. Sanger sequencing was performed on top five potential off-target 
sites for gRNA Correction in LORD3 and LORD4 gene-corrected clones to assess for potential 
off-target deleterious mutations. The sequence of all top five loci were found to be unaltered 
in both LORD3 and LORD4 gene-corrected clones (Fig. S1b), suggesting that the off-target 
activity of gRNA Correction is minimal. 
 
2.3.9 Strategy for generating C1QTNF5 KO lines 
To generate a C1QTNF5 KO line, a gRNA pair was previously designed and cloned into 
plasmids containing Cas9 and validated by Dr Selvaraj (The University of Edinburgh). The 
gRNA pair was designed to create two DSBs in exon 1 of C1QTNF5 in conjunction with Cas9 
(Fig. 2.10). The 107 bp fragment between the DSBs would be deleted and the remaining ends 





Figure 2.10 | Strategy for generating C1QTNF5 KO lines. A gRNA pair was designed to generate two 
DSBs (arrows) in exon 1 of C1QTNF5 in conjunction with Cas9. The 107 bp region between the DSBs is 
subsequently deleted and the remaining ends are ligated together via NHEJ. Thus, the 3’ T of the 
upstream fragment would join with the 5’ GA of the downstream fragment, forming an in-frame TGA 
stop codon. 
 
2.3.10 KO gRNAs test transfection of HEK 293T cells 
The designed gRNAs for generating a C1QTNF5 KO line were first tested on a wt HEK 293T 
cell line. HEK 293T cells were therefore transfected with the C1QTNF5 KO gRNA pair in 
plasmids containing Cas9. The transfected cells show a smaller size 387 bp band when the 
KO region in C1QTNF5 was PCR amplified because of the 107 bp deletion (Fig. 2.11). 






Figure 2.11 | PCR test on 
HEK293T transfected with 
C1QTNF5 KO constructs on 
population level. HEK 293T cells 
were transfected with the 
C1QTNF5 KO gRNA pair in 
plasmids containing Cas9. PCR 
amplification of the targeted KO 
region in C1QTNF5 would result 
in a 494 bp band, but when 
successfully edited in a 387 bp 
PCR band. Transfected cells had a 
mixed population with the 
expected 107 bp deletion. 
 
2.3.11 Generation of C1QTNF5 KO iPSC line 
The control wt iPSC line CS02iCTR-NTn1 was transfected with the C1QTNF5 KO gRNA pair. 
Transfected cells showed the expected 107 bp deletion band after PCR amplification of the 
C1QTNF5 target locus (Fig. 2.12). Moreover, the transfected cells that were also selected with 
puromycin show a thicker deletion band than the unselected cells, indicating enrichment of 





Figure 2.12 | PCR on wt iPSCs 
transfected with C1QTNF5 KO 
constructs on population level. 
Control wt iPSCs were 
transfected with a C1QTNF5 KO 
gRNA pair in plasmids 
containing Cas9. When 
transfected with these plasmids 
it would result in a 387 bp PCR 
band. Untransfected cells 
would have a 494 bp band. 
Treatment with puromycin 
should select for cells 
transfected with the gRNA pair. 
 
From the transfected population of cells 70 single cell-derived clones were screened and 
three C1QTNF5-/- clones were found in addition to seven possible C1QTNF5+/- clones (Fig. 
2.13a). Sanger sequencing of clone 36 showed that this clone had a successful biallelic 





Figure 2.13 | PCR on 70 wt iPSC single cell-derived clones transfected with C1QTNF5 KO constructs 
and Sanger sequencing. Control wt iPSCs were transfected with a C1QTNF5 KO gRNA pair in plasmids 
containing Cas9 and 70 single cell-derived clones were screened by PCR after puromycin selection (a). 
Three out of 70 clones showed the expected single 387 bp PCR band for a successful biallelic KO 
deletion (red boxes). Seven out of 70 clones showed the 387 bp PCR band in addition to the 494 bp 
PCR band indicating possible monoallelic KO deletion (yellow boxes). Sanger sequencing of clone 36 
showed a missing 107 bp at the predicted location (arrow), resulting in a TGA stop codon (red box) (b). 
Alignment of the C1QTNF5 sequence of clone 36 with wt C1QTNF5 sequence showed the 107 bp 




2.3.12 Checking C1QTNF5 KO clones for off-target activity 
Sanger sequencing was performed on the C1QTNF5 null clone 36 for the top four potential 
off-target sites for both the upstream and downstream gRNA to assess for deleterious 
mutations. None of these loci were changed in C1QTNF5 KO compared to its isogenic control 
(Fig. S2). However, both lines did have some SNPs compared to the reference sequence in 






The ability to use L-ORD patient-derived stem cells in combination with gene editing allows 
for a unique way to investigate the function of C1QTNF5, as well as the effects of the L-ORD 
mutation on the protein function. Here, I showed the gene correction of the L-ORD-causing 
C1QTNF5S163R mutation in two different patient-derived iPSC lines. In addition, I generated a 
biallelic KO of the C1QTNF5 in a wt iPSC line. 
One of the L-ORD iPSC lines, LORD4, was edited using a relatively new CRISPR/Cas9 editing 
method. With this method, the gRNA, tracrRNA, and the Cas9 protein are incubated together 
to form an RNP prior to transfection. This method yielded a very low successful editing 
efficiency of 0.42% (Fig. 2.7a). The low efficiency could be due to inefficient assembly of the 
RNP, degradation of RNA, inefficient transfection of the RNP, or the length of the HDR repair 
template. Further experiments are needed to address the low efficiency of the RNP method. 
A new, shorter HDR template was designed and used for the plasmid-based editing 
experiments. 
Even though the L-ORD mutation was corrected in LORD4 using the RNP method (Fig. 2.7b), 
a new C1QTNF5A154T mutation was introduced in the same corrected allele (Fig. 2.7c). Sanger 
sequencing indicates that an HDR event resulted in the correction of the C1QTNF5S163R 
mutation. Correction of the C1QTNF5S163R mutation removes the PAM site, making 
subsequent editing of this site as unlikely as editing the wt allele (Fig. 2.5 and 2.10a). The new 
C1QTNF5A154T mutation was therefore most likely introduced in the same HDR event as the 
C1QTNF5S163R mutation was corrected. It is possible that the HDR repair template used to 
correct the C1QTNF5S163R mutation had a mutation in it. 
LORD4 was edited again using a different CRISPR/Cas9 editing method. An additional L-ORD 
iPSC line, LORD3, was also edited using this method. With this method, the gRNA is cloned 
into a vector containing the tracrRNA and Cas9. Transfection of iPSCs with this vector results 
in co-expression of these three components and subsequent assembly of the RNP inside the 
cell. The C1QTNF5S163R mutation was successfully gene-corrected in LORD3 and LORD4 using 
this method (Fig. 2.8 and 2.9). Successful gene editing of the C1QTNF5S163R mutation site was 
screened by the absence of the BstNI restriction site in C1QTNF5S163R. The BstNI restriction 
site in C1QTNF5S163R can be lost by either a successful HDR event in conjunction with the 
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repair template or a NHEJ event introducing an indel mutation at the site. Gene editing using 
the plasmid-based method yielded about a 18% efficiency. Of this successful targeting and 
editing, about 50% resulted in NHEJ and about 50% in HDR. Even though HDR always resulted 
in the correction of the L-ORD mutation, some corrected clones had a different SNP 
introduced. This was again possibly due to the purity of the HDR template. The efficiency for 
complete HDR-mediated gene correction was 7.8%. The gRNA Correction did not cause off-
target editing in the wt allele nor off-target editing in top five predicted loci that are highly 
homologous to gRNA Correction (Fig. S1). However, whole genome sequencing would need 
to be performed to completely exclude any off-target editing. 
An alternative way to potentially correct the C1QTNF5S163R (c.686C>G) L-ORD mutation could 
be through base editing. Base editing is a relatively new gene editing technique relying on 
deaminases in conjunction with CRISPR/Cas9 but does not cause DSBs140,141. Therefore, no 
NHEJ could occur and no indel mutations could take place during gene editing. This could 
improve the efficiency of gene editing and could make gene editing directly in patients safer. 
Unfortunately, base editors can currently only do C-to-T and A-to-G conversions. There are 
currently no base pair editors that can change transversions142, such as G-to-C, necessary to 
correct the c.686C>G L-ORD mutation. Hypothetically, a C-to-G base editor can be 
designed143. Alternatively, a G-to-T base editor could also be used to change the L-ORD 
arginine codon back to the wildtype serine, resulting in a silent mutation. A-to-C and T-to-G 
base editors would be needed to repair the L-ORD C1QTNF5P188T (c.562C>A) and 
C1QTNF5G216C (c.646G>T) mutations respectively. Base editors will need to be designed 
regardless because deaminases have been found recently to edit off-target in RNA144. It might 
be possible to at least gene correct the c.686C>G L-ORD mutation through base editing in the 
near future. 
A C1QTNF5 KO iPSC line was generated using the CRISPR/Cas9 plasmid-based method with 
an upstream and a downstream gRNA. This method relies on NHEJ generating two DSB close 
together in exon 1 of C1QTNF5, resulting in a small deletion that leads to the generation of 
an in-frame stop codon. This strategy is highly efficient and precise compared to a single 
gRNA strategy that relies on HDR repair, because NHEJ events occur more often than HDR 
events. Therefore, fewer clones would need to be screened for the C1QTNF5 KO generation. 
Ten out of 70 clones were found to have the 107 bp deletion caused by the gene editing. Of 
these clones, three were found to have the deletion in both alleles, resulting in C1QTNF5 null 
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iPSC lines (Fig. 2.13). Neither of the two gRNAs caused off-target editing in top four predicted 
loci that are highly homologous to the respective gRNA (Fig. S2). However, whole genome 
sequencing would need to be performed to completely exclude any off-target editing. 
Together, these results show that the C1QTNF5 gene can be successfully targeted and edited 
for both gene correction of the C1QTNF5S163R L-ORD mutation, as well as gene KO. Gene 
correction was designed to be L-ORD allele-specific, which was confirmed by Sanger 
sequencing all edited clones. Correction and KO gRNAs were found to cause no off-target 
editing in loci highly homologous to the gRNAs. The isogenic lines generated here could be 
differentiated to iPSC-RPE and could provide new insights in the function of the C1QTNF5 








3.1.1 Differentiation of iPSC to RPE 
During human embryonic development optic progenitor cells (OPCs) form in the primitive 
forebrain145. The OPCs evaginate on both sides of the forebrain to form two bulges termed 
optic vesicles. OPCs of the optic vesicle are competent to become neural retina, optic stalk, 
or RPE. The optic vesicles undergo a process of cavitation, rotation, and invagination to form 
optic cups. RPE progenitor cells originate from the dorsal side of the optic cups and spread 
to surround the prospective neural retina. 
Retinal progenitor cells (RPCs) are derived of the neuroblastic layer of the optic cup. The RPCs 
divide symmetrically to increase the progenitor pool size. In addition, the RPCs eventually 
give rise to the seven mature cell types of the neural retina: RGCs, amacrine cells, bipolar 
cells, horizontal cells, rod and cone photoreceptors, and Müller glia. This requires the 
downregulation of the transcription factor MITF and upregulation of the transcription factor 
VSX2146, also known as CHX10. Conversely, if MITF is upregulated and VSX2 is downregulated, 
RPCs instead give rise to the RPE147. 
Multiple methods are reported in literature to emulate the different steps of retinal 
development in order to differentiate ESCs or iPSCs to RPE. The two main differentiation 
protocols are the continuous adherent culture method and the embryoid body (EB) method. 
The continuous adherent culture method relies on the removal of basic fibroblast growth 
factor (bFGF, also known as FGF2) from the stem cell culture. bFGF is an essential growth 
factor necessary for both pluripotency and self-renewal of human ESCs and iPSCs, and is 
therefore part of stem cell maintenance medium148-150. Moreover, bFGF is known to repress 
RPE specification145. In the continuous adherent culture method bFGF is removed after the 
cells reach confluence151-156, resulting in default differentiation. Initial pigmentation could be 
observed 1-8 weeks after bFGF removal. Pigmented foci grow over time and can be 
mechanically dissected after about 6-14 weeks. These isolated pigmented patches can then 
be cultured to generate an enriched population of RPE cells. 
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The EB method relies on the culturing of the stem cell colonies in suspended aggregates147,157. 
The EBs are maintained in a pro-neural induction medium (PIM) containing N-2 supplement, 
providing optimal growth conditions for neuronal cell types, accelerating the formation of 
neuroectoderm, and promoting retinal differentiation158. EBs are then allowed to attach to 
the culture dish which then forms neuroepithelial rosettes. The medium was then replaced 
with a retinal differentiation medium (RDM) containing B-27 supplement, known to enhance 
and accelerate retinal differentiation158. 
The continuous adherent culture method and the EB method both generate cells that have 
important RPE characteristics, in addition to the typical RPE cobble stone-like morphology 
and pigmentation. RPE generated in this way express typical RPE markers, including RPE65 
and CRALBP, which have a function in the visual cycle; MITF and PMEL, which are involved in 
melanosome development for pigmentation; BEST1, an ion channel regulator; MERTK, which 
is involved in phagocytosis; and ZO-1, a tight-junction marker for epithelial cells. 
Furthermore, RPE generated in this way establish apical/basal polarity and have the typical 
RPE ability to phagocytose POS. Stem cell-derived RPE generated by these protocols have 
also been shown to rescue visual function in RCS rats152,154. 
Both protocols can be combined to utilise the ease of the continuous adherent culture 
method and the accelerated RPE-generation of the EB method, without the need of 
additional cytokines. For this, bFGF is removed to induce default differentiation. Subsequent 
replacement of medium with PIM with N-2 supplement leads eventually to the formation of 
neuroepithelial rosettes after about two weeks. Neuroepithelial rosettes represent the early 
neural plate or neural tube stage at which cells have committed to the neural lineage and 
can be directed to differentiate to more specific neuronal fates159. At this point activin A can 
be added to favour specific differentiation towards RPE. Activin A is known to efficiently 
induce differentiation to RPE160. Pigmented foci would form and, once grown large enough, 
can be dissected out and replated to a new dish for further enrichment and expansion. The 
medium can then be replaced with RDM with B-27 supplement without retinoic acid, because 
retinoic acid is known to promote the growth of rod photoreceptors161,162 and delays RPE 





A p.S163R (c.686C>G) missense mutation is found in C1QTNF5 in patients with L-ORD80,83. 
Recently, the mutations p.P188T (c.562C>A) and p.G216C (c.646G>T) were also found to 
cause L-ORD165. C1QTNF5 is located on chromosome 11 (11q23.3), encodes for a 25 kDa 
secretory glycoprotein, and belongs to the C1QTNF family of secretory proteins166. The 
function of C1QTNF5 is still unclear. 
The C1QTNF family is involved in cellular metabolism and immunity167-169. Thus far, 17 
members of this protein family have been discovered. C1QTNF proteins are comprised of 
four domains: a N-terminal signal peptide domain, a short variable domain, a collagen G-X-Y 
repeat domain, and a C-terminal globular C1q (gC1q) domain (Fig. 3.1). The gC1q domain is 
homologous to C1q, which is a component of the classical complement pathway (see Chapter 
5). A, B, and C chains of C1q form a trimer that resembles a bouquet-like structure. Similarly, 
C1QTNF proteins form stable homotrimers and some members can also form 
heterotrimers168. C1QTNF trimers often assemble into higher order structures such as 
nonamers and dodecamers. The 3D structure of the gC1q domain is also very similar to the 
C-terminal region of the TNF homology domain167. This domain is a common feature in the 
TNF family of proteins. 
 
 
Figure 3.1 | The protein domains of C1QTNF5. All C1QTNF family members have a signal peptide 
domain (SPD), a short variable domain (SVD), a collagen domain consisting of G-X-Y repeats, and a 
globular C1q (gC1q) domain. Relative domain sizes and length of protein depicted here are from 
C1QTNF5. The three mutations known to cause L-ORD are located in the gC1q domain (arrows). 
 
C1QTNFs undergo several post-translational modifications that influence their stability and 
function169. Proline residues in the third position of the collagen G-X-Y repeat sequence can 
be hydroxylated. Furthermore, one or more G-X-K-G-(E/D) sequences are present in the 
collagen domain of C1QTNFs, except for C1QTNF4, C1QTNF12, and 
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C1QTNF15/erythroferrone. The G-X-K-G-(E/D) consensus sequence can be sequentially 
hydroxylated and glycosylated. These post-translational modifications potentially influence 
the assembly of higher-order C1QTNF structures. As recombinant C1QTNF expressed by 
bacterial systems does not have these modifications, C1QTNFs are therefore best studied in 
mammalian model systems. 
One of the best characterised members of the C1QTNF family is adiponectin. Adiponectin is 
a protein hormone exclusively expressed in adipocytes and is important for regulating 
cellular energy homeostasis, as well as glucose and lipid metabolism170,171. Adiponectin is also 
known to have anti-inflammatory functions by inhibiting macrophage phagocytic activity and 
lipopolysaccharide (LPS)-induced inflammation172. Furthermore, AMPK activation is known 
to prevent apoptosis in different cell types173-175. Adiponectin circulates in human plasma at 
relatively high concentrations, whereas other C1QTNFs are found at 1-2 orders of magnitude 
less in human circulation169. Adiponectin induces phosphorylation and activation of 5’-AMP-
activated protein kinase (AMPK) and thereby increases glucose uptake, reduces glucose 
serum levels, and increases lactate production in myocytes. Adiponectin also induces 
phosphorylation and inhibition of acetyl-CoA carboxylase (ACC) and thereby increasing fatty 
acid oxidation in myocytes and hepatocytes.  
Whilst related to adiponectin in sequence and structure, each C1QTNF member has a distinct 
tissue expression profile and function related to cellular metabolism and immunity. Similarly 
to adiponectin, C1QTNF1 and C1QTNF2 also induce phosphorylation of both AMPK and ACC, 
increase glucose uptake, reduce glucose serum levels, and promote fatty acid oxidation176,177. 
C1QTNF9 and C1QTNF13/C1QL3 also induce phosphorylation of AMPK and subsequent 
glucose uptake178,179. C1QTNF3 and C1QTNF12 have an anti-inflammatory function and, like 
adiponectin, also reduce LPS-induced inflammation in macrophages180,181. Homozygous 
missense mutations in C1QTNF4 lead to retinal degeneration, but not much is known about 
its function182. C1QTNF6 also has anti-inflammatory functions and is found to suppress the 
alternative complement pathway183,184. Mutations in C1QTNF7 were found to cause conduct 
disorder, one of the most prevalent childhood psychiatric conditions185. C1QTNF11/C1QL4 
and C1QTNF14/C1QL1 promote angiogenesis of endothelial cells186 and C1QTNF11/C1QL4 is 
also thought to regulate adipogenesis187. C1QTNF15/erythroferrone promotes iron and fatty 
acid uptake188,189. C1QTNF16/otolin-1 is part of otoconia crystals in vestibule of the inner ear 
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necessary for maintaining balance190. Not much is known yet about the function of C1QTNF8 
and C1QTNF10/C1QL2. 
The C1QTNF5 gene encodes a short-chain collagen that is highly expressed in the RPE and is 
also expressed at a lower level in adipose tissue, testes, skeletal muscle, brain, spleen, and 
uterus169. C1QTFN5 is also found in human circulation191,192. C1QTNF5 is secreted and 
associates with the cell membrane in RPE193. Monomers of C1QTNF5 assemble into trimers 
and six trimers assemble into a bouquet-like shaped octadecamer (Fig. 3.2)194,195. The 
localisation of C1QTNF5 to the cell membrane and the structural similarities with collagens 
VIII and X suggests that C1QTNF5 could also have a role in cell adhesion, cell polarisation, and 
cell-cell communication. Another possible function of C1QTNF5 is regulation of the 
complement system, like C1QTNF6, because it has a gC1q domain. The complement system 
is dysregulated in AMD (see Chapter 5). C1QTNF5 could also have a role in cellular 
metabolism like adiponectin. 
 
 
Figure 3.2 | Quaternary structure of 
C1QTNF5. C1QTNF5 forms trimers 
which assemble into a bouquet-like 
shaped octadecamer. Reproduced 
from Tu and Palczewski (2014)195. 
 
The globular domain of C1QTNF5 is about 40% homologous to that of adiponectin196. 
C1QTNF5 could therefore also have a role in the cellular response to oxidative damage and 
energy homeostasis. Recombinant C1QTNF5 is found to induce phosphorylation and 
activation of AMPK which led to an increased uptake of glucose in myocytes, similar to 
adiponectin, C1QTNF1, C1QTNF2, C1QTNF9, and C1QTNF13/C1QL3196,197. Similar to 
adiponectin, recombinant C1QTNF5 was found to inhibit reactive oxygen species (ROS) 
accumulation and caspase-3 activation, and thereby apoptosis, through activation of AMPK 
in myocytes197. Furthermore, C1QTNF5 was found to promote phosphorylation of ACC and 
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stimulate fatty acid oxidation. C1QTNF5 and C1qtnf5 expression in humans and mice 
respectively were found to be dependent on diet198. Moreover, decrease in circulating 
C1QTNF5 was found to be associated with metabolic syndrome in humans192. It is not yet 
known if C1QTNF5 also activates AMPK and regulates metabolism in RPE and the rest of the 
retina. 
The p.S163R, p.P188T, and p.G216C mutations causing L-ORD are located in the gC1q domain 
of C1QTNF5 (Fig. 3.1)165. These mutations prevent multimerisation of C1QTNF5 to 
octadecamers165,195. Moreover, the secretion of mutated protein was found to be 
impaired193. The mutated protein is retained in the endoplasmic reticulum and can still 
interact with the wild-type protein199. These changes are thought to lead to the abnormal 
changes in the extracellular matrix between the RPE and Bruch’s membrane found in patients 
with L-ORD200,201. 
Several mouse models have been generated to investigate the function of C1qtnf5. Mice with 
a C1qtnf5+/S163R knock-in show retinal abnormalities between 12 and 21 months of age, 
including RPE abnormalities, accumulation of drusen, Bruch’s membrane abnormalities, loss 
of photoreceptors, and retinal vascular leakage202. However, another C1qtnf5+/S163R knock-in 
mouse model did not recapitulate the same retinal degenerative phenotype even up to two 
years203. C1qtnf5-/- KO mice have also been generated but had no apparent retinal defects 
between four and ten months of age, the time period in which this study was conducted198. 
C1qtnf5-deficient mice had reduced fasting insulin on standard diet and had attenuated 
hepatic steatosis and improved insulin action on a high-fat diet. 
The entire C1QTNF5 gene is located within the 3′ untranslated region of the membrane 
frizzled-related protein (MFRP) gene and is co-transcribed with MFRP80,204. Dicistronic 
transcripts, like C1QTNF5 and MFRP, typically encode proteins that are involved in the same 
molecular pathways205. It is thought that 5' cap-independent ribosome recruitment and 
translation initiation has evolved to allow the cell to deal with physiological stress conditions, 
where cap-mediated initiation is repressed206. A promoter sequence has been found that 
potentially allows C1QTNF5 expression independently of MFRP207. C1QTNF5 is also found to 
interact with MFRP199,208. MFRP is a type II membrane protein with an unknown function209. 
It is thought that MFRP could be involved in lipid transport or lipid sensing in the sub-retinal 
space. Mutations in MFRP cause nanophthalmos and posterior microphthalmia210, indicating 
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that MFRP has a role in ocular development. Mfrp is mutated in the rd6 mouse model for 
retinal degeneration204. However, mutations in MFRP do not cause L-ORD. 
An important receptor for adiponectin is adiponectin receptor 1 (ADIPOR1)211,212. ADIPOR1 is 
important for the activation of the AMPK pathway and DHA transport into RPE and 
photoreceptors213. ADIPOR1 KO causes retinal degeneration, whereas adiponectin KO does 
not213. Absence of Mfrp in the rd6 mouse model for retinal degeneration causes loss of 
Adipor1 expression, specifically in the RPE and not in the photoreceptors214. It is not known 
what effect MFRP KO has on the expression of C1QTNF5. Furthermore, it is thought that one 
of the functions of C1QTNF5 is to block ADIPOR1. ADIPOR1 regulation could therefore have 
an important role in L-ORD. 
It is still not clear what the function is of C1QTNF5 and what the consequences are of the 
C1QTNF5S163R mutation on a cellular level. Studying RPE differentiated from the previously 
gene-corrected patient-derived iPSCs as well as the previously generated C1QTNF5 KO iPSCs 
(see Chapter 2) should give a better insight into the function of C1QTNF5 and how it 
contributes to macular degeneration when mutated. 
 
3.1.3 Aims and objectives 
In order to study iPSC-RPE, C1QTNF5, and the effect of the C1QTNF5S163R mutation, the 
following was carried out in this chapter: 
1. Different iPSC lines were differentiated into RPE by using a previously established 
protocol 
2. iPSC-RPE were phenotypically and functionally characterised by immunostaining for 
RPE markers, measuring their transepithelial electrical resistance, and investigating 
their capability to phagocytose POS 
3. C1QTNF5 expression, secretion, and structure in L-ORD and wt iPSC-RPE was studied 
by using qPCR and western blotting 
4. The transcriptome of L-ORD iPSC-RPE compared to its isogenic gene-corrected 
control was studied by using RNA sequencing followed by Gene Ontology enrichment 




3.2 Materials and methods 
 
3.2.1 Cell culture 
iPSCs were cultured by Dr Burr (The University of Edinburgh) and Almar Neiteler as described 
in Chapter 2 (2.2.1). 
 
3.2.2 Differentiation towards iPSC-RPE 
Differentiation was similar as described before164. The medium of the iPSCs was replaced 
with Essential 6 medium (Gibco) on day one. On day three the medium was replaced with 
PIM, consisting of Advanced DMEM/F-12 (Gibco), 2 mM GlutaMAX, and 1% N-2 supplement 
(Gibco). The medium was replaced every two to three days. PIM was supplemented with 100 
ng/ml Activin A (Peprotech, London, UK) when neural epithelia appeared around day 14. 
Medium was replaced with PIM without Activin A once pigmentation started around day 20. 
Pigmented patches were dissected with needles, digested to single cells with trypsin/EDTA, 
and transferred to a new plate coated with 1 µg/cm2 of Laminin-521 (BioLamina, Sundbyberg, 
Sweden) seven to ten days after pigmentation started. The cells were then maintained in 
RDM, consisting of 75% DMEM (Gibco), 25% F-12 (Gibco), and 2% B-27 supplement minus 
vitamin A (Gibco). The medium was replaced twice a week. RDM was supplemented with 
10% FCS for two days and was then reduced to 2% FCS until confluent. Once confluent, RDM 
without FCS was used. iPSC-RPE were used for experiments three weeks after reaching 
confluency and having regained pigmentation. 
iPSC-derived cortical astrocytes, spinal astrocytes, oligodendrocytes, and motor neurons 
were generated by Tuula Ritakari (The University of Edinburgh), Maria Stavrou (The 
University of Edinburgh), Leoli Telford-Cooke (The University of Edinburgh), and Arpan Mehta 
(The University of Edinburgh), respectively. 
 
3.2.3 Immunocytochemistry 
iPSC-RPE were washed with PBS and fixed with 4% PFA for 10 minutes. After another two 
washes with PBS the cells were permeabilised with 0.1% TritonX-100 (Sigma-Aldrich) for 15 
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minutes and subsequently blocked with 3% normal goat serum for 1 hour. Staining with the 
primary antibody was at 4 °C overnight. The cells were washed twice with PBS and 
subsequently stained with a secondary Alexa Fluor®-conjugated antibody for 30 minutes and 
counterstained with 5 µM DRAQ5™ (Abcam, Cambridge, UK) for 10 minutes. After another 
three washes with PBS, the cells were mounted in Fluorsave mounting medium (Merck 
Millipore) and imaged with a Leica DMi8 inverted microscope (Leica Microsystems). The 
antibodies and concentrations used are listed in Table S8. 
 
3.2.4 Electric cell-substrate impedance sensing 
Electric cell-substrate impedance sensing (ECIS) was performed as described before215. 
Briefly, iPSC-RPE were seeded onto ECIS® Cultureware 96-well plates (Applied BioPhysics Inc, 
Troy, NY) coated with 1 µg/cm2 of Laminin-521. The ECIS plate with iPSC-RPE was placed in 
an array holder in a humidified incubator at 37 °C with 5% CO2. iPSC-RPE were allowed to 
reach confluency and maturity as described above (see section 3.2.2) whilst impedance was 
being measured and recorded. Multiple frequency impedance measurements were recorded 
using an ECIS® Zθ instrument (Applied BioPhysics Inc) by Graham Anderson (The University 
of Edinburgh) and Dr Bagnaninchi (The University of Edinburgh). 
 
3.2.5 Transepithelial electrical resistance measurements 
The transepithelial electrical resistance (TEER) of confluent iPSC-RPE grown on transwell 
membranes with 0.4 µm pore size (Corning) coated with 1 µg/cm2 of Laminin-521 in a 12-
well plate was measured using an epithelial voltohmmeter (EVOM2; World Precision 
Instruments, Sarasota, USA) according to manufacturer’s instruction and as previously 
described216. Briefly, the electrode was sterilised with 70% ethanol prior to measurement 
with the shorter end of the electrode submerged in the medium in the cell compartment and 
the longer end of the electrode submerged in the medium outside the cell compartment. The 
net TEER was calculated by subtracting the background resistance measurement obtained 
from wells containing just medium and then multiplying the difference by the area of the 




3.2.6 Phagocytosis assay 
The phagocytosis assay was performed as described before217, with some modifications. 
Bovine rod POS (InVision BioResources, Seattle, USA) were washed three times with and 
resuspended in wash solution, consisting of 10% sucrose, 20 mM sodium phosphate buffer 
pH 7.2, and 5 mM taurine. To obtain a 2 mg/ml working solution of fluorescein-5-
Isothiocyanate (FITC), 10 mg of FITC (Invitrogen) was dissolved in 0.1 M sodium-carbonate 
buffer pH 9.5. To conjugate POS with FITC, 1.5 ml of FITC working solution was added to 5 ml 
of POS suspension and incubated at 21 °C for 1 hour whilst rotating in the dark. The POS-FITC 
conjugate was then washed twice with and resuspended in DMEM with 2.5% sucrose. 
iPSC-RPE were seeded at 7.5*103 cells/well in a 96-well plate and cultured for four weeks 
until mature and confluent. The iPSC-RPE were fed 50 POS-FITC/cell for 0.5, 1, 2, 3, or 4 hours. 
Phagocytosis was terminated by washing three times with PBS. The iPSC-RPE were then fixed 
with pre-warmed 4% PFA for 10 minutes and subsequently counterstained with 300 nM DAPI 
for 10 minutes. After three washes with PBS the cells were imaged with a Zeiss Axio Observer 
Z1 motorised inverted microscope with an automatic stage (Carl Zeiss Ltd.). 
 
3.2.7 qPCR 
iPSC-RPE cell lines were seeded at 3*105 cells/well in a 6-well plate and allowed to reach 
confluence and to mature for four weeks. RNA was extracted using TRIzol® Reagent (Ambion, 
Waltham, MA) according to manufacturer’s instructions. cDNA was made using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) according to 
manufacturer’s instructions and primers were designed by Primerdesign Ltd. (Southampton, 
UK), see Table S7 for sequences. DyNAmo ColorFlash SYBR Green kit (Thermo Scientific) was 
used in combination with a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, 
Hercules, CA). 
 
3.2.8 Denaturing and non-denaturing PAGE gels and western blotting 
For denaturing gels, confluent mature iPSC-RPE were lysed in RIPA buffer supplemented with 
Complete Mini protease inhibitor cocktail (Sigma-Aldrich) and PhosSTOP phosphatase 
inhibitor (Roche, Basel, Switzerland) and passed through a 21-gauge needle (Sterican, 
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Hessen, Germany) to shear the DNA. For non-denaturing gels confluent mature iPSC-RPE 
were lysed in Native PAGE™ Sample Buffer (Invitrogen) with 10% DDM (Invitrogen) to 
solubilise the proteins. Conditioned medium containing the secreted C1QTNF5 protein was 
also taken from mature iPSC-RPE. Cell lysate concentration was determined with a DC™ 
Protein Assay (Bio-Rad) and conditioned medium protein concentration was determined 
with a Pierce™ BCA Protein Assay Kit (Thermo Scientific). 
For denaturing gels, 20 µg of cell lysate or conditioned medium in Laemmli sample buffer 
(Bio-Rad) supplemented with 50 mM DTT was heated to 98 °C for 5 minutes and 
subsequently loaded and ran on a 12% SDS-PAGE gel. For non-denaturing gels, NativePAGE™ 
5% G-250 Sample Additive (Invitrogen) was added just before loading the samples onto the 
gel. 20 µg of cell lysate or conditioned medium were then loaded and run on a NativePAGE™ 
3-12% Bis-Tris Protein Gel (Invitrogen). 
Gels were blotted onto a polyvinylidene difluoride (PVDF) membrane (Bio-Rad), blocked with 
TBS with 5% Marvel for 1 hour at room temperature, and incubated with 1:1,000 C1QTNF5 
antibody (R&D Systems, Minneapolis, MN) overnight at 4 °C. The following day the 
membrane was incubated with 1:2,000 HRP-conjugated secondary antibody (Merck 
Millipore) for 30 minutes at room temperature. After incubation with Amersham ECL reagent 
(GE Healthcare, Little Chalfont, UK), an Amersham Hyperfilm (GE Healthcare) was exposed to 
the membrane. The same membrane was reprobed with 1:5,000 β-actin antibody (Abcam) 
for 1 hour at room temperature followed by 1:4,000 HRP-conjugated secondary antibody 
(Merck Millipore) for 30 minutes at room temperature to check for loading control. Exposed 
films were developed in a Mi-5 X-ray developer machine (Jet Xray, London, UK). The 
antibodies and concentrations used are listed in Table S9. 
 
3.2.9 RNA-seq 
For RNA sequencing (RNA-seq), total RNA was extracted from iPSC-RPE using TRIzol® reagent 
(Ambion) and the quality and quantity was assessed using RNA ScreenTape (Agilent) with a 
2200 TapeStation system (Agilent). The RNA samples were sent to Edinburgh Genomics 
(Edinburgh, UK) for RNA library preparation and sequencing. Illumina mRNA-seq libraries 
were prepared from 1 µg of total RNA using TruSeq RNA Sample Prep Kit v2 (Illumina, 
Cambridge, UK) with a 10-cycle enrichment step according to manufacturer’s protocol. Final 
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libraries were sequenced on a NovaSeq 6000 Sequencing System (Illumina) at a target depth 
of ~50 million read pairs per sample with 150 base paired-end reads. 
Reads were mapped to the primary assembly of the human (hg38) reference genome 
contained in Ensembl release 92218. Alignment was performed with STAR (version 2.5.3a)219. 
Tables of per-gene read counts were generated from the mapped reads with featureCounts 
(version 1.5.2)220. Differential expression analysis was then performed using DESeq2 (R 
package version 1.18.1)221. Sample heatmaps and PCA plots were produced using variance-
stabilized per-gene read counts. Gene ontology enrichment analysis was performed using 
topGO (R package version 2.30.1)222 and gene set analysis with the “camera” function223 from 
the R package “limma” (version 3.34.9). RNA-seq data analysis was performed by Dr Dando 
(The University of Edinburgh) and Prof Hardingham (The University of Edinburgh). 
The list of differentially expressed genes (LORD4 versus LORD4 corrected) with an adjusted 
p-value of less than 0.05 was subjected to Ingenuity Pathway Analysis (IPA; build version 
49309495; Qiagen)224 against the Ingenuity Knowledge Base, considering only relationships 
where confidence was classified as “Experimentally Observed” and species was “Human”. 
Canonical pathways enriched in the differentially expressed genes and the list of predicted 
upstream regulators was exported. Due to the high number of differentially expressed 
transcripts networks were only drawn for connected genes with a fragments per kilobase of 
transcript per million mapped reads (FPKM) of at least 10 and adjusted p-value of less than 
0.01. For the network linking C1QTNF5 to differentially expressed genes (p < 0.05) the 
network was first grown using the Ingenuity Knowledge Base considering only relationships 
where confidence was classified as either “Experimentally Observed” or “High (predicted)” 
as there were no direct connections found between the differentially expressed genes and 
C1QTNF5. RNA-seq network analysis by IPA was performed by Dr James Longden (The 
University of Edinburgh). 
 
3.2.10 Statistics 
Experiments were repeated at least three times. Statistical analysis was performed using 
Microsoft Excel version 1905 and GraphPad Prism 6 software. Student’s t-tests were used to 
determine statistical significance between groups. P-values of less than 0.05 were considered 





3.3.1 iPSC-RPE pigment and express RPE markers 
In order to study the function of C1QTNF5 and its role in macular degeneration, iPSC lines 
from two patients harbouring the heterozygous C1QTNF5S163R mutation, the corresponding 
isogenic gene-corrected lines (see Chapter 2), a healthy control line, and a C1QTNF5 KO line 
(see Chapter 2) were differentiated to RPE. 
Differentiation of iPSCs to RPE was similar to a previously published protocol164, but with 
some modifications (Fig. 3.3a). Briefly, bFGF was removed from the standard iPSC medium 
to initiate default differentiation towards neuroectoderm. The medium was replaced with 
PIM after two days. When neuroepithelial rosettes appeared, activin A was added to the 
medium until pigmentation started. Pigmented foci were mechanically dissected and 
transferred to a new plate for further enrichment in RDM. 
The resulting iPSC-RPE had a typical RPE cobble stone-like morphology and were pigmented 
(Fig. 3.3b). The iPSC-RPE also expressed typical RPE markers, including MITF, ZO-1, BEST1, 





Figure 3.3 | iPSC-RPE lines pigment and express RPE markers. iPSC to RPE protocol (a). All iPSC-RPE 
lines showed pigmentation and cobble stone morphology (b). The iPSC-RPE lines also expressed the 
RPE markers MITF, ZO-1, BEST1, and CRALBP (c). Scale bars equal 200 µm (b) and 50 µm (c). PIM = pro-




3.3.2 ECIS and TEER 
ECIS was employed to investigate if there was any difference in cell proliferation between wt 
and L-ORD iPSC-RPE during growth and maturation. With ECIS, a small non-invasive 
alternating current (1 µA) was applied to the cells using gold microelectrodes225,226. Electrical 
impedance increases as more cells attach and spread on the ECIS array microelectrodes226. 
L-ORD iPSC-RPE seemed to have a higher impedance on the ECIS array during the first 160 
hours of growth and maturation compared to its isogenic gene-corrected control (Fig. 3.4a). 
However, the impedance was found to be similar after 160 hours of cell growth. This 
difference in impedance in the initial growth phase of the L-ORD iPSC-RPE could reflect a 
difference in cell proliferation or cell adhesion to the microelectrodes. Although this 
experiment has only been performed once, it is in line with previous findings showing a 
difference in impedance between L-ORD iPSC-RPE and a non-isogenic control line215. 
iPSC-RPE were grown on porous filter supports which allows nutrient supply to the 
basolateral side and therefore promotes epithelial differentiation closer to native 
epithelium227,228. TEER can be measured to analyse the epithelial barrier function which 
reflects the quality and functional polarity of epithelial cells grown on porous filter 
supports229. The TEER for the iPSC-RPE lines was similar to human foetal RPE and iPSC-RPE 
previously described, with a TEER over 150 Ω*cm2 (Fig. 3.4b), the proposed functional 






Figure 3.4 | ECIS and TEER measurements of iPSC-RPE lines. ECIS (a) and TEER (b) was measured of 
control, C1QTNF5 KO, LORD, and LORDC iPSC-RPE grown on ECIS arrays and transwell membranes 
respectively. Dotted line demarcates proposed functional threshold. Error bars represent standard 
deviation (SD) of at least six independent experiments. 
 
3.3.3 Phagocytosis 
An important function of RPE is to phagocytose POS. iPSC-RPE were therefore tested for their 
capability to phagocytose POS. All lines used were able to phagocytose POS (Fig. 3.5). 
However, when normalised for the total number of cells, C1QTNF5 KO iPSC-RPE 
phagocytosed relatively more POS than their isogenic control (Fig. 3.5b). Moreover, also L-
ORD iPSC-RPE phagocytose more POS compared to their isogenic gene-corrected control (Fig. 






Figure 3.5 | C1QTNF5 KO and L-ORD iPSC-RPE phagocytose more POS. Control, C1QTNF5 KO, LORD3, 
and LORD3C iPSC-RPE were fed with 50 POS-FITC/cell for 0.5, 1, 2, 3, or 4 hours. After washing and 
fixation the iPSC-RPE were imaged (a). POS-FITC was quantified and divided by cell count (b). Scale bar 
equals 200 µm. Error bars represent SD of at least three independent experiments. *P<0.05 and 
**P<0.005, determined by t-test compared to respective isogenic control line. 
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3.3.4 iPSC-RPE express C1QTNF5 
All iPSC-RPE lines were found to express C1QTNF5 mRNA (Fig. 3.6). C1QTNF5 KO iPSC-RPE 
expressed significantly less C1QTNF5 mRNA, most likely due to nonsense-mediated decay 
caused by the premature in-frame stop codon. 
 
 
Figure 3.6 | C1QTNF5 mRNA 
expression in iPSC-RPE lines. 
Control, C1QTNF5 KO, LORD3, 
LORD3C, LORD4, and LORD4C iPSC-
RPE all express C1QTNF5 mRNA. 
C1QTNF5 KO iPSC-RPE express 
significantly less C1QTNF5 mRNA. 
Error bars represent SD of at least 
three independent experiments. 
*P<0.05, determined by t-test on 
ΔCT compared to isogenic control 
line. 
 
Similarly, C1QTNF5 protein was expressed in all iPSC-RPE lines, except in the C1QTNF5 KO 
line, and was also found secreted into the medium (Fig. 3.7a). C1QTNF5 was found to be 
expressed both on the apical and basal side of C1QTNF5-expressing iPSC-RPE when grown on 
transwell membranes (Fig. 3.7b). Under native physiological conditions, C1QTNF5 
multimerises into an octadecamer high molecular weight (HMW) structure and the 
C1QTNF5S163R mutant is known to destabilise this structure165,195. To investigate if the gene 
correction corrects the HMW C1QTNF5 structure, cell lysates of the iPSC-RPE lines were run 
on a native PAGE gel. L-ORD iPSC-RPE expressed less HMW C1QTNF5 and especially more 
trimer C1QTNF5 under native conditions, which was corrected in their respective gene edited 
isogenic controls (Fig. 3.7c). This indicates that the gene correction of C1QTNF5S163R does 
correct the quaternary structure of the protein. 
C1QTNF5 is also known to be expressed in the brain169. To investigate which type of cells in 
the brain express C1QTNF5, cell lysates of iPSC-derived cortical and spinal astrocytes, 
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oligodendrocytes, and motor neurons were analysed. C1QTNF5 was found to be expressed 
in cortical astrocytes and oligodendrocytes, albeit in smaller quantities than in RPE (Fig. 3.7d). 
This indicates that C1QTNF5 also has a function in these cell types. 
 
 
Figure 3.7 | iPSC-RPE express C1QTNF5 protein and L-ORD iPSC-RPE express less HMW C1QTNF5. 
iPSC-RPE express and secrete C1QTNF5 into the medium, as shown on a denaturing gel (a). All iPSC-
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RPE lines, except for C1QTNF5 KO, secrete C1QTNF5 both on the apical and basal side when grown on 
transwell membranes, as shown on a denaturing gel (b). L-ORD iPSC-RPE lines express less HMW 
C1QTNF5 in both cell lysate and in medium, as shown on a non-denaturing gel (c). C1QTNF5 was also 
found to be expressed in iPSC-cortical astrocytes, iPSC-oligodendrocytes, and iPSC-motor neurons, as 
shown on a denaturing gel (d). HMW = high molecular weight. 
 
3.3.5 RNA-seq of L-ORD iPSC-RPE 
The transcriptome of the LORD4 iPSC-RPE line was compared to its isogenic gene-corrected 
control LORD4C iPSC-RPE line using RNA-seq on three biological repeats of each. Hierarchical 
clustering and heat map analysis showed segregation between most LORD4 and LORD4C 
iPSC-RPE biological repeats (Fig. 3.8a). Principal component analysis shows the variance 
among the gene-corrected controls and the mutants and between these two groups (Fig. 
3.8b). Although PCA does not show clear grouping of the biological replicates, due to the 
variability between the biological replicates, numerous significantly differentially expressed 
genes were still found between the mutant iPSC-RPE biological replicates and their isogenic 
gene-corrected control biological replicates. In LORD4 iPSC-RPE 203 genes were found to be 
significantly upregulated and 342 genes downregulated compared to its isogenic gene-





Figure 3.8 | RNA-seq 
analysis of L-ORD iPSC-
RPE. Heat map and 
dendrogram depicting 
hierarchical clustering of 
RNA-seq reads from L-
ORD iPSC-RPE line LORD4 
and its isogenic corrected 
control LORD4C (a). PCA 
plot depicting the 
variance in transcription 
profile between the iPSC-
RPE lines and biological 
replicates (b). Scatter 
plot showing 
transcriptome reads of 
LORD4 compared to 
LORD4C. Red crosses 
denote significantly 
upregulated genes and 









Out of the 545 significantly differentially expressed genes (Table S10), several genes were 
found in literature to be involved in RPE functioning related to macular degeneration (Table 
3.1). 
 
Table 3.1 | RNA-seq Gene Ontology enrichment analysis – genes. 
a. Gene Ontology enrichment LORD4 upregulated genes 







PLIN4 3.2753 1.0561 1.3987 5.86E-05 
CAT 27.5871 11.8302 1.1229 2.22E-04 
COL8A1 175.0595 86.0702 1.0040 7.88E-04 
SULF1 177.2071 72.8288 1.1408 0.0010 
CD55 9.9747 6.3601 0.6683 0.0063 
MYRIP 38.6003 18.7759 0.9516 0.0092 
ADAMTSL1 2.7051 1.1107 1.0004 0.0100 
PTGDS 122.3596 47.1128 1.0844 0.0163 
TIMP3 903.7854 583.5120 0.6459 0.0179 
PLAG1 2.1174 1.3035 0.7152 0.0200 
SLC6A20 94.5036 49.2990 0.8831 0.0207 
C1QTNF1 8.5826 5.6379 0.6261 0.0342 
MMP17 3.5626 1.6971 0.9069 0.0356 
SGK3 11.3845 6.4815 0.7874 0.0382 
NAV3 7.3550 4.0755 0.8122 0.0400 
PLIN2 35.7211 16.8457 0.9027 0.0470 




b. Gene Ontology enrichment LORD4 downregulated genes 







ADAMTS16 27.9936 67.5930 -1.0924 2.82E-07 
LINC00461 0.5997 1.8959 -1.4268 9.45E-07 
ADAMTS18 0.6287 2.2417 -1.3336 3.02E-05 
ANO4 0.9417 2.8428 -1.1219 0.0050 
SLC6A15 27.3346 47.8335 -0.6978 0.0055 
GPM6B 9.8805 18.6140 -0.7383 0.0177 
MMP11 9.8984 18.5679 -0.7388 0.0251 
CFI 0.1006 0.4898 -1.1668 0.0271 
CCL2 16.3755 46.3386 -1.0169 0.0298 
DDR1 54.6464 82.4894 -0.5002 0.0473 
 
Using the Gene Ontology (GO) enrichment database, significantly differentially expressed 
genes between L-ORD iPSC-RPE and its isogenic gene-corrected control were found to 
differentially regulate several cellular pathways. GO gene set analysis was performed 
revealing changed cellular pathways between L-ORD iPSC-RPE and its isogenic gene-
corrected control by looking at genes that individually may not be significantly differentially 
expressed but as part of a gene set or pathway have a coherent shift in expression. 
Upregulated gene sets in L-ORD iPSC-RPE were found to have a function in the ECM, lipid 
metabolism, and cell death (Table 3.2a). In L-ORD iPSC-RPE downregulated genes were found 




Table 3.2 | RNA-seq Gene Ontology enrichment analysis – gene sets. 
a. Gene Ontology enrichment LORD4 upregulated pathways 
Notable GO terms # of genes p-value 
Basement membrane 7 0.00091 
Sterol metabolic process 5 0.00862 
Adipose tissue development 3 0.0091 
Extracellular space 60 0.01044 
Regulation of CAMKK-AMPK signaling cascade 1 0.01201 
Regulation of programmed cell death 15 0.01222 
 
b. Gene Ontology enrichment LORD4 downregulated pathways 
Notable GO terms # of genes p-value 
Extracellular space 81 0.000012 
Extracellular matrix organization 18 0.00019 
Cell surface 28 0.00034 
Cellular response to calcium ion 5 0.00357 
Extracellular region 115 0.00718 
Calcium ion binding 20 0.01151 
 
Analysis of the cellular upstream regulator network, by using IPA, revealed the 
transcriptional regulators and other important pathway regulators that control the 
differentially expressed genes between L-ORD iPSC-RPE and its isogenic gene-corrected 
control (Table S11). The p‐value of overlap measures whether there is a statistically 
significant overlap between the significantly differentially expressed genes and all genes 
that could be regulated by the upstream regulator of interest. 
Network analysis, by using IPA, of the differentially expressed genes between L-ORD iPSC-
RPE and its isogenic gene-corrected control also revealed the variety of canonical pathways 
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affected (Fig. S3). In order to reveal the most affected pathways, a subset of significantly 
differentially expressed genes was created with a FPKM of at least 10 in all biological 
repeats and an adjusted p-value of less than 0.01. This revealed two highly connected 
networks: a network enriched with genes associated with cellular metabolism (Fig. 3.9a) 
and a network enriched with genes associated with cell migration, development, and cell 







Figure 3.9 | RNA-seq Ingenuity Pathway Analysis – highly connected pathways differentially 
regulated in LORD4 and LORD4C. A subset of significantly differentially expressed genes between L-
ORD iPSC-RPE and its isogenic gene-corrected control was created with at least 10 FPKM in all 
biological repeats and an adjusted p-value of less than 0.01. This revealed two highly connected 
networks: a network enriched with genes associated with cellular metabolism (a) and a network 
enriched with genes associated with cell migration, development, and cell death and survival (b). 
Green shows upregulated and red shows downregulated significantly differentially expressed genes 
between LORD4 and LORD4C. White genes are predicted by IPA to be present in the network. 
Transcriptional regulators are indicated by a horizontal oval, receptors/enzymes/ion channels are 
indicated by a vertical oval, and all other genes were circles. 
 
Next, it was investigated how C1QTNF5 could contribute to the differences in gene 
expression between L-ORD iPSC-RPE and its isogenic gene-corrected control. Based on IPA, 
C1QTNF5 does not seem to directly regulate any of the significantly differentially expressed 
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genes (Fig. 3.10). However, some miRNAs are predicted to regulate both C1QTNF5 as well 
as some of the significantly differentially expressed genes. 
 
 
Figure 3.10 | RNA-seq Ingenuity Pathway Analysis – C1QTNF5 network. A network depicting 
C1QTNF5 and how it relates to some of the significantly differentially expressed genes between L-ORD 
iPSC-RPE and its isogenic gene-corrected control. Green shows upregulated and red shows 
downregulated significantly differentially expressed genes between LORD4 and LORD4C. White genes 
are predicted by IPA to be present in the network. Transcriptional regulators are indicated by a 







RPE generated from patient-derived stem cells are a valuable model system to study genetic 
diseases affecting the RPE. Here, I showed relatively fast and efficient generation of RPE from 
L-ORD patient-derived iPSCs and other iPSC lines. L-ORD iPSC-RPE showed differences in 
adherence to substrate, phagocytosis capability, C1QTNF5 protein structure, and gene 
expression, compared to its isogenic gene-corrected control. In addition, C1QTNF5 KO iPSC-
RPE also showed a difference in phagocytosis capability. 
iPSC-RPE were found to have a typical RPE morphology, including pigmentation, and 
expressed RPE markers (Fig. 3.3). Furthermore, iPSC-RPE also showed functional similarities 
to RPE, including having RPE-like TEER (Fig. 3.4b) and the capability to phagocytose POS (Fig. 
3.5). Therefore, iPSC-RPE resemble RPE in morphology and function. 
ECIS of iPSC-RPE revealed that L-ORD iPSC-RPE had a higher impedance during growth and 
maturation compared to its isogenic gene-corrected control (Fig. 3.4a). The higher 
impedance measured could reflect a difference in cell proliferation or cell adherence of the 
L-ORD iPSC-RPE to the ECIS microelectrodes. Although this was performed only once, the 
impedance measurements show a similar trend as what has been found before between a L-
ORD iPSC-RPE line and a non-isogenic iPSC-RPE control line215. Furthermore, it was suggested 
that the increased impedance initially measured, primarily reflected that the L-ORD iPSC-RPE 
spread and adhered more readily to the ECIS microelectrodes than the wt iPSC-RPE as the 
cells were seeded at confluence215. It is possible that the similar higher initial impedance 
measured in L-ORD iPSC-PRE and its isogenic gene-corrected control also reflects adherence 
differences rather than proliferation differences. In addition, one of the cellular pathways 
most affected in L-ORD iPSC-RPE is involved in cell migration (Fig. 3.9b). Moreover, the 
second most significant predicted upstream regulator of the differentially expressed genes 
in L-ORD iPSC-RPE, PDLIM2, regulates cell adhesion and migration (Table S11). Additional 
experiments will need to confirm the adherence and migration differences in L-ORD iPSC-
RPE. It was previously suggested that C1QTNF5S163R could lead to abnormal adhesion of RPE 
to the Bruch’s membrane because of its structural similarities with collagens80. However, it 
was found that HEK 293 EBNA cells stably transfected with either His-tagged wt C1QTNF5 or 
C1QTNF5S163R adhered less to laminin-coated plates when transfected with the latter199. It is 
possible that the cell line used is unable to properly fold C1QTNF5S163R. It is also possible that 
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the His-tag prevents proper folding of the protein or the protein adherence function. In 
addition, the His-tag could also possibly influence the assembly of C1QTNF5 into multimeric 
structures, influencing the adherence properties of C1QTNF5. 
L-ORD iPSC-RPE phagocytosed more POS (Fig. 3.5), similar to what has been found before 
(PhD thesis, Dr Borooah, The University of Edinburgh). Gene correction of C1QTNF5 reduced 
the amount of POS phagocytosed. Interestingly, C1QTNF5 KO iPSC-RPE also phagocytosed 
more POS compared to its isogenic control line. C1QTNF5 could therefore have a function in 
regulating phagocytosis. Altered phagocytosis in L-ORD RPE could influence the 
photoreceptors. Slightly increased phagocytosis could damage rod photoreceptors over the 
years and possibly cause the delayed dark adaptation in patients. 
C1QTNF5 was found to be expressed and secreted in equal amounts in both L-ORD and 
control iPSC-RPE (Fig. 3.7a). In contrast, it has been shown previously that C1QTNF5S163R is 
strongly reduced in expression and secretion in a C1QTNF5S163R-transfected cell lines165,193,199. 
L-ORD and control iPSC-RPE also both secreted C1QTNF5 in equal amounts both apically and 
basally (Fig. 3.7b). In contrast, it was previously found that C1QTNF5S163R was preferentially 
basolaterally secreted in C1QTNF5S163R-transfected mouse RPE231 and the human hTERT RPE-
1 cell line165. These differences in protein expression and secretion could be due to the 
difference between the iPSC-RPE used in this study and cell lines used in the previous studies. 
Another explanation could be that the polyclonal antibody used in this study recognises more 
C1QTNF5 epitopes than the monoclonal antibody for C1QTNF5 or tagged C1QTNF5 used in 
the previous studies. Furthermore, C1QTNF5 was tagged in these studies, which could 
influence proper folding of the protein and the assembly into multimeric structures. 
The destabilisation of the C1QTNF5 multimeric structure in L-ORD iPSC-RPE was similar as 
what has been predicted before in silico and has been found before in a hTERT RPE-1 
C1QTNF5-transfected cell line165. L-ORD iPSC-RPE showed a marked reduction in HMW 
C1QTNF5 oligomers caused by C1QTNF5S163R (Fig. 3.7c). Furthermore, there was a notable 
increase in C1QTNF5 trimers in L-ORD iPSC-RPE. This could indicate that wt C1QTNF5 and 
C1QTNF5S163R were still able to oligomerise with the collagen domain to form trimers, but 
assembly of the HMW octadecamer structure seems to be impaired by the p.S163R mutation 
in the gC1q domain. The octadecamer is predicted to be the functional unit of C1QTNF5195 
and therefore the destabilisation of the octadecamer by C1QTNF5S163R could affect the 
function of C1QTNF5. 
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C1QTNF5 was also found to be expressed in iPSC-derived cortical astrocytes and 
oligodendrocytes, but not in spinal astrocytes and motor neurons (Fig. 3.7d). Interestingly, of 
these cell types found in the brain, astrocytes and oligodendrocytes can also be found in the 
eye. Oligodendrocytes are also part of the optic nerve. Retinal astrocytes mature from 
astrocyte progenitor cells and immature astrocytes that migrate into the neural retina from 
the optic disc232. C1QTNF5 could have a similar function in cortical astrocytes and 
oligodendrocytes as in RPE. Moreover, the C1QTNF5S163R mutation could possibly also affect 
these cell types. 
Retinal astrocytes and Müller glia are the macroglia of the retina8. Macroglia provide 
metabolic and functional support, protect from oxidative stress, and maintain a homeostatic 
environment for retinal neurons. In the retina, astrocytes are essential for the development 
of retinal vasculature through angiogenesis233. In the brain, astrocytes are an important 
source of inflammatory chemokines234 and likely also in the retina. Astrocytes can become 
activated, called reactive astrogliosis, which can be triggered by injury. In AMD human retinal 
tissue, hypertrophic astrocytes were found to have phagocytosed RGCs, and astrocytes were 
found to pass through the inner limiting membrane and form a glial membrane in the 
vitreous humour of the eye together with Müller glia235. Like Müller glia, reactive astrogliosis 
can contribute to angiogenesis and CNV by increased expression of VEGF236. Astrocytes are 
also known to express various complement system proteins8,237 and express C5a receptor238. 
Therefore, retinal astrocytes play an important role in AMD pathology and possibly also in L-
ORD. Expression of C1QTNF5S163R by retinal astrocytes possibly affects their function which 
could contribute to the L-ORD phenotype. 
The RNA-seq data revealed that the iPSC-RPE expressed all the 154 RPE signature genes239 
and most of them at relatively high levels. Nine out of 154 signature genes were found to be 
differentially expressed between the L-ORD iPSC-RPE and its isogenic gene-corrected control 
(Table 3.1). GPM6B has been associated with X-linked retinitis pigmentosa239. MYRIP is 
involved in melanosome transport239. SNPs in NAV3 and SLC6A20 have been associated with 
AMD as well as a SNP in NAV3 is associated with dominant cavitary optic disc anomalies and 
a SNP in SLC6A20 is associated with dominant hereditary vascular retinopathy239. PTGDS is a 
melanocyte marker239. The other four genes PLAG1, SGK3, SLC6A15, and SULF1 have no 
known function in RPE yet. 
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Some genes typically associated with AMD were also found to be differentially expressed in 
L-ORD iPSC-RPE. SNPs near COL8A1 and DDR1 have been associated with AMD58 and these 
genes were found to be respectively significantly upregulated and downregulated in L-ORD 
iPSC-RPE (Table 3.1). However, their role in AMD pathology is still unclear. 
GO gene set enrichment analysis and IPA of the RNA-seq data revealed various significant 
ECM (Table 3.2) as well as cell migration (Fig. 3.9b and Table S11) changes respectively in L-
ORD iPSC-RPE compared to its isogenic gene-corrected control. This is consistent with the 
ECIS recordings that show that L-ORD iPSC-RPE possibly adhere differently to the substrate 
compared to its isogenic gene-corrected control (Fig. 3.4a). Several ECM remodelling proteins 
in particular were found to be significantly differentially expressed in L-ORD iPSC-RPE. It is 
therefore possible that C1QTNF5S163R causes changes in the ECM that change the adhesion 
properties of RPE. 
In particular, several MMP and MMP regulating proteins were found to be significantly 
differentially expressed in L-ORD iPSC-RPE (Table 3.1 and Fig. S3). MMPs play an important 
role in ECM remodelling (see Chapter 1). TIMP3 and MMP17 were significantly upregulated 
and ADAMTS18 and MMP11 were significantly downregulated in expression in L-ORD iPSC-
RPE (Table 3.1). Mutations in TIMP3 can cause SFD, a disease rather similar to L-ORD (see 
Chapter 1), whilst a mutation in ADAMTS18 can cause autosomal recessive early onset severe 
retinal dystrophy92. ADAMTS18 is an MMP like MMP11 and MMP17, and TIMP3 is an MMP 
inhibitor. ADAMTS16 was also found to be significantly downregulated like ADAMTS18 (Table 
3.1b). ADAMTS16 is not well characterised yet but is structurally very similar to ADAMTS18240. 
ADAMTS-like (ADAMTSL) proteins are thought to regulate ADAMTS function240. ADAMTSL1 
was also found to be significantly upregulated in L-ORD iPSC-RPE (Table 3.1a). It is thought 
that dysregulated MMP pathways are the cause of deposit formation in AMD241. MMP9, 
when mutated, was found to have an important role in the development of AMD242. It is 
therefore possible that the different expression of MMPs and MMP regulators found in L-
ORD iPSC-RPE contribute to the L-ORD phenotype in a similar manner as in AMD. 
A recent genome-wide association study identified several loci associated with macular 
thickness243. Of the genes most significantly associated with macular thickness, LINC00461 
was found to be significantly downregulated and SLC6A20 significantly upregulated in 
expression in L-ORD iPSC-RPE (Table 3.1). However, the mechanism of how these genes affect 
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macular thickness is not yet known. Nonetheless, these genes could possibly explain the 
changes in macular thickness found in L-ORD. 
The genes PLIN2 and PLIN4 were both found to be significantly upregulated in L-ORD iPSC-
RPE in the RNA-seq data (Table 3.1a). PLIN2 encodes for adipose differentiation-related 
protein (ADRP). ADRP is a structural component of retinyl ester storage structures, 
specialised lipid droplets (LDs) in RPE that are also called retinosomes244. PLIN2 expression is 
upregulated in RPE fed with PUFAs, including DHA245. PLIN4 is thought to be important for 
the stabilisation of LDs246. LDs function as neutral lipid stores. LDs are also mobilised during 
autophagy to support autophagic membrane formation247. Mice with Plin2 exon 2 and 3 
deleted were found to have aberrant trafficking of all-trans-retinyl esters in RPE caused by 
abnormal maintenance of retinosomes in the dark-adapted state248. Moreover, the mice 
were found to have delayed dark adaptation. Patients with L-ORD also have a delayed dark 
adaptation. It is possible that the increased expression of PLIN2 results in abnormal 
retinosomes, followed by aberrant trafficking of all-trans-retinyl esters in L-ORD RPE, and 
resulting in delayed dark adaptation in L-ORD patients. Increased formation of LDs caused by 
overexpression of PLIN4 can result in lipotoxicity and subsequent neurodegeneration in 
Parkinson’s disease249. Increased PLIN4 expression in L-ORD RPE could possibly also 
contribute to RPE degeneration through lipotoxicity. Altered expression of PLINs, increased 
phagocytosis, and dysregulated lipid metabolism (see below) could all contribute to altered 
delay adaptation in patients with L-ORD. 
GO gene set enrichment analysis of the RNA-seq data revealed lipid metabolism changes and 
changes to the AMPK signalling pathway in L-ORD iPSC-RPE compared to its isogenic gene-
corrected control (Table 3.2a). Furthermore, IPA of the RNA-seq data revealed metabolic 
changes between L-ORD iPSC-RPE compared to its isogenic gene-corrected control (Fig. 3.9a) 
and that AMPK is an important upstream regulator of some of the significantly differentially 
expressed genes (Table S11). The expression of C1QTNF1 and HMGCS2 were significantly 
upregulated in L-ORD iPSC-RPE (Table 3.1a). Both genes are involved in lipid metabolism. 
C1QTNF1 increases β-oxidation of fatty acids through AMPK pathway activation176. RPE can 
catabolise saturated fatty acids through β-oxidation250. In addition, RPE were found to be 
able to use fatty acids to produce ketone bodies, like the liver251. β-oxidation generates 
acetyl-CoA which subsequently enters the tricarboxylic acid (TCA) cycle, but a fraction is used 
in the ketogenic pathway which ultimately produces β-hydroxybutyrate (β-HB). β-HB is a 
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ketone body that effectively functions as an energy storage unit that can be metabolised at 
a later time point. RPE were found to produce and secrete β-HB apically through ketogenesis 
of palmitate251. β-HB could therefore possibly be used by the retina as a substrate for 
oxidative metabolism. The rate of β-HB production is dependent on HMGCS2 expression and 
activity. It is therefore possible that L-ORD iPSC-RPE increase lipid metabolism as well as 
ketogenesis to deal with cellular stress. 
Catalase was significantly upregulated in L-ORD iPSC-RPE (Table 3.1a and Fig. 3.9). Catalase 
is an important anti-oxidant to protect the RPE from oxidative stress252 (see Chapter 4). This 
could indicate that L-ORD iPSC-RPE are oxidatively stressed and therefore increase the 
expression of catalase. 
Complement system regulator proteins were also found to be significantly differentially 
expressed in L-ORD iPSC-RPE. CFI was significantly downregulated and CD55 was significantly 
upregulated (Table 3.1). CFI and CD55 both interact with C3b and inactivate it (see Chapter 
5). CD55 can also work in concert with CFH to protect self from complement system-
mediated attack. Mutations in CFI, CD55, and CFH are associated with AMD. Dysregulation 
of complement regulator proteins therefore could possibly also contribute to the L-ORD 
phenotype that is similar to AMD. 
CCL2 was found to be significantly downregulated in expression in L-ORD iPSC-RPE in the 
RNA-seq data (Table 3.1b). C-C Motif Chemokine Ligand 2 (CCL2), also known as monocyte 
chemoattractant protein-1 (MCP-1), is a chemokine that has chemotactic activity for 
monocytes and basophils. CCL2 is thought to play a role in AMD CNV formation together with 
VEGF253. It is thought that ocular‐infiltrating macrophages attracted by CCL2 play an 
important role in CNV formation. Depletion of macrophages was found to reduce CNV 
formation254,255. Additionally, deficiency of CCR2, the receptor for CCL2, reduces CNV in 
mice256. DHA was also found to reduce CCL2 expression via a PPAR-γ and NF-κB-dependent 
pathway in RPE257. DHA may therefore also potentially reduce CNV formation. CCL2 can also 
attract microglia in the retina. Microglia are also known to phagocytose debris in the retina. 
Patients with L-ORD are found to develop CNV only at a late stage in the disease81. It is 
possible that CNV formation is inhibited at the earlier stages of L-ORD through the 
downregulation of CCL2 expression and subsequent reduced macrophage infiltration in the 
retina. Furthermore, macrophages are also thought to play a role in the clearance of sub-RPE 
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debris. Downregulation of CCL2 in L-ORD RPE could therefore possibly contribute to drusen 
formation. 
Calcium regulation is important for normal RPE functioning. Ca2+ is known to be important 
for POS phagocytosis and for VEGF secretion by RPE17. Several genes involved in Ca2+ 
regulation were significantly differentially expressed (Fig. S3). Pathways involved in Ca2+ 
binding and the response to Ca2+ were downregulated in L-ORD iPSC-RPE (Table 3.2b). 
Notably, ANO4 expression was significantly downregulated in L-ORD iPSC-RPE compared to 
its isogenic gene-corrected control (Table 3.1b). ANO4 encodes for anoctamin-4 which is a 
Ca2+-dependent non-selective cation channel in RPE258. Anoctamins are known to be involved 
in Ca2+ regulation in RPE259. Dysregulation of Ca2+ signalling through mutations in BEST1 is 
known to cause macular dystrophy42,43. Therefore, it is possible that aberrant expression of 
several genes involved in Ca2+ regulation could contribute to the macular degenerative 
phenotype of L-ORD. 
These results show that iPSC-RPE can be generated and resemble native RPE in morphology 
and functionality. L-ORD iPSC-RPE differed from their isogenic gene-corrected control in 
phagocytosis capability, C1QTNF5 protein structure, gene expression, and possibly in cellular 
adherence function. Many of the transcriptomic changes found fit the clinical presentation 








4.1.1 Oxidative stress 
The mitochondria are the major source of cellular ROS generation260. The principal function 
of mitochondria is to produce ATP for cellular energy through oxidative phosphorylation, in 
addition to the oxidation of metabolites by the Krebs cycle and β-oxidation of fatty acids. 
Oxidative phosphorylation occurs in protein complexes in the inner mitochondrial 
membrane, via a process known as the electron transport chain (ETC). The ETC is a cascade 
of redox reactions that produce ATP. However, about 1-2% of electrons from the ETC can 
leak and react with oxygen to generate superoxide (O2·-) radical, which also serves as the 
precursor to most ROS. 
Mitochondria are an important target for ROS because of the generation of ROS in the ETC260. 
Mitochondria therefore have an elaborate antioxidative defence. Within mitochondria, 
superoxide dismutase (SOD) can convert O2·- into hydrogen peroxide (H2O2). The most 
important mitochondrial antioxidant is glutathione (GSH). In addition, the two GSH-linked 
antioxidant enzymes glutathione peroxidase 1 (GPX1) and glutathione peroxidase 4 (GPX4) 
are also essential to the mitochondrial antioxidative defence260. GPX1 and GPX4 catalyse the 
reduction of H2O2 and lipid hydroperoxide (LOOH) respectively, with GSH as the electron 
donor. 
The cell is said to be oxidatively stressed when the levels of ROS are high enough to damage 
the cell. In this case, the levels of ROS are higher than the antioxidant defence can cope with. 
Depending on the impact of the high levels of ROS, the cell could either repair the damage 
or trigger pathways leading to cell death. ROS can cause damage to DNA, lipids, and proteins. 
However, low levels of mitochondrial ROS act as important signalling molecules in cellular 
differentiation, tissue regeneration, and prevention of ageing261. Numerous factors can 
significantly increase cellular ROS generation, including ultraviolet (UV) radiation, air 





ROS encompass partially reduced oxygen-containing molecules, including O2·-, free radicals 
such as hydroxyl radical (HO·), and peroxides such as H2O2. Free iron (Fe2+) can react with 
H2O2 to form HO·, H2O, and ferric iron (Fe3+) through the Fenton reaction. O2·- can react with 
Fe3+ through the Haber-Weiss reaction, forming O2 and Fe2+. Fe2+ can subsequently be used 
again for the Fenton reaction, thus forming a redox cycle. However, O2·- can also be 
protonated, forming hydroperoxyl (HO·2). Subsequent protonation of HO·2 forms H2O2 for the 
Fenton reaction. 
Lipid peroxidation is caused by ROS attacking double carbon-carbon bonds in lipids, causing 
the breakdown of the double bond. Polyunsaturated fatty acids (PUFAs) are especially 
susceptible to this due to their multiple double bonds. Lipid peroxidation leads to the 
abstraction of a hydrogen from a carbon and insertion of an oxygen, resulting in lipid peroxyl 
radicals (LOO·) and LOOH262. There are three steps of the lipid peroxidation process: initiation, 
propagation, and termination262. Oxidants like HO· and HO·2 can abstract the allylic hydrogen 
from a lipid, forming the lipid radical (L·) in the initiation phase263. In the propagation phase, 
L· subsequently reacts with oxygen forming LOO· which can again subtract a hydrogen from 
a lipid forming another L·, thus forming a chain reaction. LOOH is also formed in this reaction. 
Antioxidants like vitamin E can donate a hydrogen to LOO· in the termination phase. This 
results in a vitamin E radical that reacts with another LOO·, forming non-radical products. 
Lipid peroxidation can produce a wide variety of oxidation products in addition to the primary 
product LOOH263. Many different aldehydes can be formed as secondary products during lipid 
peroxidation, including propanal, hexanal, 4-hydroxynonenal (4-HNE), and malondialdehyde 
(MDA). Of these secondary products, MDA is the most mutagenic and 4-HNE the most 
toxic264,265. 4-HNE rapidly reacts with thiols and amino groups, explaining its high toxicity266. 
MDA has specific epitopes that can trigger an immune response267. 4-HNE and MDA are also 
found to reduce lysosomal degradation of phagocytosed POS in RPE268. Moreover, impaired 
lysosomal degradation caused by these lipid peroxidation products lead to transcytosis of 




4.1.3 Oxidative stress in RPE and AMD 
Oxidative stress is commonly attributed to age-associated pathology in many diseases with 
damage from oxidative stress accumulating during ageing270. In addition, the antioxidant 
capacity diminishes and the efficiency of repair systems is compromised with age271,272. 
Oxidative stress also has an important role in the initiation and progression of AMD273,274. 
Smoking, causing oxidative stress, also increases the risk of developing AMD274-277. 
Antioxidants, such as vitamin C, vitamin E, β-carotene, and zinc, have been found to 
ameliorate AMD273. 
Various stimuli can induce different forms of oxidative stress in the eye278. Proportionally 
compared to the rest of the body, the retina consumes the most oxygen and therefore has 
several adaptations to deal with oxidative stress279. In the retina, the RPE are continuously 
exposed to oxidative stress. RPE metabolise and recycle POS17,280, have large oxygen fluxes 
near the plasma membrane16,17, and are exposed to light17,279. Therefore, RPE need to be well 
adapted to handle oxidative stress. 
RPE have several specific adaptations to deal with oxidative stress. There are several 
antioxidant enzymes including SOD, catalase, GPX, and antioxidative vitamins, such as 
vitamin C and vitamin E, all of which protect the RPE from oxidative stress252. The enzyme 
catalase is important for RPE protection from ROS produced during phagocytosis280,281. RPE 
also produce melanin in their melanosomes to absorb scattered light and thereby prevent 
excessive photo-oxidation in the retina and subsequent oxidative stress. Therefore, the RPE 
also provides protection from oxidative stress for the rest of the retina. 
An important function of RPE is to phagocytose POS22,23. POS are enriched with PUFAs, to the 
point that POS possess the highest relative concentration of PUFAs compared to all other 
body tissues282. The high amount of double bonds in PUFAs make them susceptible to 
oxidation, also called lipid peroxidation. POS phagocytosed by RPE also contain complex 
aggregates termed lipofuscin283. 
Lipofuscin are formed by autofluorescent lipid-protein complexes and accumulate in 
lysosomes of RPE with age284,285. The autofluorescent nature of lipofuscin is also the cause of 
the autofluorescence of the fundus286, making confocal laser scanning ophthalmoscopy and 
fundus photography possible. Lipofuscin accumulation has been associated with cellular 
senescence and high levels in RPE lead ultimately to photoreceptor degeneration287. 
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Lipofuscin contain lipid peroxidation products, including 4-HNE and MDA288. 2-[2,6-dimethyl-
8-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1E,3E,5E,7E-octatetraenyl]-1-(2-hydroxyethyl)-4-[4-
methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1E,3E,5E-hexatrienyl]-pyridinium (A2E), also 
known as N-retinylidene-N-retinylethanolamine, is a blue light-excitable fluorophore that is 
an important component of lipofuscin. Photoinduction of lipofuscin can lead to the 
generation of singlet O2, O2·-, H2O2, and LOOH289. Blue light radiation of A2E leads to 
photooxidation in RPE290 and it is thought that blue light radiation of A2E in lipofuscin causes 
the production of the secondary lipid peroxidation products 4-HNE and MDA in RPE291. 
Docosahexaenoic acid (DHA; 22:6) is an omega-3 PUFA that is relatively rare in human tissue. 
However, DHA accounts for 60% of the PUFAs in the retina, with its highest concentration in 
POS282. DHA is an essential structural component of the cell membrane in POS292. However, 
DHA is the most oxidizable fatty acid in humans282. RPE are constantly exposed to high 
concentrations of DHA through phagocytosis of POS and through transport of DHA from the 
choriocapillaris to the photoreceptors for photoreceptor membrane biogenesis293. Oxidative 
stress can therefore potentially cause lipid peroxidation of DHA in RPE, leading to RPE 
damage and possibly cell death. In addition, oxidation of DHA can result in a very reactive 
product, 4-hydroxy-7-oxohept-5-enoic acid (HOHA). 
Carboxyethylpyrrole (CEP) protein adducts are formed by HOHA, an oxidation product 
unique to DHA294. CEP forms when the aldehyde group on HOHA binds to an ε-lysyl amino 
group of a protein. CEP adducts are found to be more abundant in AMD retinal tissue, 
specifically in the RPE, Bruch’s membrane, and choroid73. In addition, CEP adducts are also 
found in AMD drusen73 and in lipofuscin283. These adducts have been shown to stimulate 
angiogenesis295,296. Moreover, mice immunised with CEP adducts develop a gaAMD-like 
phenotype, indicating a role for CEP adducts in the aetiology of AMD297. CEP adducts were 
also found to be elevated in the plasma of patients with AMD294. CEP adducts could therefore 
play a role in AMD pathology and possibly function as a biomarker for AMD. 
Increased iron accumulation is found within the retina of AMD patients298,299, which is 
thought to promote oxidative stress through the Fenton reaction. Iron was also recently 
found to promote oxidative cell death caused by bisretinoids in the retina300, the precursor 




Although the lens in the eye blocks most of UV radiation, some UV can still penetrate the eye 
and reach the retina to potentially cause photo-oxidation. UV is associated with various 
ocular diseases301. UV light comprises light with a wavelength between 100-400 nm and can 
be categorised into UVA (315-400 nm), UVB (280-315 nm), and UVC (100-280 nm). Light with 
a longer wavelength carries less energy and therefore has less potential to do damage but 
can penetrate deeper into tissue. About 1% of UV below 340 nm and 2% of UV between 340-
360 nm reaches the retina302. It is, however, still uncertain if UV radiation can contribute to 
the onset and progression of AMD301. 
Oxidative stress can also lead to induced cellular senescence in RPE79. Oxidative stress-
induced cellular senescence was shown to increase the expression of VEGF and reduce the 
expression of CFH303. However, prolonged severe oxidative stress can lead to cell death. In 
addition, oxidative stress makes the RPE more susceptible to complement system-mediated 
cell death304. 
 
4.1.4 Oxidative stress-mediated cell death in RPE 
Oxidative stress generally leads to two different forms of cell death: apoptosis and 
necrosis305. Apoptosis is a regulated form of cell death and necrosis is considered to be a non-
regulated form of cell death. Oxidative stress by H2O2 in RPE has been shown to lead to 
necroptosis, rather than apoptosis306. Necroptosis is a regulated form of necrosis307. This cell 
death pathway is activated by TNFα and regulated by receptor-interacting protein kinases 
(RIPKs)307-309.  
TNFα can activate different signalling pathways through its receptor TNFR1, including cell 
survival, apoptosis, and necroptosis309. RIPK1 is recruited to activated TNFR1 and regulates 
the decision between the three different downstream pathways. Normally, necroptosis is 
inhibited by caspase-8, which cleaves both RIPK1 and RIPK3. When not cleaved, RIPK1 and 
RIPK3 are autophosphorylated and together form a complex termed the necrosome. The 
necrosome functions as a signalling platform that binds to and activates regulators of 
different cellular pathways, including mitochondrial fragmentation, metabolism, autophagy, 
and growth factor signalling. An important downstream effector of the necrosome is mixed 
lineage kinase domain-like protein (MLKL)310. RIPK3 phosphorylates MLKL and thereby causes 
its oligomerisation and subsequent translocation to cellular membranes311-313. MLKL 
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activation by RIPK3 has been found to be both necessary and sufficient to cause necroptosis 
through membrane permeabilization. 
Ferroptosis is another form of regulated necrotic cell death that can be caused by oxidative 
stress. Ferroptosis is an iron- and PUFA-dependent form of cell death caused by lipid 
peroxidation in plasma membranes314. Human cells were found to undergo ferroptosis when 
oxidatively stressed with tert-butyl hydroperoxide (tBHP)315. tBHP was also recently shown 
to induce ferroptosis in RPE316. 
Ferroptosis can be induced by changes in signalling and membrane transport processes. 
Central in the regulation of ferroptosis is the glutathione peroxidase GPX4. GPX4 is the only 
known enzyme that can reduce LOOH in cellular membranes317. Inactivation or inhibition of 
GPX4 induces ferroptosis318. GPX4 inhibition has been shown to induce PUFA peroxidation 
and the generation of fatty acid radicals. An important regulator of cell membrane lipid 
composition is acyl-CoA synthetase long-chain family member 4 (ACSL4). ACSL4 catalyses the 
activation of PUFAs by esterification, producing acyl-CoA. Acyl-CoA is an intermediate in 
various metabolic pathways, including phospholipid production for membrane biogenesis. 
ACSL4 has been shown to create the right membrane lipid composition for the induction of 
ferroptosis319. It was subsequently found that specifically phosphatidylethanolamine (PE) 
phospholipids produced by ACSL4 cause ferroptosis320. PE produced by ACSL4 is inserted into 
membrane phospholipids by lysophosphatidylcholine acyltransferase 3 (LPCAT3). LPCAT3 has 
been therefore also found to be important for the induction of ferroptosis320,321. 
Still much is unknown about RPE cell death in response to oxidative stress and how this could 
be prevented for possible therapy development. 
 
4.1.5 Aims and objectives 
In order to study the response of RPE in general and L-ORD iPSC-RPE to oxidative stress, the 
following was carried out in this chapter: 
1. The mode of cell death in RPE cell lines in response to different types of oxidative 
stress was investigated by cell viability assays, immunostaining, qPCR, and western 
blotting 
2. The response of L-ORD iPSC-RPE to different types of oxidative stress was 
investigated by cell viability assays and immunostaining  
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4.2 Materials and methods 
 
4.2.1 Cell culture 
ARPE-19 (ATCC, Manassas, VA) and hTERT RPE-1 (ATCC) immortalised cell lines were cultured 
and maintained in DMEM/F12 (Gibco) supplemented with 10% foetal calf serum (FCS; Gibco) 
and L-glutamine (Gibco) at 37 °C and 5% CO2. For experiments, cells were split and seeded in 
DMEM/F12 supplemented with 1% FCS and L-glutamine unless otherwise stated. 
iPSCs were cultured as described in Chapter 2 (2.2.1) and differentiated to RPE as described 
in Chapter 3 (3.2.2). 
 
4.2.2 Fatty acid-BSA conjugation 
Palmitic acid (PA; Sigma-Aldrich) and DHA (Sigma-Aldrich) were conjugated to fatty acid-free 
bovine serum albumin (BSA; Sigma-Aldrich) as previously described322, but with some 
modifications. Briefly, PA and DHA were dissolved in 50% ethanol to 150 mM at 90 °C and 70 
°C respectively. The dissolved fatty acids were then immediately diluted, using prewarmed 
tips, in prewarmed 10% fatty acid-free BSA solution to 7.5 mM whilst stirring. This was 
incubated at 37 °C for 1 hour to achieve BSA-fatty acid conjugation. The conjugated BSA-fatty 
acids were 0.22 µm filter-sterilised, aliquoted, and stored at -20 °C. Conjugated BSA-fatty 
acids were used in medium at a final concentration of 500 µM fatty acid and 0.67% BSA unless 
otherwise stated. 
 
4.2.3 Cell viability and toxicity assays 
RPE cell lines were seeded at 7.5*103 cells/well in a 96-well plate. The following day the cells 
were pre-treated for 24 hours with 40 µM Z-VAD-FMK (Merck Millipore), 40 µM Necrostatin-
1 (Nec-1; Cayman Chemical, Ann Arbor, MI), 1 µM GSK2791840B (GSK’840B; 
GlaxoSmithKline, Brentford, UK), 1 µM Necrosulfonamide (NSA; Merck Millipore), or 5 µM 
Ferrostatin-1 (Fer-1; Sigma-Aldrich). Pre-treatment with 500 µM deferoxamine (DFO; Sigma-
Aldrich) was 1 hour before injury. The cells were then treated with a final concentration of 
500 µM H2O2 (Sigma-Aldrich) for 6 hours or 500 µM DHA for 18 hours at 37 °C and 5% CO2. 
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After treatment, the cells were incubated with PrestoBlue (Invitrogen) in medium with 1% 
FCS and L-glutamine for 1 hour at 37 °C and 5% CO2. The medium with PrestoBlue was then 
transferred to a black 96-well assay plate and read with a GloMAX plate reader (Promega). 
iPSC-RPE were seeded at 7.5*103 cells/well in a 96-well plate and cultured for four weeks 
until mature and confluent. The medium was replaced with DMEM without additions two 
days before H2O2, DHA or tBHP treatment. The cells were treated with different 
concentrations of H2O2, DHA or tBHP for 24 hours at 37 °C and 5% CO2. The medium was 
subsequently replaced with DMEM without additions and the cells were incubated for 
another 24 hours at 37 °C and 5% CO2. The cells were stained with 3 µg/ml Hoechst and 6 
µg/ml propidium iodide (PI) for 20 minutes at 37 °C and 5% CO2, and subsequently fixed with 
pre-warmed 4% PFA for 10 minutes. After three washes with PBS the cells were imaged with 
a Zeiss Axio Observer Z1 motorised inverted microscope with an automatic stage (Carl Zeiss 
Ltd.). 
iPSC-RPE were seeded at 7.5*103 cells/well in a 96-well plate and cultured for four weeks 
until mature and confluent. The medium was replaced with DMEM without phenol red 
(Gibco) and without additions one day before UV exposure. The cells were exposed to UV 
light (290 nm) for 24 hours at 37 °C and 5% CO2. The medium was subsequently replaced with 
DMEM without additions and the cells were incubated for another 24 hours at 37 °C and 5% 
CO2. The cells were then stained with 0.2 µM DRAQ7 and trypsinised. The samples were kept 
on ice until analysis with a NovoCyte flowcytometer (Acea Biosciences Inc, San Diego, CA). 
UV light exposure and flowcytometric analysis were carried out by Graham Anderson (The 




(C11-BODIPY581/591; Invitrogen) was used to assess lipid peroxidation in RPE cell line 
membranes. C11-BODIPY581/591 incorporates into membranes and the excitation and 
emission fluorescence spectra of this lipid analogue both shift to shorter wavelengths when 
oxidised323. 
Cells were treated with inhibitors as described above (see section 4.2.3) in 96-well plates. 
The cells were stained with 3 µM C11-BODIPY581/591 before H2O2, DHA or POS treatment. H2O2 
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or DHA treatment was done as described above (see section 4.2.3). POS-FITC were prepared 
as described before (see section 3.2.6). After treatment, the cells were washed with PBS and 
subsequently stained with 6 µg/ml Hoechst 33342 (Sigma-Aldrich). The cells were then fixed 
with prewarmed 4% PFA for 10 minutes at 21 °C and washed with PBS. For pMLKL and PI 
staining, the cells were washed with PBS after H2O2 treatment and subsequently stained with 
3 µg/ml PI (Sigma-Aldrich) for 20 minutes at 21 °C. The cells were then fixed with prewarmed 
4% PFA for 10 minutes and permeabilised with 0.1% Triton™ X-100 (Sigma-Aldrich) for 15 
minutes at 21 °C. The cells were then incubated with 1:100 phospho S358 MLKL antibody 
(Abcam) in 3% goat serum for 1 hour at 4 °C. After two washes with PBS, the cells were 
incubated with 1:250 Alexa Fluor 647 antibody (Molecular Probes, Eugene, OR) for 30 
minutes at 21 °C covered from light. After another two washes with PBS, the nuclei were 
counterstained with 300 nM DAPI (Biotium) for 10 minutes at 21 °C covered from light, 
followed by another three washes with PBS. Stained cells were imaged with a Leica DMi8 
inverted microscope (Leica Microsystems). The antibodies and concentrations used are listed 
in Table S8. 
iPSC-RPE were seeded at 7.5*103 cells/well in a 96-well plate and cultured for four weeks 
until mature and confluent. Pre-treatment with inhibitors was done as described above (see 
section 4.2.3). The iPSC-RPE were treated with 1 mM H2O2 for 18 hours. The cells were then 
fixed, permeabilised, stained with phospho S358 MLKL antibody and DAPI, and imaged as 
described above. 
 
4.2.5 Flow cytometry for lipid peroxidation 
RPE cell lines were seeded and treated with inhibitors in 96-well plates as described above 
(see section 4.2.3). Medium with inhibitors was transferred to a new plate and kept at 37 °C 
and 5% CO2. The cells were then incubated for 1 hour at 37 °C and 5% CO2 with a final 
concentration of 3 µM C11-BODIPY581/591 in DMEM/F12 without phenol red (Gibco) and no 
FCS. The cells were washed once with PBS and the medium with inhibitors was transferred 
back to the cells. The cells were then treated with a final concentration of 500 µM H2O2 for 3 
hours at 37 °C and 5% CO2. After H2O2 treatment, the cells were washed once with PBS, 
trypsinised, and transferred to Eppendorf’s containing medium with 10% FCS to inactivate 
the trypsin. The cells were then washed once with flow buffer, resuspended in 250 µl of flow 
buffer containing a final concentration of 2.4 µM DRAQ7 (Biostatus, Shepshed, UK). The 
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samples were kept on ice until analysis with a BD Accuri C6 flowcytometer (BD Biosciences, 
Franklin Lakes, NJ). 
 
4.2.6 Flow cytometry for Annexin V, PI, MLKL, and pMLKL 
RPE cell lines were seeded and when needed treated with inhibitors in 96-well plates as 
described above (see section 4.2.3). The cells were then treated with a final concentration of 
500 µM H2O2 for 3 hours at 37 °C and 5% CO2. After H2O2 treatment, the cells were washed 
once with PBS, trypsinised, and transferred to Eppendorf’s containing medium with 10% FCS 
to inactivate the trypsin. 
For Annexin V and PI staining, the cells were stained using the Annexin V-FITC Apoptosis 
Detection Kit (Affymetrix, Santa Clara, CA) according to the manufacturer’s instructions. 
For MLKL and pMLKL staining, the cells were fixed in prewarmed 4% paraformaldehyde for 
10 minutes at room temperature. After washing with flow buffer, consisting of PBS with 1% 
BSA and 0.05% NaN3, the cells were permeabilised with 0.2% Triton X-100 for 5 minutes at 
room temperature. After washing with flow buffer the cells were incubated with 1:100 MLKL 
antibody (Abcam) or 1:100 phospho S358 MLKL antibody (Abcam)313 in 10% normal goat 
serum in flow buffer for 1 hour on ice. After washing the cells were incubated with 1:250 
Alexa Fluor 488 antibody (Cell Signaling Technology, Danvers, MA) or 1:250 Alexa Fluor 647 
antibody (Molecular Probes) for 30 minutes on ice. The cells were then washed once with 
flow buffer, resuspended in 250 µl of flow buffer. The samples were kept on ice until analysis 




RPE cell lines were seeded at 3*105 cells/well in a 6-well plate. The following day the cells 
were treated with 300 µM H2O2 and 300 µM BSA-DHA for 24 hours. RNA was extracted using 
TRIzol® Reagent (Ambion) according to manufacturer’s instructions. cDNA was made using 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to 
manufacturer’s instructions and primers were designed by Primerdesign Ltd., see Table S7 
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for sequences. Power SYBR® Green PCR Master Mix (Applied Biosystems) was used in 
combination with a StepOnePlus™ Real-Time PCR System (Applied Biosystems). 
 
4.2.8 Western blotting 
RPE cell lines were seeded at 2.5*105 cells/well in a 6-well plate. The following day the cells 
were treated with 500 µM H2O2, 500 µM BSA-PA, and 500 µM BSA-DHA for 6 hours. The cells 
were then lysed in RIPA buffer supplemented with Complete Mini protease inhibitor cocktail 
(Sigma-Aldrich) and PhosSTOP phosphatase inhibitor (Roche) and passed through a 21-gauge 
needle (Sterican) to shear the DNA. 20 µg of cell lysate in Laemmli sample buffer (Bio-Rad) 
supplemented with β-mercaptoethanol was heated to 98 °C for 5 minutes and subsequently 
loaded and ran on a 12% SDS-PAGE gel. The gel was then blotted onto a nitrocellulose 
membrane (Bio-Rad), blocked with TBS +5% Marvel for 30 minutes at room temperature, and 
incubated with 1:500 ACSL4 antibody (Santa Cruz, Santa Cruz, CA) overnight at 4 °C. The 
following day the membrane was incubated with 1:4,000 HRP-conjugated secondary 
antibody (Merck Millipore) for 30 minutes at room temperature. After incubation with 
Amersham ECL reagent (GE Healthcare), an Amersham Hyperfilm (GE Healthcare) was 
exposed to the membrane. The same membrane was reprobed with 1:5,000 β-actin antibody 
(Abcam) for 1 hour at room temperature followed by 1:4,000 HRP-conjugated secondary 
antibody (Merck Millipore) for 30 minutes at room temperature to check for loading control. 
Exposed films were developed in a Mi-5 X-ray developer machine (Jet Xray). The antibodies 
and concentrations used are listed in Table S9. 
 
4.2.9 UV exposure and ECIS 
UV light (340 nm) exposure was performed as described above (4.2.3) and ECIS was 
performed as described in Chapter 3 (3.2.4). UV light exposure and ECIS recording were both 
performed by Graham Anderson (The University of Edinburgh) and Dr Bagnaninchi (The 





Experiments were repeated at least three times. Statistical analysis was performed using 
Microsoft Excel version 1905 and GraphPad Prism 6 software. Student’s t-tests were used to 
determine statistical significance between groups. P-values of less than 0.05 were considered 






4.3.1 RPE undergo necrosis and not apoptosis after H2O2 exposure 
RPE were exposed to 500 µM H2O2 for 3 hours to investigate the mode of cell death RPE 
undergo when oxidatively stressed. PI, which stains necrotic cells, was found to stain RPE 
treated with H2O2 (Fig. 4.1). In contrast, H2O2-treated RPE did not stain for Annexin V, which 
stains apoptotic cells. Therefore, exposure to H2O2 caused necrosis rather than apoptosis in 
RPE. In contrast, staurosporine, a known inducer of apoptosis, caused apoptosis but no 
necrosis in RPE (Fig. 4.1). 
 
 
Figure 4.1 | H2O2 exposure 
leads to necrotic and not 
apoptotic cell death in RPE. 
ARPE-19 cells were treated 
with 5 µM staurosporine or 
500 µM H2O2 for 3 hours. 
Staurosporine but not H2O2 
exposure leads to increased 
Annexin V staining. H2O2 
but not staurosporine 




4.3.2 Increased RPE cell viability by necroptosis and ferroptosis inhibitors after H2O2 or DHA 
exposure 
PUFAs, like oxidative stress, could possibly also induce RPE cell death at high concentrations. 
RPE cell death in response to oxidative stress or PUFA injury was further investigated. RPE 
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were therefore pre-treated with specific cell death inhibitors, followed by H2O2 or DHA injury. 
The necroptosis inhibitor NSA and the ferroptosis inhibitor Fer-1 were able to significantly 
alleviate H2O2 injury in RPE (Fig. 4.2a). Both NSA and Fer-1 combined did not increase cell 
viability even further. The necroptosis inhibitor Nec-1 and Fer-1 were able to significantly 
alleviate DHA injury in RPE (Fig. 4.2b). However, the apoptosis inhibitor Z-VAD did not 
alleviate H2O2 or DHA injury. This suggests that necroptosis and ferroptosis, but not 
apoptosis, play a role in H2O2- and DHA-mediated cell death. 
 
 
Figure 4.2 | H2O2- and DHA-induced RPE cell death is ameliorated by necroptosis and ferroptosis 
inhibitors. ARPE-19 and hTERT RPE-1 cells were treated with 40 µM Z-VAD, 40 µM Nec-1, 1 µM 
GSK’840B, 1 µM NSA, 5 µM Fer-1, or 1 µM NSA and 5 µM Fer-1 24 hours before 6-hour treatment with 
500 µM H2O2 (a) or 18-hour treatment with 500 µM DHA (b). Cell viability was measured with 
PrestoBlue after treatment. Error bars represent SD of at least three independent experiments. 
*P<0.05, **P<0.01, and ***P<0.0001, determined by t-test compared to vehicle. 
 
4.3.3 Increased lipid ROS in RPE after H2O2, DHA, or POS exposure and is inhibited by Fer-1 
and DFO 
Next, the role of ferroptosis was investigated in RPE stressed with H2O2, DHA, or POS. 
Ferroptosis is an iron- and PUFA-dependent form of cell death and is characterised by 
peroxidation of PUFAs. The iron chelator DFO should therefore reduce the amount of PUFA 
peroxidation and thereby reduce cell death through ferroptosis. Pre-treatment with DFO or 
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the ferroptosis inhibitor Fer-1 reduced the amount of lipid ROS caused by H2O2, DHA, or POS 
injury (Fig. 4.3a and b). The apoptosis inhibitor Z-VAD did not reduce lipid ROS (Fig. 4.3a) and 
neither did the necroptosis inhibitor Nec-1 (Fig. 4.3b). This indicates that iron chelation or 
Fer-1 are more effective to reduce lipid ROS common to ferroptosis that is caused by H2O2, 
DHA, or POS injury. 
Addition of DHA or POS to H2O2-injured RPE could possibly increase lipid peroxidation. Injury 
of RPE with both H2O2 and DHA or H2O2 and POS increased the amount of lipid ROS more 
than H2O2 injury alone (Fig. 4.3c). This shows that oxidative stress-induced lipid peroxidation 







Figure 4.3 | H2O2-, DHA-, and POS-induced lipid ROS in RPE are reduced by Fer-1 and DFO. ARPE-19 
cells were treated with 40 µM Z-VAD, 40 µM Nec-1, or 5 µM Fer-1 24 hours or 500 µM DFO 1 hour 
before injury. Subsequent 3-hour treatment with 500 µM H2O2, 500 µM DHA, or 50 POS/cell shows 
increase of lipid ROS (BODIPY) (a and b). Pre-treatment with Fer-1 and DFO reduces the amount of 
lipid ROS after injury. Injury with DHA or POS in addition to H2O2 increases the amount of lipid ROS 
compared to H2O2 alone (c). Scale bar equals 200 µm. 
 
4.3.4 MLKL is phosphorylated after H2O2 or POS exposure in RPE 
Next, the role of necroptosis was investigated in RPE stressed with H2O2, DHA, or POS. MLKL 
is the effector protein of necroptosis when activated through phosphorylation. RPE were 
found to express MLKL (Fig. 4.4a). Treatment with H2O2 increases the amount of pMLKL (Fig. 
4.4b) and therefore causes necroptosis. DHA or POS treatment did not increase the amount 
of pMLKL in RPE and therefore likely do not cause necroptosis. 
 
 
Figure 4.4 | Increase of pMLKL in RPE after H2O2 or POS exposure. ARPE-19 cells express MLKL (a). 
Treatment of ARPE-19 cells with 500 µM H2O2, but not 500 µM DHA or 50 POS/cell, for 3 hours 
increases phosphorylation of MLKL (b). 
 
4.3.5 Expression changes after H2O2 or DHA exposure in RPE 
Prolonged exposure to H2O2 or DHA can cause cellular stress in RPE. However, the cellular 
response to either injury may vary. SQSTM1, also known as p62, is a multifunctional protein 
involved in cellular processes including autophagy and stress. H2O2 causes a significant 
downregulation of SQSTM1 expression (Fig. 4.5a). In contrast, DHA causes a significant 
upregulation of SQSTM1 expression. HSPA1B, also known as Hsp70, is involved in a wide 
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range of cellular processes, including protection of the proteome to stress. HSPA1B 
expression is significantly upregulated by both H2O2 and DHA exposure (Fig. 4.5a). CDKN2A, 
which expresses the protein p16INK4a, is involved in regulating the cell cycle and is regarded 
as a marker of cellular senescence. CDKN2A expression was significantly downregulated by 
DHA exposure, but not H2O2 exposure (Fig. 4.5a). 
Cellular stress can lead to cell death. To investigate the role of apoptosis in H2O2- or DHA-
mediated cell death in RPE, expression of certain apoptosis markers was measured after H2O2 
or DHA exposure. BCL2 is an important regulator of apoptosis and blocks apoptotic cell death. 
BAX and BAK1 are both BCL2 antagonists and therefore have a proapoptotic function. BCL2 
expression was significantly downregulated in RPE exposed to H2O2 (Fig. 4.5b), indicating that 
apoptosis could play a role in H2O2-mediated cell death. However, BAX expression did not 
significantly change and moreover BAK1 expression was significantly downregulated (Fig. 
4.5b). BCL2, BAX and BAK1 expression did not significantly change in RPE exposed to DHA 
(Fig. 4.5b). 
Expression differences of ferroptosis-related genes was also assessed in H2O2- or DHA-
mediated cell death in RPE. The expression of ACSL4 and LPCAT3 were significantly 
downregulated in RPE treated with H2O2 (Fig. 4.5c). In contrast, in DHA treated RPE only 
LPCAT3 expression was significantly downregulated (Fig. 4.5c). 
Prolonged cellular stress can also affect cellular metabolism. PPARG plays a role in regulating 
lipid metabolism and its expression was significantly downregulated in H2O2-treated RPE but 










Figure 4.5 | Differential gene expression in RPE exposed to H2O2 or DHA. ARPE-19 cells were to 300 
µM H2O2 or 300 µM DHA for 24 hours. The fold change in mRNA expression was determined of genes 
related to cellular stress (a), apoptosis (b), ferroptosis (c), and lipid metabolism (d). Error bars 
represent SD of three independent experiments. *P<0.05 and **P<0.001, determined by t-test on ΔCT 
values. 
 
4.3.6 Decreased expression of ACSL4 after H2O2 and DHA exposure in RPE 
RPE were exposed to H2O2 and PA or H2O2 and DHA to further investigate the downregulation 
of ACSL4 caused by H2O2 and the possible role that fatty acids could have in this. H2O2 
significantly reduced the ACSL4 protein levels and addition of DHA but not PA exacerbated 





Figure 4.6 | ACSL4 is 
downregulated in RPE after H2O2 
and DHA exposure. ARPE-19 cells 
were exposed to 500 µM H2O2, 500 
µM PA, and 500 µM DHA for 6 
hours. Representative blot out of 
three depicting ACSL4 expression 
changes to H2O2 and fatty acids (a). 
Densitometric analysis (b). Error 
bars represent SD of three 
independent experiments. *P<0.05, 
determined by t-test. BSA = bovine 
serum albumin; PA = palmitic acid; 
DHA = docosahexaenoic acid. 
 
 
4.3.7 H2O2 and DHA exposure of iPSC-RPE 
The effect of oxidative stress induced by H2O2 and DHA were also tested on iPSC-RPE. iPSC-
RPE were exposed for 24 hours to different concentrations of H2O2 with and without DHA 
(Fig. 4.7a) and to different concentrations of DHA with and without H2O2 (Fig. 4.7b). DHA was 
not found to increase oxidative stress caused by H2O2. C1QTNF5 KO did not affect the 
susceptibility of iPSC-RPE to oxidative stress. Only the L-ORD iPSC-RPE line LORD4 showed a 
higher susceptibility to oxidative stress-mediated cell death compared to its isogenic gene-
corrected control line (Fig. 4.7a and b). However, LORD3 did not show the same behaviour. 
iPSC-RPE were also exposed to different concentrations of tBHP, but none of the 







Figure 4.7 | iPSC-RPE cell toxicity after H2O2 and DHA exposure. iPSC-RPE lines were exposed for 24 
hours to different concentrations of H2O2 with and without DHA (a), to different concentrations of 
DHA with and without H2O2 (b), or to different concentrations of tBHP (c) and relative cell toxicity was 




4.3.8 Increased membrane pMLKL in L-ORD iPSC-RPE after H2O2 exposure 
Even though the iPSC-RPE did not show increased toxicity when stressed with H2O2, it is still 
possible to investigate early signs of cell death. Therefore, iPSC-RPE were stained for pMLKL, 
a marker of necroptosis, after H2O2 treatment. pMLKL was found to be increased and located 
in the plasma membrane of L-ORD iPSC-RPE compared to its isogenic gene-corrected control 
when oxidatively stressed with H2O2, especially in areas where there was cell death (Fig. 4.8a 
and b). The amount of pMLKL was reduced with Nec-1, GSK’840B, and Fer-1. Although this 
experiment was performed only once, the result does fit with the RPE cell line data, and 










Figure 4.8 | pMLKL is increased in L-ORD iPSC-RPE after H2O2 exposure. iPSC-RPE cells were treated 
with 40 µM Z-VAD, 40 µM Nec-1, 1 µM GSK’840B or 5 µM Fer-1 24 hours before injury. Subsequent 
18-hour treatment with 1 mM H2O2 shows increase of pMLKL staining in L-ORD iPSC-RPE (a and b). 
Pre-treatment with Nec-1, GSK’840B, and Fer-1 reduces the amount of pMLKL after injury. Scale bar 
equals 100 µm. Error bars represent SD of three technical repeats. 
 
4.3.9 UV exposure of iPSC-RPE 
RPE can also be photo-oxidatively stressed with UV radiation. Exposure of L-ORD iPSC-RPE to 
UVA light (340 nm) resulted in a relative more rapid decline in cellular impedance measured 
by ECIS (Fig. 4.9a). This could signify increased cell death caused by the UV irradiation and a 
subsequent detachment of the cells form the ECIS arrays. Furthermore, the cell viability of L-
ORD iPSC-RPE was lower compared to its isogenic gene-corrected control when exposed to 
UVB light (290 nm; Fig. 4.9b). Although these experiments were performed only once, 





Figure 4.9 | Adherence and cell viability differences in L-ORD iPSC-RPE when exposed to UV light. 
LORD3 (purple, blue, and cyan) and LORD3C (green, yellow, and orange) iPSC-RPE were exposed to 
340 nm UV for 24 hours and ECIS was recorded after exposure (a). LORD3 and LORD3C iPSC-RPE were 
also exposed to 290 nm UV for 24 hours, incubated for another 24 hours, stained with DRAQ7, and 





Oxidative stress is important in the pathology of AMD. Especially RPE endure high levels of 
oxidative stress in the retina. RPE can cope with high levels of oxidative stress but dysfunction 
of RPE or an excess of oxidative stress could cause RPE cell death as part of the AMD 
pathology. Investigating the cause of oxidative stress and the subsequent effects it has on 
RPE could lead to a better understanding of how RPE die in AMD and could potentially lead 
to the development of new therapies for AMD. Here, I have shown that oxidative stress in 
RPE leads to necrotic cell death and that this could be alleviated with necroptosis and 
ferroptosis inhibitors. Furthermore, I showed that oxidative stress leads to gene expression 
changes and that the expression of important ferroptosis regulators are affected. 
RPE were found to undergo necrosis rather than apoptosis (Fig. 4.1), similar as what has been 
found before306. Consistent with previous findings, necroptosis inhibitors reduced RPE cell 
death caused by H2O2-induced oxidative stress (Fig. 4.2). The PUFA DHA also caused oxidative 
stress-mediated cell death that could be alleviated with a necroptosis inhibitor. Furthermore, 
both H2O2- and DHA-mediated cell death could be alleviated with a ferroptosis inhibitor, 
suggesting that ferroptosis also plays a role in oxidative stress-induced cell death. Together 
these data show that two forms of regulated necrosis play a role in oxidatively stressed RPE. 
H2O2, DHA, and POS were found to increase the amount of lipid ROS in RPE (Fig. 4.3), a 
hallmark of ferroptosis. The ferroptosis inhibitor Fer-1 reduced the amount of lipid ROS. 
Furthermore, the iron chelator DFO also reduced the amount of lipid ROS, indicating that this 
process is iron-dependent, like ferroptosis. The amount of lipid ROS could be further 
increased when RPE were exposed to both H2O2 and DHA or H2O2 and POS (Fig. 4.3c). This 
could indicate that the high turnover of DHA that RPE naturally have leave them susceptible 
to exogenous oxidative stress leading to increased lipid ROS generation and subsequent 
ferroptotic cell death. 
DHA, although able to induce ferroptosis, is essential for normal functioning of the retina. 
Omega-3 long-chain PUFAs (LC-PUFAs; C20-C22), like DHA, are thought to be protective of 
the retina274,292. It is also thought that omega-3 PUFAs reduce the progression of AMD324,325. 
Approximately 50% of the phospholipids in the vertebrate rod photoreceptors contain 
DHA326. DHA-containing phospholipids are reservoirs for docosanoids, potent bioactive 
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mediators. The docosanoid neuroprotection D1 (NPD1) forms after oxidative stress and 
promotes RPE survival327,328. Furthermore, another function of DHA is that it serves as a ligand 
for nuclear hormone receptors such as PPAR-α. However, increasing dietary DHA uptake has 
shown to improve intermediate AMD, but not advanced AMD329. Phospholipids in 
photoreceptor membranes consist mostly of dipolyunsaturated molecular species. 
Phosphatidylcholine (PC) phospholipids especially in rod photoreceptors consist of very-long-
chain PUFAs (VLC-PUFAs; C≥28) and LC-PUFAs330. DHA is the predominant partner of VLC-
PUFAs in dipolyunsaturated PC331,332. Phospholipids containing VLC-PUFA and DHA are 
important for proper photoreceptor functioning because a deficit in VLC-PUFA production 
caused by a mutation in the enzyme ELOVL4 causes Stargardt-like macular dystrophy 
(STGD3), an autosomal dominant juvenile macular degeneration332. Nonetheless, too much 
DHA in combination with oxidative stress could be detrimental to RPE. 
The reduction of lipid ROS by DFO shows that lipid ROS caused by H2O2, DHA, and POS is iron-
dependent in RPE, consistent with a ferroptotic phenotype. Moreover, patients with AMD 
have increased accumulation of iron in the retina298,299. Iron was also recently found to 
promote oxidative cell death in the retina300. DFO is also commonly used to treat patients 
with hemosiderosis caused by blood transfusions. However, DFO treatment has been found 
to be toxic to RPE and to cause retinopathy333-335. If ferroptosis is an important form of cell 
death in AMD it is possible that DFO could be beneficial to RPE instead of toxic. 
Oxidative stress of RPE caused by H2O2 or DHA resulted in different gene expression changes 
(Fig. 4.5). SQSTM1, also known as p62, was upregulated in RPE exposed to DHA (Fig. 4.5a). 
This is consistent with previous findings where DHA induces SQSTM1 expression and thereby 
increases autophagy336. H2O2 and DHA did not cause gene expression changes necessary for 
apoptosis, suggesting that RPE use an alternate mode of cell death when oxidatively stressed 
(Fig. 4.5b). However, the ferroptosis inducers ACSL4 and LPCAT3 were both found to be 
downregulated in RPE exposed to H2O2, suggesting that ferroptosis is actively inhibited in RPE 
(Fig. 4.5c). LPCAT3 was also downregulated in RPE when exposed to DHA. However, it is not 
yet known if LPCAT3 can incorporate DHA into membranes and thereby can cause 
ferroptosis. DHA is known to be incorporated in phospholipids by lysophosphatidic acid 
acyltransferases (LPAATs)337,338. PPARG expression, important for regulating lipid 
metabolism, was downregulated in RPE exposed to H2O2, but upregulated when exposed to 
DHA (Fig. 4.5d). This suggests that lipid metabolism regulation is important during oxidative 
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stress in RPE. This data is also consistent with previous finding where phagocytosis of POS, 
rich in DHA content, leads to increased PPARG expression339. 
The important regulator of ferroptosis ACSL4 was found to be downregulated in RPE exposed 
to H2O2 but not DHA (Fig. 4.5c and 4.6). However, exposure of RPE to both H2O2 and DHA 
even further lowered the expression of ACSL4 (Fig. 4.6). This shows that when DHA is 
peroxidised by H2O2 ACSL4 is even further downregulated. ACSL4 is known to be able to 
target DHA for conversion to acyl-CoA and subsequent incorporation into 
phospholipids340,341. DHA in cellular membranes is known to efficiently cause ferroptosis319. 
Downregulation of ACSL4 would therefore result in less DHA incorporation into RPE 
membrane phospholipids, leading to less ferroptosis. A pathway to protect from ferroptosis 
is possibly activated in RPE when PUFAs are peroxidised to lower ACSL4 expression. 
It is thought that necroptosis and ferroptosis can compensate each other when either one is 
inhibited342. Inhibition of ACSL4 is known to promote necroptosis342. H2O2 was found to 
downregulate ACSL4 expression (Fig. 4.5 and 4.6) and was also found to increase 
phosphorylation of MLKL (Fig. 4.4). Phosphorylated MLKL is a hallmark of necroptosis313. It is 
possible that H2O2-induced cell death in RPE also inhibits ferroptosis and thereby promotes 
necroptosis. Neither DHA nor POS alone increased the phosphorylation of MLKL (Fig. 4.4). 
This suggests that the importance of necroptosis in oxidative stress-induced cell death 
depends on the cause of oxidative stress in RPE. 
H2O2-induced oxidative stress was also found to increase phosphorylated MLKL in the plasma 
membrane of L-ORD iPSC-RPE, especially around areas with cell death (Fig. 4.8). This was 
found to be less in the isogenic gene-corrected control iPSC-RPE. Moreover, phosphorylated 
MLKL was found to be reduced with necroptosis inhibitors. Even though this experiment was 
performed only once, these results suggest that L-ORD iPSC-RPE undergo necroptotic cell 
death in response to H2O2-induced oxidative stress. 
The proclivity of RPE to undergo cell death through necroptosis and ferroptosis after 
oxidative injury have both been found before306,315. Ferroptosis in particular seems a logical 
form of cell death in RPE. RPE accumulate PUFAs through the phagocytosis of DHA-rich POS. 
DHA when incorporated into cellular membranes is known to efficiently cause ferroptosis319. 
Moreover, CEP adducts generated by an oxidation product unique to DHA are abundant in 
AMD retinal tissue73. This indicates that DHA peroxidation is increased and that ferroptosis 
could be a common form of cell death in AMD. Furthermore, the levels of the antioxidant 
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GSH decreases with age and this has been linked to AMD272. The important ferroptosis 
inhibitor GPX4 is GSH-dependent. However, oxidative stress caused by H2O2 or DHA did not 
change the expression of GPX4 or GSH in RPE (Fig. 4.5c). 
Control, L-ORD, and C1QTNF5 KO iPSC-RPE seemed to react similarly to H2O2-induced 
oxidative stress (Fig. 4.7). Except LORD4 seemed to be more sensitive at 1 mM H2O2. 
Additional exposure to DHA did not seem to cause more cell death in iPSC-RPE and relatively 
high concentrations of tBHP did not seem to affect iPSC-RPE. This shows that iPSC-RPE are 
more robust in handling oxidative stress than RPE cell lines like ARPE-19 and hTERT RPE-1. 
One explanation for this could be that iPSC-RPE are more similar to primary RPE than RPE cell 
lines by expressing all the mature RPE markers, pigmenting, and only have a limited capacity 
to proliferate. It is also possible that iPSC-RPE have a more developed antioxidant defence 
similar to primary RPE than RPE cell lines. 
UV light-induced oxidative stress was found to have a differential response on L-ORD iPSC-
RPE compared to its isogenic gene-corrected control. The electrical resistance of L-ORD iPSC-
RPE declined faster than compared to its control (Fig. 4.9a), as opposed to the increased 
resistance of L-ORD iPSC-RPE during proliferation (see Chapter 3). This could indicate that L-
ORD iPSC-RPE are more sensitive to UV light-induced oxidative stress and this causes them 
to detach faster. Moreover, L-ORD iPSC-RPE seemed to be more sensitive to UV light-induced 
cell death (Fig. 4.9b). Both of these experiments have been performed only once, but 
together suggest that L-ORD iPSC-RPE are more sensitive to UV-mediated photo-oxidative 
stress. 
DHA and light exposure are known to induce cell toxicity through CEP-adduct formation in 
RPE343. Furthermore, constant illumination causes reduction of DHA through lipid 
peroxidation and subsequent photoreceptor degeneration in rats344. Increased DHA levels 
are known to increase stress-induced photoreceptor cell death345. Conversely, low levels of 
DHA protect the photoreceptors from light-induced cell death346. Although DHA did not show 
increased cell toxicity in combination with H2O2 in RPE, it is possible that DHA levels can 
influence photo-oxidative stress in a similar way in RPE as in photoreceptors. 
The results in this chapter show that RPE undergo regulated necrotic cell death when 
oxidatively stressed. Importantly, the mode of regulated necrotic cell death seems to depend 
on how oxidative stress was induced. H2O2 seems to induce mostly necroptosis, whereas DHA 
seems to induce ferroptosis. H2O2 also seems to induce more necroptosis in at least one L-
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ORD iPSC-RPE line, but there was no difference found between L-ORD and control iPSC-RPE 
in sensitivity towards H2O2- and DHA-induced oxidative stress. However, L-ORD iPSC-RPE 
were found to be more sensitive to UV light-induced oxidative stress. Together, this shows 
that RPE have a differential response to different types of oxidative stress and that L-ORD 








5.1.1 The complement system 
The complement system is part of the innate immune system and functions to clear bacteria 
and damaged cells347-350. It complements the antibacterial activity of antibodies, but it can 
also be activated in the absence of antibodies. The complement system consists of over 30 
proteins that react with each other to opsonise pathogens and to induce a series of 
inflammatory responses. Several complement proteins are zymogens, proteases that are 
themselves activated by proteolytic cleavage. 
The complement system has three functions in immune surveillance349. One function is 
probing of healthy cells by a constant low level of complement activation. The presence of 
membrane-bound regulators prevents a strong complement system response. Bacteria, 
however, activate a stronger response induced by various pattern recognition proteins and 
is strongly amplified in the absence of regulators. This leads to opsonisation of the bacteria 
by complement proteins and pro-inflammatory signalling. Subsequently, macrophages are 
recruited for phagocytosis, the membrane attack complex (MAC) is formed for cell lysis, and 
further downstream immune responses are activated. Pattern recognition proteins also 
recognise apoptotic cells. Recruited regulator proteins, however, prevent amplification of the 
complement response and formation of the MAC. Nevertheless, opsonisation still facilitates 
clearance of the apoptotic cell without a further immune response. When dysregulated, the 
complement system can also attack healthy cells, leading to immune and inflammatory 
diseases348. 
The complement system consists of three independent but interacting pathways349,350. These 
are the classical, alternative, and lectin pathways, whose independent activation leads to the 





Figure 5.1 | The complement system pathways. The complement system comprises the classical 
pathway, the lectin pathway, and the alternative pathway, which are initiated by antigen-antibody 
(Ag-Ab) recognition, microbial carbohydrates, and activating surfaces respectively. The three 
pathways converge into the terminal complement pathway, which leads to the formation of the C5b-
9 complex. Reproduced from Rus et al. (2005)351. 
 
The classical pathway is activated when IgM or IgG antibodies complexed with antigens bind 
C1q or when C1q binds the surface of a pathogen (Fig. 5.1). C1q then forms the C1 complex 
together with two molecules of C1r and two molecules of C1s. C1q bound to an antibody or 
a pathogen causes conformational changes in C1q. This leads to activation of C1r in the C1 
complex and subsequent cleavage of C1s. The active C1 complex cleaves C4 and subsequently 
C2 into C4a and C4b, and C2a and C2b respectively. C4b then binds C2a to form the C3 
convertase (C4b2a complex) and this promotes the cleavage of C3 into C3a and C3b. C3b 
binds to the C3 convertase to from the C5 convertase (C4b2a3b complex). C3b acts also as 
an opsonin and binds covalently to a pathogen to mark it for phagocytosis. When bound to a 
pathogen, C3b can also bind the C5 convertase.  
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The alternative pathway is continuously activated at a low level. In this pathway, C3 is 
spontaneously hydrolysed to C3a and C3b (Fig. 5.1). C3b can be further spontaneously 
hydrolysed into iC3b and C3dg. Complement factor B (CFB) can bind iC3b, which allows 
complement factor D (CFD) to cleave CFB into Ba and Bb. This results in the formation of a 
C3 convertase different from the classical pathway (C3bBb complex). This complex is 
unstable until it binds the serum protein properdin. An additional C3b binds this complex 
forming the C5 convertase of the alternative pathway (C3bBbC3bP complex). 
In the lectin pathway, mannose-binding lectin (MBL) or ficolin bind certain saccharides, as 
found on carbohydrate or glycoprotein components of pathogen membranes352 (Fig. 5.1). 
Multimers of MBL form a complex with MBL-associated serine protease 1 (MASP1), MASP2, 
and MASP3. MASPs cleave and activate C4 and C2, similar to the C1 complex of the classical 
pathway. However, unlike the classical pathway, C4b then binds C2b instead of C2a to form 
the C3 convertase (C4b2b complex). This results therefore also in a different C5 convertase 
(C4b2b3b complex). 
The different C5 convertases generated by the three complement pathways have the same 
function and lead to the same terminal complement pathway349,350 (Fig. 5.1). C5 convertase 
promotes the cleavage of C5 into C5a and C5b. C5b, C6, C7, C8, and C9 assemble a protein 
complex known as the MAC (C5b-9 complex) which is capable of forming pores in the 
membranes of pathogens and inducing subsequent cell lysis. 
The fragments C3a, C4a, and C5a are anaphylatoxins, small proteins that mediate a number 
of important effects. These effects include vasodilation and enhanced vascular permeability, 
release of histamine from mast cells, smooth muscle contraction, chemotaxis, inflammation, 
and oxygen radical formation353. 
The complement system has the potential to do a lot of damage to host tissue and is 
therefore tightly regulated349,350. There are several regulators of the complement system 
termed complement control proteins (CCPs). CCPs comprise a range of membrane-
associated and soluble, fluid phase, proteins. CCPs contain CCP domains. Two important non-
CCP complement regulators are C1 inhibitor and complement factor I (CFI). An important 
regulator of the classical and lectin pathways is the C1 inhibitor354,355. CFI cleaves, as a 
cofactor of CFH, C3b and C4b and thereby modulates C3 convertase activity of all three 




5.1.2 Regulation of the alternative pathway 
C3b in the alternative pathway is continuously generated and opsonises membrane surfaces 
in an indiscriminate manner. C3b therefore needs tight regulation to prevent host plasma 
membranes being targeted by the alternative pathway. Cells of the host express integral 
membrane proteins that control complement activation. These CCP membrane proteins 
include CD35 (complement receptor type 1; CR1), CD46 (membrane cofactor protein; MCP), 
CD55 (decay accelerating factor; DAF), and CD59. CD35, CD46, and CD55 promote C3b 
inactivation, whilst CD59 prevents MAC formation. 
The main regulator of the alternative pathway is CFH357-359. CFH is a soluble 150 kDa 
glycoprotein and contains 20 CCP domains and the N-terminus is responsible for complement 
regulation360,361. CFH has multiple binding sites for C3b362 and is therefore thought to 
compete with CFB for C3b to prevent the formation of the C3 convertase of the alternative 
pathway. RPE expresses CFH363, and its expression can be downregulated with the pro-
inflammatory cytokines TNF-α and IL-6364, as well as oxidative stress303,304,365. In contrast, the 
pro-inflammatory cytokine IFN-γ can increase CFH expression in RPE365,366. The CFH gene is 
located in a cluster with five paralogs on chromosome 1 (1q31.3)367. The five CFH-related 
(CFHR) gene paralogs are CFHR1, CFHR2, CFHR3, CFHR4, and CFHR5. It is not yet clear what 
the function is of the CFHRs. Complete deletion of CFHR1 and CFHR3 is common and confers 
protection against AMD368,369. 
CFH can also attach to the cell surface with its C-terminus370-372. The C-terminus is important 
for the membrane-associated protective function of host cells by CFH373. Host cells can 
display polyanionic molecules to allow discrimination of self from non-self by binding CFH 
and thereby providing host protection from C3b374. CFH works in concert with CD46, CD55, 
and CD59 to provide host cell protection from the complement system373. 
RPE is known to express the membrane CCPs CD46, CD55, and CD59375. These membrane 
CCPs were found to be increased in expression in response to inflammatory cytokines375 and 
in the presence of activated T-cells376. Moreover, CD55 was found to protect RPE from human 
complement377. Oxidative stress reduces the expression of membrane CCPs in RPE, making 
RPE more susceptible to complement-mediated cell death304. This is most likely also due to 
the oxidative stress-mediated downregulation of CFH. Moreover, RPE were also found to 
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release microparticles with CD46, CD55, and CD59 after oxidative stress378. Therefore, RPE 
can regulate the alternative pathway of the complement system, but this ability can be 
modulated by inflammation as well as oxidative stress. 
 
5.1.3 The complement system and AMD 
Components of the complement system are small proteins primarily synthesised by liver 
hepatocytes and released into the bloodstream. Most tissues are therefore dependent on 
circulating complement system components. Some tissues can however produce 
complement system components locally. Tissues with limited access to blood such as the 
brain and the retina mainly produce these components locally379. 
Many genes that confer risk of AMD are involved in the complement system and, in 
particular, the alternative pathway. Furthermore, complement system proteins are often 
found in drusen. Dysregulation of the complement system is therefore thought to play an 
important role in the progression of AMD380. 
A common p.Y402H mutation in CFH was found to be strongly associated with AMD381-385. 
The CFHY402H mutation changes the seventh CCP domain and therefore affects CFH binding to 
a number of ligands386. Notably, CFH was found to bind less to glycosaminoglycan (GAG) 
chains of proteoglycans. CFH uses GAGs to anchor itself to cell surfaces and the ECM387. Less 
localisation of CFH on cell surfaces and in the Bruch’s membrane could lead to local 
inflammation. Moreover, more C5b-9 was found in the choroid and the Bruch’s membrane 
of individuals with the homozygous CFHY402H mutation than aged-matched controls388. The 
amount of C5b-9 also increases in the choroid and Bruch’s membrane with age389. Both CFH 
and ARMS2, another gene strongly associated with AMD, are associated with systemic 
complement system activation when mutated59. 
More complement system gene mutations have been associated with AMD. Mutations in C3 
have been associated with increased risk of AMD390,391. A p.R102G mutation in C3 causes 
reduced binding of C3 to CFH, leading to reduced CFI cofactor activity and subsequent 
increased C3 convertase lifetime392. This results in alternative pathway amplification. In 
contrast, mutations in CFB and C2 can have a protective effect against AMD393,394. A common 
SNP near CFI and a rare mutation in CFI have also been associated with an increased risk of 
AMD395,396. However, the precise effects of these mutations are not yet known. 
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One of the early hallmarks of AMD is deposit-formation between the RPE and the Bruch’s 
membrane, termed drusen68. Drusen consist of various proteins and lipid components. It is 
thought that lipoproteins in drusen could stimulate complement activation397. Modified 
proteins and lipids from damaged RPE also accumulate in drusen and are thought to trigger 
complement activation398,399. Moreover, various components of the complement system as 
well as activators of this system have been found in drusen379, including CFH, C3, C5, C6, C7, 
C8, C9, and C5b-973,400,401. Complement regulatory proteins such as vitronectin and clusterin 
are also found in drusen73. 
C1QTNF5 is also thought to be involved in complement regulation. C1QTNF5 has been found 
to bind to CFH (PhD thesis, Dr Slingsby, The University of Edinburgh and PhD thesis, Dr 
Borooah, The University of Edinburgh). By binding CFH on the cell membrane C1QTNF5 could 
possibly protect the host cells from complement-mediated inflammation and lysis. In 
addition, family member C1QTNF6 is found to suppress the alternative complement pathway 
by competing with CFB for C3 binding184. It is possible that C1QTNF5 has a similar function in 
the retina which could be affected when mutated in L-ORD. 
 
5.1.4 APOE 
Apolipoprotein E (APOE) is one of the most common proteins found in AMD drusen73,77. APOE 
is a transport protein for lipids, fat-soluble vitamins, and cholesterol. It is thought that APOE 
also plays a role in innate immunity402. APOE is highly expressed in RPE and is a polymorphic 
gene, with three major alleles: APOE-ε2 (cys112, cys158), APOE-ε3 (cys112, arg158), and 
APOE-ε4 (arg112, arg158). The allelic different forms alter APOE structure and function and 
can therefore result in different physiological phenotypes. APOE-ε4 is known to be a strong 
genetic risk factor for Alzheimer’s disease, whilst APOE-ε2 is protective. In AMD the reverse 
is true, APOE-ε2 is associated with increased risk of AMD and APOE-ε4 is protective403. APOE-
ε2 is associated with increased mononuclear phagocyte infiltration and inflammation in the 
subretinal space in AMD404. However, APOE-ε2 is a rare variant. 
RPE exposed to serum containing the complement system should form deposits on the basal 
side resembling drusen405,406. APOE should also be found in these deposits if it can function 
as a marker for drusen. In addition, C5b-9 and C1QTNF5 can also be localised to reveal which 
components are contained in the deposits and if there is a difference between L-ORD iPSC-
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RPE and its isogenic gene-corrected control, as well as if there is a difference between 
C1QTNF5 KO iPSC-RPE and its isogenic control. Localisation of possible drusen components 
could lead to a better understanding of how drusen are formed. 
 
5.1.5 Aims and objectives 
In order to study the response of L-ORD iPSC-RPE to human complement serum, the following 
was carried out in this chapter: 
1. C5b-9 deposition on L-ORD iPSC-RPE after human complement serum exposure was 
investigated by immunostaining and confocal microscopy 
2. iPSC-RPE cytotoxicity after human complement serum exposure was investigated by 
cell toxicity assays 
3. Localisation of C5b-9 with C1QTNF5 on iPSC-RPE after human complement serum 
exposure was investigated by immunostaining and confocal microscopy 
4. Localisation of C5b-9 with APOE on iPSC-RPE after human complement serum 




5.2 Materials and methods 
 
5.2.1 Cell culture 
iPSCs were cultured as described in Chapter 2 (2.2.1) and were differentiated to RPE as 
described in Chapter 3 (3.2.2).  
 
5.2.2 Human complement serum treatment and immunocytochemistry 
For C5b-9 imaging experiments iPSC-RPE were seeded onto 0.4 µm pore membrane transwell 
inserts coated with 1 µg/cm2 of Laminin-521 in a 12-well plate and allowed to mature for four 
weeks. iPSC-RPE were grown on porous filter supports which allows nutrient supply to the 
basolateral side and therefore promotes epithelial differentiation closer to native 
epithelium227,228. RPE grown on a porous membrane generate drusen-like deposits in the 
pores405. 
iPSC-RPE were treated with 40% human complement serum for 12 hours at 37 °C and 5% 
CO2. The cells were then washed with PBS and fixed with 4% PFA for 10 min. After another 
two washes with PBS the cells were permeabilised with 0.1% TritonX-100 for 15 min and 
subsequently blocked with 3% normal goat serum for 1 hour. Staining with the primary 
antibody was at 4 °C overnight. The cells were washed twice with PBS and subsequently 
stained with a secondary Alexa Fluor®-conjugated antibody for 30 minutes and 
counterstained with 300 nM DAPI for 10 minutes. After another three washes with PBS, the 
cells were mounted in Fluorsave mounting medium and imaged with a Leica DMi8 inverted 
microscope (Leica Microsystems). The antibodies and concentrations used are listed in Table 
S8. 
Z-stack images were made with a Zeiss LSM 710 Confocal Laser Scanning Microscope. 
 
5.2.3 Cell toxicity assay 
iPSC-RPE were seeded at 7.5*103 cells/well in a 96-well plate and cultured for four weeks 
until mature and confluent. The medium was replaced with DMEM without additions two 
days before human complement serum treatment. The cells were treated with different 
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concentrations of human complement serum for 12 hours at 37 °C and 5% CO2. The medium 
was subsequently replaced with DMEM without additions and the cells were incubated for 
another 24 hours at 37 °C and 5% CO2. The cells were stained with 3 µg/ml Hoechst and 6 
µg/ml PI for 20 min at 37 °C and 5% CO2, and subsequently fixed with pre-warmed 4% PFA 
for 10 minutes. After three washes with PBS the cells were imaged with a Zeiss Axio Observer 
Z1 motorised inverted microscope with an automatic stage. 
 
5.2.4 Statistics 
Experiments were repeated at least three times. Statistical analysis was performed using 
Microsoft Excel version 1905 and GraphPad Prism 6 software. Student’s t-tests were used to 
determine statistical significance between groups. P-values of less than 0.05 were considered 






5.3.1 C5b-9 binds more to L-ORD iPSC-RPE after human serum exposure 
iPSC-RPE were exposed to human serum containing active complement system pathways. If 
complement system regulation is compromised, more terminal complement system complex 
C5b-9 should bind to the iPSC-RPE. Exposure to human complement serum resulted in higher 
levels of C5b-9 deposits on L-ORD iPSC-RPE compared to its isogenic gene-corrected control 
(Fig. 5.2a and b). No difference in C5b-9 binding was found between C1QTNF5 KO iPSC-RPE 
and its isogenic control. 
Confocal microscopy can be used to image the iPSC-RPE monolayer in multiple layers on the 
Z-axis. These layers can be stacked to construct a Z-stack, which provides positional 
information on the Z-axis. The constructed Z-stack image essentially provides a side view of 
the iPSC-RPE monolayer allowing to discriminate between the apical and basal side of the 
cells. Using this method, the binding of C5b-9 to iPSC-RPE was found to occur mostly at the 








Figure 5.2 | L-ORD iPSC-RPE bind more C5b-9 after human complement serum exposure. Control, 
C1QTNF5 KO, LORD3, and LORD3C iPSC-RPE were exposed for 12 hours to 40% human complement 
serum. L-ORD iPSC-RPE bind more C5b-9 than control and C1QTNF KO iPSC-RPE lines (a and b). C5b-9 
binds mostly to the basal side of iPSC-RPE as shown in a Z-stack image (c). Scale bar a equals 100 µm. 
Scale bar c equals 20 µm. Error bars represent SD of at least three independent experiments. *P<0.05, 




5.3.2 iPSC-RPE are resistant to human serum exposure 
Increased binding of C5b-9 could lead to more complement-mediated cell death. To 
investigate if increased C5b-9 binding results in more iPSC-RPE cell death, iPSC-RPE were 
exposed to different concentrations of human complement serum and cell toxicity was 
measured 24 hours after exposure. No increased cell toxicity was found for any of the 
concentrations used of human complement serum for this length of exposure (Fig. 5.3). 
 
 
Figure 5.3 | iPSC-RPE cell toxicity after human complement serum exposure. iPSC-RPE lines were 
exposed for 12 hours to different concentrations of human complement serum and relative cell 
toxicity was measured with PI staining 24 hours after exposure. Error bars represent SD of three 
independent experiments. 
 
5.3.3 C5b-9 colocalises only apically with C1QTNF5 after human serum exposure 
To investigate the role of C1QTNF5 in regulating the binding of C5b-9 to iPSC-RPE, both C5b-
9 and C1QTNF5 were localised on iPSC-RPE through immunostaining. C1QTNF5 did not seem 
to colocalise with all C5b-9 deposits (Fig. 5.4a). Using confocal microscopy, multiple cross 
sections of the iPSC-RPE monolayer were imaged and a Z-stack was constructed to determine 
protein localisation on the apical/basal axis. The Z-stack image showed colocalisation of 
C1QTNF5 with C5b-9 only at the apical side of the iPSC-RPE in deposits (Fig. 5.4b). No 





Figure 5.4 | C5b-9 and C1QTNF5 colocalise in aggregates on the apical side of iPSC-RPE. LORD4 and 
LORD4C iPSC-RPE were exposed for 12 hours to 40% human complement serum. C5b-9 did not appear 
to colocalise often with C1QTNF5 (a). C5b-9 did colocalise with C1QTNF5 in aggregates on de apical 




5.3.4 C5b-9 colocalises with APOE after human serum exposure 
APOE is highly expressed by RPE and is often found in AMD drusen73,77. L-ORD sub-RPE 
drusen-like deposits could likely also contain APOE. C5b-9 and APOE were found to colocalise 
together, typically in deposits (Fig. 5.5a). The colocalisation of C5b-9 and APOE in aggregates 
was found to be on both the apical as well as basal side of the iPSC-RPE (Fig. 5.5b). No 





Figure 5.5 | C5b-9 and APOE colocalise in aggregates on iPSC-RPE. LORD4 and LORD4C iPSC-RPE were 
exposed for 12 hours to 40% human complement serum. C5b-9 colocalises with APOE (a). C5b-9 







Complement system activation is important in the onset and progression of AMD. Several 
genes that confer a high risk of AMD when mutated encode for complement system proteins. 
Furthermore, complement system proteins are found in abundance in drusen, the hallmark 
of AMD. Here, I showed that C5b-9 binds relatively more to L-ORD iPSC-RPE, that C5b-9 
colocalises apically with C1QTNF5, and that C5b-9 colocalises with APOE in deposit-like 
aggregates. These results indicate a role for complement system dysregulation in L-ORD that 
is similar in AMD. 
iPSC-RPE treated with human complement serum resulted in more C5b-9 binding to L-ORD 
iPSC-RPE compared to its isogenic gene-corrected control (Fig. 5.2). Binding of C5b-9 to iPSC-
RPE was found to be predominantly to the basal side (Fig. 5.2c). Increased binding of C5b-9 
could potentially lead to more complement-mediated cell death. However, more binding of 
C5b-9 to L-ORD iPSC-RPE did not seem to affect cell toxicity (Fig. 5.3) and KO of C1QTNF5 did 
not seem to cause any difference in C5b-9 binding (Fig. 5.2). This indicates that the 
C1QTNF5S163R has a specific negative effect on iPSC-RPE, leading to more C5b-9 binding. 
C1QTNF5 exogenously expressed in RPE cell lines is known to be able to bind to CFH (PhD 
thesis, Dr Slingsby, The University of Edinburgh and PhD thesis, Dr Borooah, The University 
of Edinburgh). It is therefore possible that C1QTNF5 has a role in regulating CFH and that this 
role is compromised by the L-ORD mutation. This could explain why there is more C5b-9 
binding to L-ORD iPSC-RPE. 
Treatment of iPSC-RPE with human complement serum resulted in mostly basal C5b-9 
aggregates resembling drusen-like deposits (Fig. 5.2c). Some apical pseudodrusen-like 
deposits were observed as well. Pseudodrusen are drusen-like deposits in the subretinal 
space between the photoreceptors and the RPE407,408. Only the apical pseudodrusen-like 
deposits contained both C5b-9 and C1QTNF5 (Fig. 5.4b). It is possible that C1QTNF5 only 
facilitates CFH binding to the cell surface and subsequent complement system protection at 
the apical side of RPE. Since C1QTNF5 is secreted on both sides of iPSC-RPE (Fig. 3.7b), it is 
possible that C1QTNF5 binds differently to CFH when not bound to a cell surface. 
All C5b-9 deposits contained accumulation of APOE (Fig. 5.5). APOE is a common component 
found in drusen73,77. APOE could therefore possibly function as a marker of drusen. Exposure 
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of human fRPE or iPSC-RPE to exogenous serum is known to produce sub-RPE deposits 
containing both C5b-9 and APOE405,406. Importantly, in iPSC-RPE models of SFD and ML/DHRD, 
also C5b-9 and APOE-containing deposits were formed after serum exposure but did not 
affect the number of deposits406. L-ORD iPSC-RPE were also found to have similar amounts of 
APOE-containing deposits compared to control. The thickness of sub-RPE deposits between 
L-ORD and control was also previously found to be not significantly different (PhD thesis, Dr 
Borooah, The University of Edinburgh). 
RNA-seq data analysis revealed that CFI was significantly downregulated and CD55 was 
significantly upregulated in L-ORD iPSC-RPE (see Chapter 3). Downregulation of CFI would 
lead to less cleavage of C3b and C4b, increased lifespan of the C3 convertase, and subsequent 
amplification of the alternative complement pathway. However, CD55 expression was 
upregulated in L-ORD iPSC-RPE and CD55 also promotes C3b and C4b inactivation. It is 
possible that L-ORD iPSC-RPE react to the increased amount of C5b-9 binding by increasing 
cell-surface bound CD55 expression for protection at the expense of soluble CFI expression. 
These results show that dysregulation of the complement system is a pathological feature of 
L-ORD, similar to AMD. C1QTNF5 possibly has a direct role in the regulation of the 
complement system by binding CFH. The C1QTNF5S163R mutation caused more binding of C5b-
9 to the cell surface, likely due to aberrant regulation of the complement system. C1QTNF5 
was also found to localise with C5b-9 at the apical surface of iPSC-RPE. C5b-9 was also found 
to localise with APOE in deposits. Together, these results show that L-ORD iPSC-RPE respond 





Chapter 6 Discussion 
 
6.1 AMD and L-ORD 
AMD is one of the leading causes of vision loss, affecting nearly 200 million people worldwide 
in 202048. With an ageing global population, this is expected to increase. An increase in AMD 
prevalence will inevitably increase the burden on health care systems worldwide. AMD is a 
complex disease with both environmental and genetic risk factors. Unfortunately, there is 
still a lack of understanding about the molecular mechanisms affected in AMD. Hereditary 
macular degenerations are relatively rare but often have a very similar clinical presentation 
to AMD. Hereditary macular degenerations therefore are likely to have similar molecular 
pathways affected and studying these diseases could therefore contribute to the 
understanding of macular degeneration onset and progression. One of these diseases is L-
ORD. L-ORD is caused by a single mutation in C1QTNF5 but it is not yet clear what the function 
is of C1QTNF5. C1QTNF5 likely plays a role in molecular pathways that can lead to macular 
degeneration when dysregulated. Studying C1QTNF5 could reveal its function and could 
uncover currently unknown molecular mechanisms that lead to macular degeneration. To 
this end, L-ORD patient-derived iPSCs were gene corrected using CRISPR/Cas9, differentiated 
into RPE, and these iPSC-RPE were used to study the C1QTNF5 protein, transcriptomics, and 
cellular pathways typically affected in macular degeneration (Fig. 6.1). 
 
 
Figure 6.1 | Experimental overview. L-ORD patient-derived iPSCs were gene edited by using 
CRISPR/Cas9 to correct the L-ORD mutation. In addition, a C1QTNF5 null line was generated by using 
CRISPR/Cas9. These iPSC lines were then differentiated to RPE. These iPSC-RPE were used to study the 
C1QTNF5 protein function, to analyse and compare using RNA-seq, and to study macular 




6.2 The main findings of this study 
Gene editing allows for the study of the effect of a single mutation causing a disease. L-ORD 
patient-derived iPSC lines were therefore C1QTNF5 gene-corrected to generate isogenic pairs 
with an efficiency of 7.8%. In addition, C1QTNF5 was knocked out in a wt iPSC line in both 
alleles with an efficiency of 4.3%. Absence of C1QTNF5 could contribute to the understanding 
of the function of the protein. No evidence was found for off-target editing for any of the 
gRNAs used. 
L-ORD, gene-corrected, wt, and C1QTNF5 KO iPSC lines were differentiated to RPE. iPSC-RPE 
generated had RPE-like morphology and functionality. However, L-ORD iPSC-RPE were found 
to possibly adhere differently to the substrate compared to their isogenic gene-corrected 
control, indicating a possible function of C1QTNF5 in cellular adhesion. L-ORD and C1QTNF5 
KO iPSC-RPE were found to phagocytose more, indicating a possible function of C1QTNF5 in 
regulating phagocytosis. 
The C1QTNF5S163R mutation that causes L-ORD was found to have a destabilising effect on the 
octadecamer quaternary structure of C1QTNF5. C1QTNF5 was also found to be expressed in 
cortical astrocytes and oligodendrocytes. Transcriptomic comparison of L-ORD iPSC-RPE and 
its isogenic gene-corrected control revealed differences in MMPs expression which are 
responsible for ECM remodelling, PLINs expression which are involved in dark adaptation, 
lipid metabolism, oxidative stress management, complement system regulation, 
macrophage recruitment, and calcium regulation. These transcriptomic differences are in 
line with the symptoms that L-ORD patients present. 
One of the main environmental risk factors for AMD is oxidative stress. RPE cell lines were 
found to undergo necroptosis and ferroptosis in response to oxidative stress. However, iPSC-
RPE were found to be very resistant to oxidative stress. LORD4, but not LORD3, iPSC-RPE 
were found to be more sensitive to H2O2-induced oxidative stress at high concentrations. 
LORD3 iPSC-RPE did seem to be more affected by UV light-induced photo-oxidative stress in 
preliminary experiments. 
Dysregulation of the complement system has often been implicated in AMD. The terminal 
complement system complex C5b-9 was found to bind more often to L-ORD iPSC-RPE 
compared to its isogenic gene-corrected control when exposed to human serum containing 
active complement system pathways. C5b-9 was found to bind mostly to the basal side of 
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iPSC-RPE and typically in aggregates resembling drusen-like deposits. Moreover, APOE, 
commonly found in drusen, colocalised in these drusen-like deposits with C5b-9. C5b-9 was 
occasionally found in apical pseudodrusen-like deposits, where it colocalised with C1QTNF5. 
 
6.3 Effects of the p.S163R mutation on C1QTNF5 function in L-ORD iPSC-RPE 
Structurally, it is known that C1QTNF5S163R assembles into multimers with wt C1QTNF, and 
C1QTNF5S163R-containing multimers are unable to assemble HMW multimers165 (Fig. 3.7c). 
The C1QTNF5S163R mutation causing L-ORD is thought to be a dominant negative mutation, 
based on the ability of C1QTNF5S163R to retain wt C1QTNF5 inside the cell165. This was not 
observed in this study, as wt and L-ORD iPSC-RPE secreted equal amounts of C1QTNF5 (Fig. 
3.7a). L-ORD iPSC-RPE and C1QTNF5 KO iPSC-RPE both showed increased phagocytosis of 
POS compared to their isogenic controls (Fig. 3.5). This could indicate that C1QTNF5S163R is a 
loss-of-function mutation. However, serum treatment of L-ORD iPSC-RPE showed increased 
binding of C5b-9 which was not observed in C1QTNF5 KO iPSC-RPE (Fig. 5.2). This could 
indicate that the C1QTNF5S163R mutation is a gain-of-function mutation instead. The 
C1QTNF5S163R mutation leads to a loss of function if the C1QTNF5 octadecamer is the 
functional unit for phagocytosis regulation. Therefore, depending on the cellular process 
C1QTNF5 is involved in, the C1QTNF5S163R mutation could lead to either a loss of function or 
a gain of function. 
 
6.4 Altered lipid metabolism and oxidative stress response in L-ORD iPSC-RPE 
RNA-seq data revealed that catalase was significantly upregulated in L-ORD iPSC-RPE (Table 
3.1a) and is part of a metabolic network affected in L-ORD (Fig. 3.9a). Catalase is an important 
antioxidant in RPE and protects the RPE from ROS produced during phagocytosis280,281 (see 
section 4.1.3). Increased phagocytic capability found in L-ORD iPSC-RPE (Fig. 3.5) could 
explain why the L-ORD iPSC-RPE would need to upregulate catalase expression. However, L-
ORD iPSC-RPE still showed increased pMLKL staining when treated with H2O2 (Fig. 4.8) and 
were more sensitive to photo-oxidative stress (Fig. 4.9). 
Increased phagocytosis found in L-ORD iPSC-RPE and C1QTNF5 KO iPSC-RPE (Fig. 3.5) could 
lead to more accumulation of DHA in the RPE. This provides an increased pool of PUFAs that 
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can be peroxidised, leading to increased sensitivity to oxidative stress. In addition, RNA-seq 
data revealed that L-ORD iPSC-RPE have an altered (lipid) metabolism (Table 3.2a and Fig. 
3.9a). If DHA is more incorporated in RPE cell membranes because of the increased DHA pool, 
it is possible that RPE are more susceptible to oxidative stress-mediated cell death through 
ferroptosis. However, the combination of H2O2 and DHA did not show any increased cell 
death of L-ORD or C1QTNF5 KO iPSC-RPE (Fig. 4.7). Nonetheless, this could be dependent on 
the concentrations used and the length of the treatment. In addition, a cellular pathway 
involved in both cell death and survival was significantly changed in L-ORD iPSC-RPE (Fig. 
3.9b), indicating that iPSC-RPE cell death and survival is tightly regulated. 
 
6.5 Protection from oxidative stress by CFH is possibly affected in L-ORD 
CFH can bind the lipid peroxidation product MDA (see section 4.1.2) and thereby protects 
from oxidative stress409. CFH also interacts with oxidised phospholipids410. The AMD risk 
mutation CFHY402H leads to less binding of CFH to MDA409. MDA is known to have oxidation-
specific epitopes that can trigger both innate and adaptive immune responses267. CFH 
therefore appears to have an important function in regulating oxidative stress. However, it 
is known that oxidative stress can downregulate the expression of CFH in RPE303,304,365. In 
addition, oxidative stress makes the RPE more susceptible to complement system-mediated 
cell death304,411. C1QTNF5 has been shown to be able to bind to CFH (PhD thesis, Dr Slingsby, 
The University of Edinburgh and PhD thesis, Dr Borooah, The University of Edinburgh) and 
could therefore have a function in oxidative stress regulation together with CFH. 
 
6.6 Changes in ECM remodelling in L-ORD iPSC-RPE 
RNA-seq data revealed changes in ECM remodelling in L-ORD iPSC-RPE (Table 3.2). Several 
proteins have been identified that when mutated cause an increased risk to AMD or directly 
cause macular degeneration, such as EFEMP1 and TIMP3 (see section 1.5). The hallmark of 
AMD, the formation of drusen, is also located in the ECM on the basal side of the RPE. 
Changes in the ECM caused by the EFEMP1R345W mutation are known to cause RPE to produce 
deposits and to activate the alternative complement pathway412. It is possible that ECM 
changes caused by C1QTNF5S163R mutation could have a similar effect. Moreover, it was found 
that L-ORD iPSC-RPE treated with human complement serum developed more C5b-9-
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containing deposits (Fig. 5.2c). These drusen-like deposits also contained APOE, a protein 
commonly found in drusen (Fig. 5.5). 
 
6.7 Dysregulated complement regulation in L-ORD iPSC-RPE 
CFI expression was found to be significantly downregulated in L-ORD iPSC-RPE (see Chapter 
3). CFI is an important regulator of the complement system (see sections 5.1.1 and 5.1.2). CFI 
functions as an important cofactor for CFH to cleave C3b and C4b356. Downregulation of CFI 
would therefore cause more generation of the C3 convertase and amplify the alternative 
complement pathway. This could explain the increased amount of C5b-9 binding to L-ORD 
iPSC-RPE (Fig. 5.2). Mutations in and near CFI have been associated with AMD395,396 (see 
section 5.1.3). CD55 was, however, found to be significantly upregulated in L-ORD iPSC-RPE 
(see Chapter 3). CD55 is also an important regulator of the complement system (see section 
5.1.2) and is known to protect RPE from human complement377. 
 
6.8 Macular degeneration and dementia 
AMD has in the recent years often been linked to dementia, and in particular Alzheimer’s 
disease413-418. Multiple studies have shown that patients with Alzheimer’s disease have an 
increased risk of AMD. Similarly, patients with AMD have increased risk of cognitive 
impairment, such as Alzheimer’s disease419. 
Alzheimer’s disease and AMD also share phenotypical similarities. Both diseases can be 
characterised by deposit formation. Plaques in Alzheimer’s disease and drusen in AMD 
contain Aβ. Aβ modulates CFI activity in both AMD and Alzheimer’s420. HTRA1, a risk protein 
in AMD, is known to participate in APP processing60. Furthermore, both diseases are 
influenced by APOE variants (see section 5.1.4). 
C1QTNF5 was found to be expressed in cortical astrocytes and oligodendrocytes (Fig. 3.7d), 
which was confirmed in cortical astrocytes RNA-seq data (unpublished data, Tuula Ritakari, 
The University of Edinburgh). In addition, iPSC-derived microglia also showed expression of 
C1QTNF5 in RNA-seq data (unpublished data, Dr Banerjee, The University of Edinburgh). It is 
therefore possible that C1QTNF5 has a similar function in these cell types in regulation of 
phagocytosis, cellular adhesion, and complement regulation. The C1QTNF5S163R mutation 
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could therefore also affect the function of these cell types in the brain. However, it is not 
known if patients with L-ORD have an increased risk of cognitive impairment. Nonetheless, it 
was found that APP is predicted to be involved in cellular networks affected in L-ORD based 
on IPA of RNA-seq data (Fig. 3.9b). In addition, the third most significant predicted upstream 
regulator of genes significantly differentially expressed in L-ORD was found to be C9orf72 
(Table S11), a protein when mutated can cause familial frontotemporal dementia as well as 
amyotrophic lateral sclerosis421,422. Together, this could indicate that a possible link could be 
found between L-ORD patients and an increased risk of cognitive impairment. 
 
6.9 L-ORD therapy development 
The eyes are one of the most easily accessible organs of the human body, which makes them 
an ideal target for regenerative medicine. Current approaches for therapy in the retina are 
transplantation of RPE, exogenous expression of protein, or in vivo gene editing. 
Of the cell types in the retina, RPE are relatively easy to transplant into the eye. RPE can be 
transplanted as single cells or monolayer patches and do not require synaptic integration like 
retinal neural cells. RPE transplantation does come with some difficulties but different 
methods are being tested for delivery as a cell suspension or as a monolayer graft423. 
Transplantation of allogenic ESC-derived RPE can rescue visual function long-term in RCS 
rats424. Transplantation of ESC-derived cells does require immunosuppression for several 
months to prevent rejection of the transplanted cells. ESC-RPE have already been used in 
clinical trials on patients to treat Stargardt's macular dystrophy, gaAMD, and nvAMD425-427. 
One study did not find significant improvements in visual acuity and the other found some 
improvement in visual acuity in some patients. The first trial was followed up and was found 
to be safe for medium to long-term428. 
iPSC-derived RPE have an important advantage over ESC-derived RPE for transplantation. An 
iPSC-based approach allows for autologous transplantation: iPSCs are derived from a patient, 
converted to RPE ex vivo, and transplanted back to the same patient. The transplanted cells 
are therefore genetically identical and should not evoke an immune response and the 
patients therefore do not require immunosuppression. However, an important concern with 
transplantation of iPSC-derived cells is the risk of tumorigenicity429, because iPSCs are 
reprogrammed with transcription factors of which some have been implicated with inducing 
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tumorigenicity. Furthermore, iPSC-derived cells used for transplantation can still evoke an 
immune response, even when genetically identical430. Additionally, iPSC-RPE have been 
found to inhibit T-cell activation431. Nonetheless, iPSC-RPE have been recently transplanted 
to a patient with nvAMD for the first time432. One year after transplantation visual acuity was 
not improved, but no signs of tumorigenicity were found either. 
An ESC- or iPSC-RPE-based treatment could also be an option for patients with L-ORD. 
Patient-derived iPSCs could be gene-corrected, as shown in this work, before differentiation 
to RPE and subsequent transplantation. However, the efficacy and long-term safety of iPSC-
RPE will need to be assessed first. Nonetheless, development of cell replacement therapy is 
necessary to replace lost RPE in late-stage L-ORD. 
In early stage hereditary macular degeneration, before the loss of RPE and photoreceptors, 
gene therapy would be the preferred treatment. The mutated gene could be replaced or 
repaired in vivo. Different viral vectors have been developed for precise targeting of the 
different cell types in the retina433. In particular, adeno-associated viruses (AAVs) are well-
suited for gene delivery434. AAVs can be used for transient exogenous expression of the gene 
of interest or used in combination with CRISPR/Cas9 for permanent correction of the 
mutated gene. 
AAV vectors targeted at RPE for exogenous expression of protein have been tested in clinical 
trials. Patients with choroideremia have been treated in this way435,436 and were found to 
have improved visual acuity437. AAV vectors have also been used for exogenous expression 
of RPE65 in RPE from patients with a form of Leber’s congenital amaurosis (LCA), an early on-
set autosomal recessive retinal dystrophy, which was found to only have a small temporary 
improvement of visual acuity438,439. Exogenous expression of C1QTNF5 via AAV vectors in L-
ORD patients may only have a limited effect, since the C1QTNF5S163R mutation is thought to 
cause both a gain of function and a loss of function (see section 6.3). 
CRISPR/Cas9 deliver by AAVs would lead to a more permanent solution and has been 
extensively tested on mouse models440. CRISPR/Cas9 deliver by AAVs need to be well 
optimised, because of their relatively small packaging capacity441. Nonetheless, CRISPR/Cas9 
constructs have been delivered by an AAV targeted to photoreceptors to effectively treat a 
form of retinal degeneration442, autosomal dominant forms of retinitis pigmentosa443,444, and 
a form of LCA445 in mice. Furthermore, AAV-delivered CRISPR/Cas9 has been used to target 
Vegfa and Hif1a in RPE of a mouse model of nvAMD and was found to reduce CNV446 and to 
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have a long-lasting effect447. CRISPR/Cas9 deliver by AAVs are currently not yet used in clinical 
trials. The C1QTNF5S163R allele could potentially be repaired or knocked out in patients using 
the gRNA Correction for targeting used in this work, packaged in an AAV vector together with 
Cas9 or a base editor. 
 
6.10 Future directions 
The generation of the C1QTNF5 KO iPSC line could be supplemented with the generation of 
C1QTNF5 KO in one of the patient-derived LORD iPSC lines. This could provide a unique 
insight in the function of the protein and the effect of the mutation in an identical genetic 
background.  
Comparison of L-ORD with other hereditary macular degenerations would greatly contribute 
to the understanding of the common molecular mechanisms affected in macular 
degenerations. ML/DHRD and SFD patient-derived iPSC could be generated. Alternatively, 
the EFEMPR345W and TIMP3S181C mutations, responsible for ML/DHRD and SFD respectively, 
could be introduced in a wt iPSC line with gene editing to generate isogenic pairs. These 
CRISPR/Cas9 constructs have already been made (data not shown) but still need to be tested. 
The degree to which necroptosis and ferroptosis contribute to oxidative stress-mediated cell 
death could be further investigated in iPSC-RPE. iPSC-RPE showed a similar proclivity to 
undergo necroptotic cell death as the RPE cell lines but this will need to be repeated. 
Although UV light-induced photo-oxidative stress showed a trend where L-ORD iPSC-RPE 
appeared to be more sensitive than their isogenic gene-corrected controls, these 
experiments will need to be repeated. In addition, blue light could be more relevant since 
blue light strongly reacts with lipofuscin that accumulate in the RPE with age. The UV light 
experiments could therefore be replicated with blue light instead and in combination with 
POS phagocytosis. 
A potential role for C1QTNF5 in regulating autophagy should be investigated. Dysregulated 
autophagy in RPE is a contributing factor to AMD pathology448. It is thought that cell death in 
AMD is regulated by autophagy449. Moreover, dysregulated autophagy is associated with 
increased susceptibility to oxidative stress in RPE450. The expression of SQSTM1 was found to 
be downregulated in RPE exposed to H2O2 but upregulated when exposed to DHA (Fig. 4.5a). 
It is thought that one of the functions of C1QTNF5 is to block ADIPOR1. Adiponectin is known 
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to induce the AMPK pathway through ADIPOR1, at least in myocytes451. The AMPK/mTOR 
pathway plays are role in autophagy regulation452. C1QTNF5S163R could therefore potentially 
differentially regulate ADIPOR1 activation, leading to altered AMPK pathway signalling, 
followed by dysregulated autophagy and subsequent increased susceptibility to oxidative 
stress. 
The role of complement system dysregulation in L-ORD should be further investigated. In 
particular, the importance of C1QTNF5 binding to CFH and the subsequent effect on 
complement system regulation could be further investigated. Furthermore, inhibitors that 
prevent C5b-9 formation could be tested on the iPSC-RPE and may form the basis of a 
macular degeneration therapy. 
C1QTNF5 has been shown to play a role in regulating cellular lipid metabolism in other cell 
types. It is likely that C1QTNF5 has a similar function in RPE as is revealed by the RNA-seq 
data analysis (Table 3.2a and Fig. 3.9a). L-ORD and wt iPSC-RPE can be compared in the 
amount of AMPK and ACC phosphorylation via western blotting or ELISA. In addition, a 
Seahorse XF analyser could be used to measure possible fatty acid oxidation differences 
between L-ORD and wt iPSC-RPE. 
The expression of C1QTNF5 in astrocytes and microglia could have implications for a role of 
these glia in L-ORD pathology. The C1QTNF5S163R mutation could also affect the function of 
these cell types in a similar fashion as in RPE. Astrocytes and microglia also phagocytose and 
therefore C1QTNF5 could also affect this function in these cells. Microglia also play an 
important role in the complement system, which could also be regulated by C1QTNF5. In 
addition, studying C1QTNF5 KO astrocytes and microglia should give an indication of the 
importance of C1QTNF5 in normal astrocyte and microglia functioning. Moreover, C1QTNF5 
KO astrocytes and microglia could confirm possible functions of C1QTNF5. Similarly, the role 
of C1QTNF5 in cortical astrocytes, oligodendrocytes, and microglia in brain could also be 
studied. A follow up of patients with L-ORD to assess their cognitive ability should be an initial 
indication of the importance of the C1QTNF5S163R mutation in the brain. 
The relative ease of accessibility of the retina and the apparent ease of gene-correcting the 
L-ORD mutation could make L-ORD an ideal candidate disease for the first AAV-delivered 
CRISPR/Cas9-mediated gene correction therapy in humans. For this, AAV vectors will need to 
be designed and tested on L-ORD iPSC-RPE and possibly L-ORD mouse models before a phase 
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Table S1 | crRNA ssODN sequences for annealing and pSpCas9n ligation. 
Name Sequence (5`-3`) 
C1QTNF5 crRNA-1 Top CACCGACGGCGAAGTAGTAGACCCC 
C1QTNF5 crRNA-1 Bottom AAACGGGGTCTACTACTTCGCCGTC 
C1QTNF5 crRNA-2 Top CACCGGGCCAGCCTGCAGTTTGATC 
C1QTNF5 crRNA-2 Bottom AAACGATCAAACTGCAGGCTGGCCC 
C1QTNF5 crRNA-3 Top CACCGCCGGTAGACGGTGGCATGGA 
C1QTNF5 crRNA-3 Bottom AAACTCCATGCCACCGTCTACCGGC 
C1QTNF5 crRNA-4 Top CACCGCAGTTTGATCTGGTGAAGAA 
C1QTNF5 crRNA-4 Bottom AAACTTCTTCACCAGATCAAACTGC 
C1QTNF5 crRNA-5 Top CACCGAGTAGTAGACCCCAGGCACC 
C1QTNF5 crRNA-5 Bottom AAACGGTGCCTGGGGTCTACTACTC 
C1QTNF5 crRNA-6 Top CACCGCGTCCATGCCACCGTCTACC 
C1QTNF5 crRNA-6 Bottom AAACGGTAGACGGTGGCATGGACGC 
 
Table S2 | crRNA sequences for pSpCas9 ligation. 
Name Sequence (5`-3`) 
C1QTNF5 crRNA Correction ATGCCACCGTCTACCGGGCCAGG 
C1QTNF5 crRNA KO Forward CAAGATCCCCAGCCTCTGCCCGG 
C1QTNF5 crRNA KO Reverse CCGCCCTCGCCTTTCTCTCCCGG 
 
Table S3 | RNA sequences for RNP complex formation. 
Name Sequence (5`-3`) 







Table S4 | HDR template ssODN sequences. 
Name Sequence (5`-3`) 


































Table S5 | Top possible gene editing off-target sites. 
Name Sequence (5`-3`) Locus Strand Type 
Correction 1 AGGCCACTGTCTCCTGGGCCCGG 1:10625252-
10625274 
- Intronic 
Correction 2 ATGCCACTGTCCAGCAGGCCAGG 1:18387308-
18387330 
+ Intergenic 
Correction 3 TTTCCACCGTCTCCCGGGCAGGG 1:21933559-
21933581 
+ Intronic 
Correction 4 ATCCCACCCTCAGCCGGGCCCGG 1:22955453-
22955475 
- Intronic 
Correction 5 CTGCCACCATCGACTGGGCCAGG 1:160360396-
160360418 
+ Intergenic 
KO Forward 1 CAAGATCCCCAGTCCCTGCCCGG 12:125255642-
125255664 
- Intronic 
KO Forward 2 CTTCATCCCCAGCCTCTGCCAGG 7:43991301-
43991323 
+ Intergenic 
KO Forward 3 CACCACCCCCAGCCTCTGCCTGG 16:10566025-
10566047 
+ Intronic 
KO Forward 4 CAGAATGCCCAGCCTCTGCCAGG 7:72239723-
72239745 
+ Intronic 
KO Forward 5 CCACATCCTCAGCCTCTGCCTGG 7:271883-
271905 
- Intergenic 
KO Reverse 1 CAGACCTCGCCTTTCTCTCCTGG 22:43244109-
43244131 
+ Intronic 
KO Reverse 2 CCGACCTCCCCTTTCTCTCCCGG 19:9974187-
9974209 
+ Exonic 
KO Reverse 3 GAGCCCTGGCCTTTCTCTCCAGG 9:133726626-
133726648 
+ Intronic 
KO Reverse 4 CCCTCCTCTCCTTTCTCTCCTGG 18:45594527-
45594549 
+ Intronic 






Table S6 | PCR primer sequences. 
Name Forward (5`-3`) Reverse (5`-3`) 
C1QTNF5 ACGAGCAGGGACATTACGAC AGAAATCCGGAGAAGGTGCT 







Correction Off-Target 1 CTGTGTAGACATGGGACGGT AGTGGGTGTTCTGGAGCTAC 
Correction Off-Target 2 CACGCCTGTAATCCCAACAC GCTCATCTGCAGGGTATGGA 
Correction Off-Target 3 AGGTGTAGAGGAGGGTGTCT TGAGCGCAGACAAGTTAGGA 
Correction Off-Target 4 TGAGGTGATGTGGGCTCTTT GCAGTTAGTATGTGCCAGGC 
Correction Off-Target 5 GGGTCTCAAGCACTCCTCTT GGATGGCTGTGCTCCTTCTA 
KO Forward Off-Target 1 CTTTCTCTGTATGTGGGCGC AACATGTCCTTCCAGAGCCA 
KO Forward Off-Target 2 CCAGGCTCAAGGTTCTCAGA CACCTCGGCCTCTCAAAATG 
KO Forward Off-Target 3 CCCCTTTGGTTTCTCTGCAG TTCTGAAGCTTAGGGTCCGG 
KO Forward Off-Target 4 GATTCTGTGACGCTCTGCTG TTGGCTTGTGTTGTCTCTGC 
KO Forward Off-Target 5 TGGCGGATTTAGGAGCTGAA GAAATCTGGGATGCAGGCAC 
KO Reverse Off-Target 1 TGGAAGCTCTGCCTATGGAG ACTCATTAGACACCTCCGCC 
KO Reverse Off-Target 2 CCAAAAGGCCACATTGACCA TGACTTCATTCCCAAGCCCT 
KO Reverse Off-Target 3 CATGCCTGTAGTCCCAGCTA ATCAGGCAGGGATCAGATGG 
KO Reverse Off-Target 4 GGAGTCTGGGGAAAGCAGAA TGAAGTCTCACAGGGGTTGG 







Figure S1 | Sanger sequencing of potential off-target gene editing sites for gRNA Correction. All 34 
edited clones of LORD4 were sequenced and aligned. All edits, gene correction or NHEJ, were found 
to be in the L-ORD allele, as the wt trace is always in the background and the wt C is always visible 
(arrows; not all clones shown) (a). Top five predicted off-target sites for gRNA Correction were 
sequenced in the corrected LORD clones and the LORD parent line (b). Predicted off-target sequences 
shown with mismatches compared to gRNA Correction highlighted in red. Predicted off-target 







Figure S2 | Sanger sequencing of potential off-target gene editing sites for gRNA KO Forward and 
Reverse. Top four predicted off-target sites for both gRNA KO Forward and gRNA KO Reverse were 
sequenced in the C1QTNF5 KO clone 36 and the wt parent line. Predicted off-target sequences shown 
with mismatches compared to gRNA KO Fw and gRNA KO Rev highlighted in red. Predicted off-target 
sequences are highlighted in blue in the alignment. Alignment shows no off-target edits. 
 
Table S7 | qPCR primer sequences. 
Name Accession Forward (5`-3`) Reverse (5`-3`) 
18S M10098 * * 
ACSL4 NM_004458 ATTCTTCTCCGCTTACACTCTCT CTCTTGGACTTTGCTCATAA
CATTC 
ADIPOR1 NM_00129055 CTTCAAGAGCATCTTCCGCATT GGTCTGAGCATGGTCAAGA
TTC 
BAK1 NM_001188 GCCAAGGTCCTGCTCAACT CACCCCAAGCCCAGAATCC 
BAX NM_138761 ATGGAGCTGCAGAGGATGAT CAGTTGAAGTTGCCGTCAGA 
BCL2 NM_000633 GAGGTCACGGGGGCTAATT GAGGCTGGGCACATTTACT
G 



















NFE2L2 NM_006164.4 CCCAGCACATCCAGTCAGA CAGTCATCAAAGTACAAAGC
ATCT 
















*Primerdesign proprietary sequence 
 
Table S8 | Antibodies used for immunocytochemistry and FACS. 
Name Dilution Company Cat. No. 
APOE 1:100 Abcam ab7620 
BEST1 1:100 Merck Millipore MAB5466 
C1QTNF5 1:800 R&D Systems AF3167 
C5b-9 1:100 Dako M077701 
CRALBP 1:250 Abcam ab15051 
MITF 1:500 Abcam ab80651 
pMLKL (phospho Ser358) 1:100 Abcam ab187091 
NANOG 1:800 Cell Signaling 
Technology 
3580 
Nestin 1:100 Merck Millipore MAB5326 
Oct-3/4 1:250 Santa Cruz SC5279 
PAX6 1:250 Proteintech 12323-1-AP 
TRA-1-60 1:100 Santa Cruz sc-21705 
ZO-1 1:100 Abcam ab59720 
Donkey anti-goat, Alexa Fluor 488 conjugate 1:250 Thermo Scientific A11055 
Donkey anti-goat, Alexa Fluor 647 conjugate 1:250 Thermo Scientific A32849 
Donkey anti-mouse, Alexa Fluor 488 
conjugate 
1:250 Thermo Scientific A21202 
Donkey anti-mouse, Alexa Fluor 594 
conjugate 
1:250 Thermo Scientific A21203 
Goat anti-mouse, Alexa Fluor 488 conjugate 1:250 Thermo Scientific A11017 
172 
 
Goat anti-mouse, Alexa Fluor 594 conjugate 1:250 Thermo Scientific A11020 
Goat anti-mouse, Alexa Fluor 647 conjugate 1:500 Abcam Ab150123 
Goat anti-rabbit, Alexa Fluor 488 conjugate 1:250 Cell Signaling 
Technology 
4412S 
Goat anti-rabbit, Alexa Fluor 594 conjugate 1:250 Thermo Scientific A11037 
Goat anti-rabbit, Alexa Fluor 647 conjugate 1:250 Thermo Scientific A21244 
 
Table S9 | Antibodies used for western blot. 
Name Dilution Company Cat. No. 
ACSL4 1:500 Santa Cruz sc-271800 
AMPKα 1:1000 Cell Signaling 
Technology 
2603 
pAMPKα (phospho Thr172) 1:1000 Cell Signaling 
Technology 
2535 
pAMPKα 1 (phospho Ser487) 1:1000 Abcam ab131357 
C1QTNF5 1:1000 R&D Systems AF3167 
MLKL 1:1000 Abcam ab184718 
RIPK3 1:1000 Abcam ab56164 
TBP 1:1000 Cell Signaling 
Technology 
8515 
β-actin 1:5000 Abcam ab6276 
Anti-rabbit, HRP conjugate 1:2000 Cell Signaling 
Technology 
7074 
Goat anti-mouse, HRP conjugate 1:2000 Upstate 12-349 
Rabbit anti-goat, HRP conjugate 1:2000 Merck Millipore AP106P 
 
Table S10 | RNA-seq significantly differentially expressed genes between LORD4 and LORD4C. 







NCAN 0.351711 39.09155 4.959128 1.26E-61 
FABP7 1.858688 20.24663 2.957222 8.77E-39 
GFAP 6.386901 155.627 3.572968 6.19E-34 
NEUROD2 0.009434 0.705084 3.407816 3.41E-22 
173 
 
PI15 0.83122 4.814303 2.158834 6.31E-19 
PEX5L 1.064751 3.996574 1.694427 2.71E-14 
A2M 2.193618 28.6967 2.540108 1.07E-13 
MYH14 0.832318 0.027981 -2.70842 4.19E-13 
KRT17 6.958446 35.28958 1.991943 1.67E-11 
FXYD6 8.796219 26.42434 1.387183 3.28E-11 
PMP2 0.1452 3.244355 2.518652 3.72E-11 
NF1P8 0.046664 3.214651 2.575884 5.42E-11 
KCNJ10 0.041434 0.750729 2.468895 6.07E-11 
LIX1 2.901954 8.042419 1.29036 3.61E-10 
SLC38A11 1.276815 0.128636 -2.25345 8.27E-10 
HEY1 0.670907 2.829073 1.731384 1.09E-09 
GABRG3 0.57645 1.623173 1.333956 1.09E-09 
PCDHB5 1.653035 0.140253 -2.29779 1.11E-09 
WFIKKN2 59.37098 9.807661 -2.01348 1.28E-09 
CNTN6 2.751911 12.40976 1.730998 2.84E-09 
HEPHL1 0.154845 1.000389 1.961815 3.92E-09 
PLP1 1.768414 5.691758 1.430034 3.92E-09 
FOXG1 0.573012 2.377033 1.71463 6.00E-09 
TCEA3 7.127021 1.913379 -1.65247 8.84E-09 
TMEM176A 8.950373 24.99288 1.297048 8.91E-09 
B3GALT2 2.835654 9.129678 1.414959 2.33E-08 
BCL11A 0.464199 1.556001 1.460813 4.53E-08 
DSC3 6.300826 13.53714 0.988484 6.74E-08 
RAMP2 5.838449 16.62644 1.305167 9.70E-08 
SIM1 0.291972 0.012868 -2.17468 9.70E-08 
GALNT14 12.34868 49.81081 1.622615 9.70E-08 
SOX2 1.87372 6.592339 1.581792 9.74E-08 
TMEM176B 23.26508 66.01043 1.294012 1.10E-07 
APC2 0.412364 1.511352 1.508002 1.50E-07 
PRELP 12.0015 2.526136 -1.71386 1.78E-07 
ADAMTS16 27.99358 67.59305 1.092365 2.82E-07 
CD109 1.854881 0.477473 -1.6104 2.82E-07 
GLIPR2 14.95094 34.6606 1.060985 4.09E-07 
BHMT 0.100381 1.19332 2.015839 5.89E-07 
CITED1 0.703256 3.183296 1.669625 6.09E-07 
COL26A1 7.631402 22.3782 1.306915 6.27E-07 
PRPH 9.585109 26.77121 1.258272 7.14E-07 
EDN1 0.788645 2.882947 1.516809 7.94E-07 
LINC00461 0.599685 1.895855 1.426772 9.45E-07 
CEBPZOS 13.21205 5.766974 -1.14379 9.45E-07 
LPCAT2 8.294364 2.924539 -1.37559 9.45E-07 
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SPOCK2 0.56644 2.614646 1.646248 1.18E-06 
LTBR 8.7125 4.262616 -1.02925 1.49E-06 
HHATL 1.082598 0.075697 -1.99192 1.54E-06 
PDGFB 0.255953 1.194958 1.669525 2.04E-06 
FAM69C 0.259793 1.549753 1.824421 2.20E-06 
TUBB2B 11.1484 40.59888 1.454002 2.36E-06 
LTF 0.007842 1.241859 1.927756 3.84E-06 
EFHD1 3.83879 11.50907 1.297043 4.47E-06 
ZNF667 0.359374 0.003504 -1.91503 4.78E-06 
LRRC17 30.20186 86.89149 1.246112 5.33E-06 
AL391650.1 4.151594 17.40048 1.573608 6.75E-06 
CHRDL1 8.276747 21.73588 1.146052 6.75E-06 
MME 3.849118 0.536053 -1.79644 6.75E-06 
ADGRG1 6.493311 20.16526 1.320479 7.18E-06 
EGLN3 3.505399 8.297092 1.056952 7.37E-06 
R3HDML 2.221798 13.73306 1.730951 7.83E-06 
CNN1 1.147883 4.96319 1.566028 8.99E-06 
LGR6 0.711747 3.225721 1.553695 9.15E-06 
MYCN 1.963107 5.033458 1.156265 9.86E-06 
TNFRSF19 4.698116 10.65713 1.016487 1.00E-05 
SHISA9 0.325108 1.306355 1.49984 1.01E-05 
SALL1 0.845075 3.449676 1.520222 1.14E-05 
CRMP1 11.44185 28.36865 1.133759 1.46E-05 
SUSD4 0.915239 2.6703 1.260961 1.75E-05 
GDF6 1.175103 4.441005 1.464597 1.81E-05 
XAF1 0.48973 0.009527 -1.81605 2.01E-05 
ANKRD1 3.85967 16.79221 1.56466 2.25E-05 
DMRTA2 0.020361 0.384196 1.818952 2.38E-05 
AC120042.3 0.078238 0.549806 1.727307 2.40E-05 
ABCC3 0.353728 2.597419 1.721424 2.80E-05 
RBFOX1 0.096538 0.578468 1.681949 2.80E-05 
SEZ6 0.391266 1.827133 1.560069 2.82E-05 
ADAMTS18 0.628661 2.241709 1.333639 3.02E-05 
SELENBP1 20.67617 9.748562 -1.04233 3.02E-05 
CACNG8 0.154994 0.529811 1.388272 3.43E-05 
LY6H 2.652626 9.048783 1.423221 3.52E-05 
PLA2G2A 1.85207 0.087947 -1.7826 3.66E-05 
JPH4 0.139695 0.983782 1.709036 3.73E-05 
POU3F2 0.070604 0.500636 1.703887 3.94E-05 
JCAD 5.836781 3.081388 -0.90211 3.94E-05 
HSPA2 0.989575 0.204224 -1.61777 4.25E-05 
ABCC9 1.977251 0.960131 -1.03265 4.41E-05 
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MLC1 0.675424 5.50358 1.71939 4.81E-05 
KIF5C 11.23707 30.14822 1.173776 4.98E-05 
GFRA2 1.291776 3.637876 1.232596 5.11E-05 
CACNG4 3.303094 6.7694 0.911915 5.11E-05 
SYT1 8.751664 18.03568 0.900096 5.52E-05 
PLIN4 3.275269 1.056122 -1.39868 5.86E-05 
CDH4 0.125862 0.607535 1.556713 5.95E-05 
RTN1 1.2693 3.923519 1.287576 5.95E-05 
LINC01630 0.609002 1.778531 1.250543 6.09E-05 
RGS8 0.368217 1.573276 1.469551 6.20E-05 
PDE3A 1.331159 0.478417 -1.31822 6.20E-05 
MEGF11 0.342594 1.01863 1.300588 6.23E-05 
CLDN23 0.995714 0.187765 -1.63396 7.17E-05 
AC009271.1 0.727132 3.855373 1.596695 7.39E-05 
AC092490.1 1.116618 0.23282 -1.57988 8.26E-05 
TRIM38 1.312588 0.655447 -0.98367 8.48E-05 
SLPI 9.519877 0.965494 -1.70849 8.48E-05 
CLDN1 22.8755 74.66089 1.28746 9.63E-05 
EYA1 1.78257 0.824605 -1.06751 9.63E-05 
IGFL3 0.095924 3.814542 1.6809 9.92E-05 
CHCHD2 52.17219 173.0574 1.378166 1.04E-04 
ZNF662 0.980089 0.322118 -1.32819 1.19E-04 
PITX3 0.731813 2.610552 1.378114 1.21E-04 
GREM2 0.415138 0.024457 -1.68345 1.28E-04 
FAM109B 1.69111 0.554692 -1.3278 1.42E-04 
HFE 3.394978 1.725283 -0.9625 1.43E-04 
RDH10 34.11247 15.92008 -1.03937 1.46E-04 
SERPINE3 455.484 203.7129 -1.11233 1.46E-04 
ATCAY 0.277968 0.908474 1.339884 1.47E-04 
SLCO1A2 0.816421 0.270944 -1.35189 1.57E-04 
CACNG7 0.137417 1.035937 1.628151 1.68E-04 
IGFBP3 113.5208 327.1978 1.223447 1.75E-04 
LRFN2 0.350941 1.256095 1.368601 1.79E-04 
CXCL14 8.459074 20.01815 1.029167 2.16E-04 
CAT 27.58707 11.83021 -1.12293 2.22E-04 
SOCS2 1.649981 5.591685 1.334436 2.76E-04 
THUMPD3 9.79677 5.492265 -0.83759 2.78E-04 
FIBCD1 4.750792 23.71655 1.503263 3.03E-04 
MLIP 3.851365 12.41174 1.312129 3.05E-04 
APLNR 0.020272 1.302029 1.57204 3.10E-04 
C2orf80 0.47763 2.105205 1.455978 3.35E-04 
LAMA2 10.95936 6.523727 -0.75464 3.38E-04 
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SNED1 2.734914 0.786731 -1.40422 3.70E-04 
CHD5 0.341663 1.019571 1.227126 3.77E-04 
ARX 0.075858 0.771314 1.58516 4.46E-04 
ALPK2 1.007161 6.040642 1.530565 4.46E-04 
BEX1 17.27324 42.37619 1.100573 4.46E-04 
EBF2 0.388357 0.004069 -1.52982 4.52E-04 
AC021504.1 2.886711 7.042254 1.071513 4.61E-04 
ENPP2 42.24926 18.19891 -1.12398 4.61E-04 
MISP 0.510643 1.77785 1.328458 4.68E-04 
PI16 2.757728 0.141542 -1.56357 4.70E-04 
AGAP2 0.165022 0.581645 1.334109 4.74E-04 
HLA-DRA 0.350329 3.037733 1.569036 4.96E-04 
PPP1R14C 0.85566 2.842558 1.296076 4.96E-04 
ZNF471 0.146431 0.011071 -1.57207 4.96E-04 
NRCAM 1.403533 3.794152 1.217247 5.17E-04 
OPN3 10.46509 25.50158 1.042733 5.17E-04 
PAPPA2 1.252011 5.176303 1.399715 5.33E-04 
GYPC 4.047407 1.781547 -1.08603 5.39E-04 
JPH2 3.357661 9.524408 1.168147 5.43E-04 
NKX6-1 0.05847 0.469728 1.554402 5.44E-04 
BFSP2 2.384788 6.71239 1.180655 5.44E-04 
CBFA2T3 0.872146 2.157552 1.082285 5.51E-04 
TOX 11.86688 29.65707 1.064674 5.89E-04 
TFAP2C 0.066304 0.784996 1.548167 6.80E-04 
COLGALT2 10.63803 31.3822 1.199704 7.06E-04 
NLGN1 1.694656 3.233039 0.802807 7.28E-04 
PCDHGB7 2.85617 0.532929 -1.48744 7.44E-04 
SIAH3 0.523353 1.250856 1.032882 7.71E-04 
ABCA2 43.82226 18.6783 -1.09407 7.71E-04 
COL8A1 175.0595 86.07025 -1.00403 7.88E-04 
HNMT 3.142927 1.164984 -1.21156 7.91E-04 
LFNG 2.878806 7.016738 1.035048 8.01E-04 
MEIS3 13.1533 24.36134 0.765875 8.07E-04 
PLN 0.007801 0.445353 1.486047 8.42E-04 
SLC2A10 12.33835 7.422419 -0.75323 8.66E-04 
GPD1 6.71373 18.84305 1.171813 8.96E-04 
DPP10 5.204859 9.133357 0.714104 9.01E-04 
BBOX1-AS1 1.994285 6.650903 1.266157 9.16E-04 
TBX5 0.203059 0.013425 -1.50995 9.16E-04 
GNG4 1.747424 4.065871 1.012345 9.72E-04 
NCALD 10.67611 20.29239 0.785068 9.92E-04 
COL13A1 1.504038 0.600126 -1.14103 9.94E-04 
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SULF1 177.2071 72.82885 -1.14075 0.001016 
NANOS1 61.45329 17.94749 -1.35609 0.001017 
OR51E2 10.85608 4.082407 -1.21646 0.001086 
AC103770.1 7.044894 1.383414 -1.44035 0.001195 
PRKAG2 3.783159 7.746967 0.86463 0.001309 
RORC 1.744124 0.404831 -1.4206 0.001352 
TMEM178A 2.656013 6.317702 1.026451 0.001353 
HACD4 0.520378 0.224587 -1.09352 0.001411 
CYP4V2 8.866884 4.61616 -0.92274 0.001515 
NRXN2 0.786139 1.848706 1.027331 0.001522 
AJ009632.2 0.176949 1.022862 1.441418 0.001535 
GREM1 5.269527 14.7182 1.133202 0.001575 
SCN2A 0.497947 1.011444 0.864485 0.001593 
STXBP6 4.607873 9.511727 0.880746 0.001601 
ERC2 3.04359 5.802396 0.807221 0.001601 
NECAB1 6.490323 3.419795 -0.93679 0.001601 
LMO2 0.262806 1.457631 1.425364 0.001669 
HAPLN3 9.563245 28.44675 1.174526 0.001669 
FBN3 0.7832 1.621798 0.910197 0.001754 
ITIH5 18.47779 10.14867 -0.84546 0.001754 
CHST2 5.631105 14.28557 1.010073 0.001765 
SLC16A14 43.60143 13.20966 -1.32576 0.001767 
CRYBG1 2.606571 0.747031 -1.36087 0.001773 
AC022424.1 1.488557 4.392112 1.190763 0.001779 
ACTA2 127.7662 405.0608 1.21383 0.001814 
SALL3 0.010748 0.196733 1.43815 0.001833 
WNT10A 0.347562 1.204463 1.266508 0.001838 
ADARB2 0.040976 0.235278 1.423526 0.001896 
CPXM1 8.829 25.26135 1.172539 0.001896 
PLEKHG1 1.15532 2.690523 1.026652 0.001943 
DYSF 0.419489 0.956059 0.982082 0.001943 
CHCHD2P9 1.712678 7.307371 1.362374 0.001945 
SIPA1L2 4.878551 8.698055 0.720176 0.001963 
LBX1-AS1 0.108412 0.710307 1.434799 0.00198 
SLC5A12 0.346213 1.185226 1.247944 0.002125 
ASPA 0.56894 0.221405 -1.15256 0.002148 
CDH20 5.423603 16.71998 1.219541 0.002203 
TMEFF2 5.15671 20.86116 1.318264 0.00222 
ADCY1 0.85314 1.619748 0.784341 0.002245 
DGAT2 2.206464 4.028374 0.753613 0.002276 
RARRES2 39.16267 14.98395 -1.15921 0.002319 
FLRT2 3.885719 2.398248 -0.71276 0.002333 
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TMEM200C 0.527864 1.260164 1.01324 0.00253 
KMO 4.262386 11.849 1.111367 0.002549 
NTN1 1.34719 3.280296 1.003488 0.002556 
ANK1 0.091282 0.355605 1.321023 0.002642 
PDXK 45.15398 83.12267 0.748731 0.002735 
VWA1 2.588889 5.63553 0.916633 0.002855 
LINC00862 0.298975 1.415787 1.372066 0.003027 
GRIN2B 0.018037 0.065648 1.284463 0.003027 
TMEM30B 1.025952 0.2022 -1.36873 0.00311 
STMN3 17.65255 32.5247 0.744199 0.003242 
TMEM163 0.229996 0.876654 1.276756 0.003407 
HLA-DRB1 0.17717 1.128296 1.385646 0.003495 
ACKR3 8.965796 20.98408 0.956587 0.003954 
EMID1 6.36054 11.32491 0.727975 0.003954 
NDP 0.43728 1.35552 1.192697 0.004105 
SMPD5 0.801237 2.225384 1.120976 0.004317 
ECE1 6.680625 14.02013 0.865421 0.004345 
NALCN 5.126381 1.942898 -1.16487 0.004345 
NEAT1 2.647717 1.731408 -0.6433 0.00438 
LAMC3 0.207158 0.765612 1.243369 0.004473 
RHOU 5.349324 2.699705 -0.93142 0.004495 
KL 4.299751 2.195228 -0.95803 0.004495 
AC004947.2 0.420479 1.210717 1.133452 0.004686 
CRYBB2 6.103567 34.53898 1.330622 0.004717 
PTHLH 6.727362 15.09334 0.978008 0.004763 
NES 2.008197 7.57003 1.250061 0.004909 
ANO4 0.941726 2.842843 1.12192 0.004994 
NPNT 5.336293 10.30965 0.77982 0.005009 
MT1E 10.89793 2.696095 -1.29433 0.005125 
PSG4 0.287264 0.011161 -1.30908 0.005141 
C14orf180 0.938151 0.191198 -1.33601 0.005449 
GJA3 0.283187 0.728507 1.077862 0.00551 
SLC6A15 27.33461 47.8335 0.697834 0.00551 
NFIL3 9.764172 17.44126 0.711448 0.005607 
MEGF6 2.705413 6.192241 0.952071 0.005612 
HCN4 0.165093 0.459538 1.104211 0.005757 
CPED1 0.417477 0.134954 -1.20649 0.005757 
AC015522.1 8.393674 27.5848 1.181706 0.006056 
RIPK4 2.857324 5.383602 0.765279 0.006056 
LINC01551 0.170571 1.394733 1.340103 0.00609 
USH2A 0.360422 0.093626 -1.28749 0.006136 
CD55 9.974705 6.360052 -0.66831 0.006343 
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CGREF1 2.941204 1.07278 -1.13327 0.006389 
LMNB1 2.590117 5.199112 0.838108 0.006494 
L1CAM 2.170502 4.361408 0.829773 0.006712 
PCDHA4 0.93883 1.776351 0.76921 0.006904 
FBP2 1.794463 0.293396 -1.33004 0.006904 
CLIC6 75.85745 31.4988 -1.08393 0.00702 
NDRG1 16.16913 10.17478 -0.67623 0.007085 
SLC1A3 1.051997 4.320158 1.252608 0.007184 
MAN2A1 40.97327 19.91283 -0.96535 0.007202 
CCND1 66.68193 46.02734 -0.57867 0.007242 
FAR2P4 0.016121 0.498759 1.261611 0.007266 
PAX6 18.62451 38.42171 0.844312 0.007266 
SLC2A12 70.48869 28.74859 -1.10666 0.007266 
PAK3 1.771286 3.058714 0.670925 0.007291 
ERICH5 33.35037 60.511 0.720117 0.007312 
SOCS2-AS1 0.70563 2.325378 1.186242 0.007352 
CHGA 0.027152 0.497222 1.282848 0.007758 
HOXB2 0.05921 0.838545 1.290003 0.008043 
CADM3 9.25381 21.48556 0.951203 0.008043 
NCAM1 3.023272 9.231307 1.124461 0.008293 
NOTCH3 9.514927 16.17455 0.659021 0.008428 
ENPEP 0.279819 0.06082 -1.28308 0.008428 
LRRC3B 0.207021 0.919373 1.27152 0.00846 
CSRNP1 7.942957 14.46387 0.722855 0.008493 
CD38 0.008515 0.129825 1.278175 0.0085 
EDN2 8.162437 21.59656 1.06756 0.0085 
ZNF558 1.84471 4.685276 1.052476 0.0085 
JUP 24.76212 44.55463 0.706991 0.0085 
NTNG1 7.452195 3.341732 -1.00635 0.0085 
CLEC3B 3.418851 0.120918 -1.23491 0.008507 
LINC01139 0.444171 0.010488 -1.22525 0.008612 
LHX1 0.024044 0.24601 1.292128 0.008768 
LINC02009 0.9571 0.243156 -1.25416 0.008834 
PLEKHG4 0.770346 0.369776 -0.9365 0.008863 
GALNT8 0.161001 1.256231 1.299513 0.008973 
ROBO2 2.93862 1.362972 -0.9725 0.009206 
MYRIP 38.60031 18.77586 -0.95159 0.009209 
PPP1R1A 0.515518 1.34037 1.052107 0.009248 
ZXDA 0.176144 0.67636 1.226307 0.009403 
TOX2 1.33337 2.803434 0.897445 0.009496 
CLVS1 0.172653 0.643239 1.219666 0.009515 
MCAM 7.109842 17.45069 0.971995 0.009645 
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OLFM2 28.20953 48.43134 0.684332 0.009758 
LBX1 0.096193 0.578629 1.285039 0.009885 
DRAXIN 0.119862 0.793519 1.285167 0.009915 
MAMDC2 18.23339 53.10391 1.094366 0.009915 
AP000892.3 2.082873 5.751682 1.080626 0.009915 
RAMP2-AS1 0.887941 1.854884 0.877097 0.009915 
TSPAN12 16.23866 31.32936 0.782313 0.009915 
ADD2 2.261461 3.986018 0.699731 0.009915 
ANKH 4.772498 3.09013 -0.65437 0.009915 
NID2 41.87008 22.1325 -0.87564 0.009915 
SPRY1 7.070796 2.928354 -1.07952 0.009989 
ADPRH 2.017884 0.915272 -0.99535 0.010044 
ADAMTSL1 2.705108 1.1107 -1.00039 0.010045 
KCNJ5 0.536637 2.088576 1.197477 0.010068 
KIFC3 7.73318 16.06885 0.831461 0.010125 
CSDC2 5.740875 12.38024 0.900907 0.010195 
SSX1 0.093013 1.149498 1.252304 0.010902 
GPC2 1.477085 2.920454 0.814641 0.010902 
PPP1R3D 1.966414 1.02684 -0.86832 0.011011 
HUNK 0.943663 1.708615 0.731414 0.01129 
AJAP1 0.008657 0.086322 1.260249 0.011302 
TRIM55 0.166808 0.625761 1.201302 0.011302 
GPR153 5.706489 10.97215 0.76987 0.011302 
NTRK3 0.242109 0.885625 1.180653 0.011516 
FADS3 18.11564 9.058898 -0.89938 0.011763 
CHCHD2P6 1.648078 5.186994 1.139348 0.012025 
ENC1 5.792835 13.15441 0.917371 0.012025 
LGI2 0.120477 0.462448 1.197162 0.012047 
SCRG1 9.426024 30.60447 1.141767 0.012047 
PDE1C 1.330988 3.681184 1.073833 0.012047 
BANCR 2.161818 6.099455 1.085858 0.012079 
EBF1 0.576644 0.06456 -1.25644 0.012115 
GHR 6.826249 4.071213 -0.77648 0.012179 
CRYAB 794.8187 1572.041 0.807383 0.012316 
CCDC68 2.743942 0.508534 -1.25929 0.012316 
SRGAP1 1.095857 1.773787 0.593407 0.012529 
PLPPR3 12.25072 23.13652 0.820785 0.013442 
LRRN3 2.240987 5.759691 1.020917 0.013564 
CDH2 50.98751 85.88191 0.62788 0.0137 
ITGA10 0.797389 0.044442 -1.20167 0.013755 
AC113137.1 0.07517 1.18049 1.208235 0.013891 
SNAP91 4.265208 7.367713 0.667617 0.013891 
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LINC02302 2.070354 0.720865 -1.11362 0.014388 
CRABP2 28.8192 14.16891 -0.90884 0.015251 
PCOLCE2 1.849924 0.880085 -0.968 0.015251 
GRB14 0.872685 2.368151 1.038328 0.01552 
GNG3 0.451356 2.094392 1.218111 0.015673 
SLC30A8 3.919738 2.163079 -0.82935 0.016243 
PTGDS 122.3596 47.11283 -1.08438 0.01625 
MARCHF11 0.472541 1.745793 1.17066 0.016463 
DMXL2 8.100777 5.242511 -0.65591 0.017174 
JAKMIP2 0.765284 1.748051 0.934657 0.017312 
HEG1 13.14896 8.455954 -0.64349 0.017312 
MGAM2 0.534435 0.204347 -1.09385 0.017312 
AC145212.1 0.260528 0.003699 -1.12581 0.017312 
ABL2 14.80557 8.943586 -0.74035 0.017518 
SLC16A12 4.393971 2.457419 -0.85084 0.017518 
PREX2 0.19463 0.526559 1.026798 0.017703 
GPM6B 9.880538 18.61397 0.738342 0.017703 
CNTN4 1.666319 2.896883 0.672768 0.017703 
DNAJC15 6.29453 4.278373 -0.59196 0.017703 
LAMA1 1.554283 3.988059 0.994291 0.017852 
SLC6A17 7.675304 20.52341 1.030684 0.017856 
TIMP3 903.7854 583.512 -0.64585 0.017856 
B3GNT8 0.968792 2.334744 0.963149 0.018167 
LINC01133 1.738433 0.131913 -1.18036 0.018167 
CBLN2 0.145454 0.680321 1.197997 0.018241 
CRABP1 14.68031 44.89269 1.096494 0.018535 
PCDH8 0.826474 1.737195 0.861205 0.018623 
ICAM5 0.506795 1.175689 0.950112 0.018769 
F3 13.34273 8.540333 -0.65931 0.019378 
C9orf64 2.34569 1.06363 -0.9856 0.019378 
PLAG1 2.117448 1.303471 -0.71515 0.019986 
PCDH18 22.65418 13.32161 -0.76276 0.019986 
SLC15A3 0.570423 0.221975 -1.06293 0.019986 
LCN9 0.070063 1.348786 1.152855 0.020236 
SLC6A20 94.50356 49.29904 -0.8831 0.020657 
PSMB9 0.925159 1.958303 0.861111 0.020725 
AL355916.1 0.305926 1.170629 1.160303 0.020767 
TAGLN 60.33831 170.584 1.04971 0.020988 
RASSF2 8.128666 13.92591 0.654486 0.021093 
GRIN2A 0.037533 0.140119 1.15105 0.02112 
KALRN 1.582242 2.875846 0.707526 0.021185 
AHNAK2 12.38944 22.17633 0.704964 0.021185 
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CHADL 4.877 1.560058 -1.13788 0.021185 
MED15P8 0.042673 1.914789 1.105668 0.021196 
LRRC32 13.39921 39.38392 1.074682 0.021196 
BCAS1 0.463888 1.125126 0.976515 0.021535 
CNGB3 8.395277 3.44404 -1.04419 0.021535 
FZD5 4.753588 2.573411 -0.83362 0.022103 
AC013451.2 0.301534 1.663119 1.193399 0.022332 
ZNF667-AS1 1.5096 0.053122 -1.10628 0.022362 
KRT81 0.147033 0.626338 1.176523 0.022428 
AC131571.1 0.686141 3.850977 1.192372 0.02248 
LINC01122 0.369502 0.850273 0.939299 0.022599 
GEN1 3.178045 1.775946 -0.8185 0.02285 
RASGRP1 0.440972 1.44126 1.10655 0.022862 
CASC10 1.096048 2.274411 0.852907 0.023205 
LPAR5 0.071395 0.440621 1.188122 0.023527 
AC098864.1 1.65669 5.930678 1.11958 0.023811 
ATP10B 0.632767 0.302258 -0.92274 0.023811 
RNF152 2.003947 1.165075 -0.77013 0.024306 
RASGRF1 0.69031 2.400968 1.108228 0.024591 
CYP27A1 110.6218 46.53698 -1.01918 0.024678 
SMIM24 1.072162 2.460019 0.924827 0.024717 
MMP11 9.898381 18.56788 0.738786 0.025094 
GLDN 0.14445 0.467165 1.096933 0.025214 
NEK2P4 0.043585 0.478609 1.151344 0.025501 
WIPF1 14.37785 9.4564 -0.62907 0.025594 
RBM24 11.60248 24.89456 0.863407 0.02562 
SLC4A5 4.380466 1.324626 -1.14092 0.02562 
ACKR1 0.522332 1.474328 1.047896 0.025883 
EPPK1 0.33783 0.609736 0.715412 0.026831 
CFI 0.100605 0.489829 1.166799 0.027054 
GRIA4 3.06663 8.367085 1.026788 0.027054 
LRRK2 0.434605 0.201651 -0.96334 0.027726 
HMX1 3.887326 13.21412 1.106917 0.02801 
MRO 2.332524 1.285026 -0.81745 0.02801 
PRKCG 0.27607 0.825986 1.075317 0.028163 
PLA1A 6.57165 2.610381 -1.05683 0.028163 
CPA2 3.108882 0.913583 -1.1378 0.028272 
ADGRD1 0.271435 0.077424 -1.13881 0.028272 
ARSI 2.717855 7.287069 0.982435 0.028463 
KRT23 0.143841 0.566435 1.143174 0.028886 
FYB2 22.33292 12.49619 -0.82675 0.029064 
IGSF10 0.319735 0.115857 -1.08773 0.029064 
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ENOX1 2.662463 1.362299 -0.85527 0.029267 
PMEPA1 17.84535 36.13797 0.805899 0.029325 
GRASP 5.13448 9.628551 0.729129 0.029384 
CCL2 16.37548 46.33865 1.01686 0.029773 
ITPR1 8.325793 5.338162 -0.65535 0.029773 
GABRQ 0.083951 0.285604 1.10037 0.029838 
CAPN6 6.656705 12.63695 0.753747 0.029856 
GEM 69.1456 32.33381 -0.95362 0.030146 
CHRM4 5.859824 16.18971 1.027076 0.030166 
ZIC3 0.092263 0.362894 1.129569 0.030529 
OR10J3 0.246542 1.06176 1.146369 0.030753 
IL17RB 6.00833 1.984978 -1.09438 0.030753 
MARCHF1 2.694182 6.318632 0.909521 0.031438 
CACNA1C 2.946595 1.814096 -0.69301 0.031438 
MGST1 36.46606 21.50817 -0.73429 0.031438 
TMEM56 4.973333 2.805052 -0.77874 0.031729 
SMC6 30.1715 16.2122 -0.84858 0.03227 
PDCD1 0.124274 0.553502 1.142019 0.03244 
CA10 1.409737 5.389413 1.108649 0.032852 
LRP8 7.73131 3.29275 -0.95015 0.033092 
CHGB 0.232141 0.859596 1.115883 0.033326 
KCNMB4 1.511414 2.618722 0.659159 0.033635 
SULT1A1 2.627207 1.356297 -0.85765 0.033635 
CST3 885.3399 374.332 -0.98966 0.033635 
AMPD3 1.885394 0.820888 -0.9895 0.033652 
DNAJA4 0.601619 0.204221 -1.08679 0.033652 
CACNB3 9.027352 14.29709 0.580422 0.033858 
NR2E1 5.708187 2.21891 -1.0229 0.033897 
PCSK1N 91.39807 138.0201 0.505693 0.033948 
C1QTNF1 8.582561 5.637892 -0.62609 0.034163 
CPQ 36.12607 25.54798 -0.53335 0.034269 
SLC46A1 15.5716 7.616223 -0.89763 0.034491 
MX1 1.448329 0.808215 -0.78129 0.034596 
PLD5 31.9427 13.28825 -1.01341 0.034596 
TACC1 50.33945 31.86349 -0.67233 0.0346 
SPINK5 0.288925 0.942258 1.071035 0.034648 
SST 3.610237 10.76443 1.031192 0.034648 
LAYN 31.3236 20.90921 -0.58379 0.034648 
UMODL1 0.244903 0.069702 -1.11764 0.034737 
SLC25A18 0.194636 0.666928 1.096828 0.034929 
FRMPD4 0.127806 0.034509 -1.12169 0.03505 
CHDH 6.649692 2.748223 -1.00404 0.035075 
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SCG5 382.3171 156.6115 -1.01521 0.035245 
GABRA5 0.52868 1.215788 0.911551 0.035537 
SORL1 3.278723 1.665301 -0.88092 0.035627 
MMP17 3.562602 1.697067 -0.90694 0.035627 
AC025263.1 0.727799 0.254232 -1.06089 0.03572 
SERPINB1 2.645578 1.176419 -0.9542 0.035916 
PTN 137.0249 85.19698 -0.67283 0.036042 
CYP2W1 16.8503 7.704391 -0.93831 0.036195 
ACP6 17.05622 9.76243 -0.78088 0.036324 
ACTC1 1.377804 2.972658 0.862894 0.036636 
IGDCC3 0.32051 0.787975 0.943152 0.03665 
PLAU 3.21765 8.139613 0.949048 0.037235 
ITGB8 8.124477 3.731999 -0.93402 0.037235 
SLC39A12 58.2968 21.72415 -1.04484 0.037235 
AL451048.1 1.30366 5.569376 1.117742 0.038158 
SGK3 11.38454 6.481526 -0.78745 0.038158 
PADI3 0.652314 1.439556 0.865931 0.038312 
HOXB4 0.006218 0.127551 1.052214 0.038325 
KIRREL3 0.385572 1.579598 1.095473 0.039167 
PTGER4 1.250438 3.085278 0.933944 0.039332 
NAV3 7.354966 4.075473 -0.81221 0.039591 
SLC16A3 37.68725 19.00596 -0.87037 0.039591 
AMIGO1 7.122306 4.696758 -0.61881 0.039819 
DSP 36.85902 17.91474 -0.90807 0.040247 
POPDC3 3.99386 1.58119 -1.02568 0.040247 
KCNE3 0.526327 0.148017 -1.10407 0.040247 
CKB 44.73071 67.82438 0.532432 0.040743 
TBC1D30 3.391251 1.766063 -0.8271 0.040743 
LYPD6B 0.901783 2.819284 1.016288 0.040966 
NPW 12.74968 21.06025 0.636682 0.040988 
WNT2 0.112672 0.418502 1.089011 0.041224 
AP000280.1 0.817416 2.396849 1.025926 0.041224 
CPEB2 6.188542 4.289493 -0.56347 0.041756 
ROBO4 0.1521 0.029677 -1.11213 0.041814 
NRIP3 1.18844 2.745064 0.897532 0.041833 
ZFYVE16 16.73191 9.491923 -0.76441 0.041833 
SPHKAP 0.223951 0.581151 0.979249 0.042479 
ME3 10.5699 5.339776 -0.85691 0.042479 
ARHGEF37 24.15753 11.41884 -0.91907 0.042479 
TSPAN13 32.22851 14.90658 -0.94687 0.042479 
SP140 0.365418 0.089204 -1.10757 0.042479 
NKAIN3 0.059769 0.489077 1.089618 0.042599 
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AMPH 5.828826 10.68743 0.700421 0.042599 
ITGB6 0.137911 0.498536 1.080617 0.042651 
MIR503HG 1.519562 5.265762 1.067998 0.042861 
TRIM71 0.027699 0.119941 1.100984 0.042876 
COL24A1 0.407148 0.154442 -1.02892 0.042876 
AGTR1 0.234149 0.023506 -1.06544 0.044072 
MAPK4 11.997 5.607216 -0.91034 0.044131 
FBXO27 2.887902 1.68286 -0.73829 0.044184 
TRIM4 4.619858 8.289172 0.688854 0.04439 
TEAD3 10.0987 17.53703 0.650186 0.044818 
BCAN 8.825931 18.09492 0.821449 0.045039 
FSTL3 26.70418 53.28903 0.802347 0.045039 
GADD45B 16.15501 25.3136 0.555329 0.045059 
DDR2 36.39646 26.07857 -0.51578 0.045059 
PIP4P2 9.207809 6.020449 -0.62882 0.045059 
SEMA4A 13.48697 6.213251 -0.91241 0.045059 
IL16 0.797647 0.307857 -1.02494 0.045059 
NTF3 1.381221 4.265771 1.031011 0.046275 
PLIN2 35.72114 16.8457 -0.90269 0.04699 
JPT1 12.98186 21.68676 0.611103 0.04734 
DDR1 54.6464 82.48943 0.500245 0.04734 
C2CD4C 1.352368 2.978355 0.901708 0.047459 
FICD 5.938805 4.142017 -0.55359 0.047459 
TANC2 6.369184 2.896855 -0.91223 0.047459 
AIFM3 4.823406 1.960527 -0.97853 0.047459 
AL139384.2 0.534659 1.171379 0.864081 0.047501 
DLK1 0.072848 0.325543 1.090427 0.047528 
SLC1A2 0.058205 0.22699 1.075983 0.047528 
HBEGF 0.987761 2.386771 0.927445 0.047617 
MALT1 3.624718 7.565516 0.807217 0.047793 
HMGCS2 4.642353 1.153068 -1.08593 0.04807 
PARD6G 4.125095 6.388233 0.535934 0.048648 
STRIP2 206.0972 92.89444 -0.95904 0.049514 
CD248 3.860373 0.903112 -1.08403 0.049514 
BEND4 0.210284 0.583556 0.996158 0.049799 
MGARP 6.132964 15.9295 0.948454 0.049949 





Table S11 | RNA-seq Ingenuity Pathway Analysis predicted upstream transcriptional regulators and 
other regulators of the differentially expressed genes between LORD4 and LORD4C. 
Upstream Regulator 
Expr Log 
Ratio Molecule Type 
p-value of 
overlap 
ZNF217 -0.214 transcription regulator 3.19E-06 
PDLIM2 -0.012 other 3.29E-06 
C9orf72 0.108 other 4.77E-06 
BMP4 -0.396 growth factor 7.86E-06 
AMBP -0.003 transporter 1.76E-05 
SMARCA4 0.047 transcription regulator 0.000038 
PKNOX1 0.227 transcription regulator 6.89E-05 
RUNX2 -0.197 transcription regulator 9.56E-05 
NRXN1 0.404 transporter 0.000106 
EPAS1 -0.692 transcription regulator 0.000117 
HIC1 0.417 transcription regulator 0.000156 
ACTG1 0.187 other 0.000169 
SBDS -0.014 other 0.000366 
TREM1 -0.218 transmembrane receptor 0.000471 
KDM3A -0.052 transcription regulator 0.000492 
PPP1R13L 0.342 transcription regulator 0.000494 
CEACAM1 0.112 transporter 0.000494 
TGFB1 -0.183 growth factor 0.000598 
Growth hormone   group 0.0006 
estrogen receptor   group 0.000829 
PDGF BB   complex 0.000874 
MGAT3 0.277 enzyme 0.000892 
TAZ -0.238 enzyme 0.000892 
NEUROG1 0.041 transcription regulator 0.000914 
TNF 0.083 cytokine 0.00106 
Notch   group 0.00114 
TEAD4 0.479 transcription regulator 0.00117 
TEAD1 0.178 transcription regulator 0.00132 
CTCF 0.023 transcription regulator 0.00175 
MUC1 0.146 other 0.00175 
SNAI2 -0.33 transcription regulator 0.00191 
PELP1 0.068 other 0.00193 
PRDM5 -0.248 transcription regulator 0.00194 
Beta Secretase   group 0.002 
CYP2E1 0.335 enzyme 0.002 
HOXB1   transcription regulator 0.002 
EPHA2 0.59 kinase 0.002 
PRKAA1 -0.132 kinase 0.00202 
MYOCD 0.104 transcription regulator 0.00224 
ETV5 0.11 transcription regulator 0.00228 
CD44 0.305 other 0.00246 
RORA -0.255 ligand-dependent nuclear 
receptor 0.00248 
TEAD2 0.353 transcription regulator 0.0029 
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SP3 0.1 transcription regulator 0.00295 
SNCA 0.215 enzyme 0.00315 
SFN 0.444 other 0.0032 
let-7a-5p (and other 
miRNAs w/seed 
GAGGUAG) 
  mature microRNA 
0.00324 
PTTG1 0.486 transcription regulator 0.00324 
TEAD3 0.65 transcription regulator 0.00326 
Hdac   group 0.00358 
IGF1 0.354 growth factor 0.00358 
HNRNPA2B1 0.05 other 0.0037 
ZXDC -0.048 transcription regulator 0.00392 
NOTCH4 -0.134 transcription regulator 0.00392 
SLPI -1.708 other 0.00392 
RGCC 0.232 other 0.00392 
TNFAIP6 -0.797 other 0.00392 
Ap1   complex 0.00407 
MUC4   other 0.00414 
MRTFB -0.174 transcription regulator 0.00425 
LIN28B 0.106 other 0.00516 
NOTCH1 0.053 transcription regulator 0.00543 
SMAD2 0.14 transcription regulator 0.00567 
EZH2 0.195 transcription regulator 0.00602 
EGR1 -0.666 transcription regulator 0.00609 
AR -0.477 ligand-dependent nuclear 
receptor 0.00611 
PCA3 0.181 other 0.00643 
PDGFA 0.114 growth factor 0.00643 
NFIC -0.09 transcription regulator 0.00643 
ST8SIA1 0.271 enzyme 0.00643 
miR-145-5p (and other 
miRNAs w/seed UCCAGUU) 
  mature microRNA 
0.00645 
SMAD3 -0.176 transcription regulator 0.00684 
UPF2 -0.046 other 0.00729 
RAD21 -0.032 transcription regulator 0.00729 
SUZ12 -0.094 enzyme 0.0076 
Akt   group 0.00808 
IL1B 0.075 cytokine 0.00861 
ITGB1 0.216 transmembrane receptor 0.00918 
NCF1 -0.008 enzyme 0.00948 
COL1A1 -0.207 other 0.00948 
PLSCR1 -0.299 enzyme 0.00948 
CBR3-AS1 -0.228 other 0.00948 
TNFRSF11A -0.846 transmembrane receptor 0.00948 
SF1 -0.04 transcription regulator 0.00948 
Hif   complex 0.00948 
STAT3 0.228 transcription regulator 0.00972 
KMT2D -0.185 transcription regulator 0.0103 
HOTAIR 0.045 other 0.0107 
FN1 0.127 enzyme 0.0107 
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TWIST2 -0.275 transcription regulator 0.0107 
CXCR4 0.256 G-protein coupled receptor 0.0107 
SOX2 1.582 transcription regulator 0.0121 
YAP1 -0.154 transcription regulator 0.0121 
SENP7 -0.106 peptidase 0.013 
CIITA -0.424 transcription regulator 0.013 
TFDP1 0.074 transcription regulator 0.013 
PRKG1 0.281 kinase 0.013 
CD4 -0.102 transmembrane receptor 0.013 
TIMP1 0.028 cytokine 0.013 
XPO1 0.032 transporter 0.013 
DSP -0.908 other 0.013 
NAB2 0.229 transcription regulator 0.013 
TRKC-miR2   microRNA 0.013 
SPI1 -0.182 transcription regulator 0.0141 
SMAD4 0.018 transcription regulator 0.0149 
NORAD -0.053 other 0.0152 
SNAI1 -0.009 transcription regulator 0.0152 
ERG -0.444 transcription regulator 0.0156 
CTNNB1 -0.019 transcription regulator 0.016 
POU2F1 -0.039 transcription regulator 0.0165 
PIN1 0.072 enzyme 0.0165 
CCN2 0.303 growth factor 0.0165 
TCF4 0.389 transcription regulator 0.0167 
Nuclear factor 1   group 0.0171 
CSNK2B -0.048 kinase 0.0171 
RETN   other 0.0171 
PITX2 -0.244 transcription regulator 0.0171 
RIPK1 0.024 kinase 0.0171 
LRP1 -0.441 transmembrane receptor 0.0171 
BTG2 -0.342 transcription regulator 0.0171 
IFNA1/IFNA13   cytokine 0.0171 
TLR7 -0.057 transmembrane receptor 0.018 
FGF2 -0.375 growth factor 0.0182 
PDX1   transcription regulator 0.0182 
H2AFY 0.181 other 0.0186 
RNF31 -0.03 enzyme 0.0187 
KLF5 0.318 transcription regulator 0.0187 
DICER1 -0.333 enzyme 0.019 
EGFR -0.273 kinase 0.0199 
BMP7 -0.678 growth factor 0.0211 
WWC1 -0.08 transcription regulator 0.0216 
TUG1 -0.055 other 0.0216 
GLI1 -0.323 transcription regulator 0.0219 
FSH   complex 0.0221 
JAK1 -0.262 kinase 0.0237 
SP1 0.05 transcription regulator 0.0239 
GPER1 -0.08 G-protein coupled receptor 0.0252 
CIP2A 0.274 other 0.0255 
FKHR   group 0.026 
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DNAJ   group 0.026 
ASB9 0.098 transcription regulator 0.026 
MYCNOS 0.663 other 0.026 
IFNA10   cytokine 0.026 
TET3 0.227 enzyme 0.026 
IFNA21   cytokine 0.026 
TFAP2E 0.098 transcription regulator 0.026 
CALCOCO1 0.109 transcription regulator 0.026 
REM2 0.015 enzyme 0.026 
SDR9C7   enzyme 0.026 
IFNA5   cytokine 0.026 
ABCB6 -0.346 transporter 0.026 
PHF20L1 0.032 other 0.026 
CMKLR1 -0.775 G-protein coupled receptor 0.026 
PLAC1 0.166 other 0.026 
UBE2D3 0.057 enzyme 0.026 
EIF2B5 -0.256 other 0.026 
XDH -0.043 enzyme 0.026 
IFNA7   cytokine 0.026 
BAD 0.008 other 0.026 
MAT2B 0.037 enzyme 0.026 
TUNAR 0.414 other 0.026 
SEMA4D 0.152 transmembrane receptor 0.026 
MYF6   transcription regulator 0.026 
ABCC2 -0.262 transporter 0.026 
GRPR -0.041 G-protein coupled receptor 0.026 
mir-140   microRNA 0.026 
miR-139-3p (miRNAs 
w/seed GGAGACG) 








  mature microRNA 
0.026 
PDE3A -1.318 enzyme 0.026 
TOB2 0.048 other 0.026 
HOXB13   transcription regulator 0.026 
MGAT4A -0.115 enzyme 0.026 
ACOT8 -0.023 enzyme 0.026 
DES 0.434 other 0.026 
ITIH5 -0.845 other 0.026 
KLF3 -0.091 transcription regulator 0.026 
IFNA14   cytokine 0.026 
LRRN1 0.031 other 0.026 
KIF1B 0.021 transporter 0.026 
IFNA4   cytokine 0.026 
IFNA6   cytokine 0.026 
FBXO4 -0.503 enzyme 0.026 
SHCBP1 0.274 other 0.026 
CCHCR1 -0.074 other 0.026 
RSL1D1 -0.011 other 0.026 
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SNX1 0.068 transporter 0.026 
CASP2 0.032 peptidase 0.026 
CASP9 0.111 peptidase 0.026 
CD72 -0.366 transmembrane receptor 0.026 
VCAM1 -0.399 transmembrane receptor 0.026 
ITGA11 0.349 other 0.026 
BAMBI 0.277 other 0.026 
TFF3 -0.057 other 0.026 
FXYD5 -0.268 ion channel 0.026 
IFNLR1 -0.261 transmembrane receptor 0.026 
AZIN1 0.003 enzyme 0.026 
AP2B1 -0.025 transporter 0.026 
KRT10 0.002 other 0.026 
IFNG   cytokine 0.0263 
Fcer1   complex 0.0264 
NFAT5 -0.095 transcription regulator 0.0264 
HDAC6 0.006 transcription regulator 0.0264 
Ctbp   group 0.0265 
LINC01139 -1.225 other 0.0265 
IGFBP5 -0.551 other 0.0265 
HSPA9 -0.108 other 0.0265 
PLG -0.018 peptidase 0.0265 
CHD4 -0.054 enzyme 0.0265 
RFX5 0.054 transcription regulator 0.0265 
COL18A1 0.01 other 0.027 
IgG   complex 0.0272 
CLOCK -0.162 transcription regulator 0.0284 
TGFBR2 -0.165 kinase 0.0287 
NR3C1 -0.443 ligand-dependent nuclear 
receptor 0.0287 
CHUK -0.044 kinase 0.0293 
STAT5A -0.061 transcription regulator 0.0309 
miR-146a-5p (and other 
miRNAs w/seed GAGAACU) 
  mature microRNA 
0.0314 
let-7   microRNA 0.0316 
SNHG20 -0.201 other 0.0319 
NFIX -0.133 transcription regulator 0.0319 
CCAT2 -0.07 other 0.0319 
JMJD1C 0.143 enzyme 0.0319 
PPARG 0.038 ligand-dependent nuclear 
receptor 0.0321 
PGR -0.818 ligand-dependent nuclear 
receptor 0.0326 
FGF8 0.063 growth factor 0.0336 
LGALS3 0.318 other 0.036 
ERBB2 0.144 kinase 0.0367 
SOX2-OT 0.184 other 0.0376 
SMAD1 0.502 transcription regulator 0.0376 
mir-373   microRNA 0.0376 
AGER 0.211 transmembrane receptor 0.0376 
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KDM5A -0.083 transcription regulator 0.0376 
PAEP -0.057 other 0.0376 
STAT1 0.045 transcription regulator 0.0376 
TP63 0.686 transcription regulator 0.0381 
NFATC2 -0.387 transcription regulator 0.0389 
EOMES 0.266 transcription regulator 0.0409 
mir-29   microRNA 0.0424 
miR-21-5p (and other 
miRNAs w/seed AGCUUAU) 
  mature microRNA 
0.0424 
MAPK14 0.218 kinase 0.0424 
Ap2   group 0.0437 
DANCR 0.135 other 0.0437 
PARG 0.092 enzyme 0.0437 
PGF -0.574 growth factor 0.0437 
PLAUR 0.036 transmembrane receptor 0.0437 
NOTCH2 -0.161 transcription regulator 0.0437 
INHBA -0.377 growth factor 0.0448 
PRKCD 0.037 kinase 0.0453 
HIF1A 0.489 transcription regulator 0.0529 
IL2   cytokine 0.0571 
Mek   group 0.076 
ESR1 -0.039 ligand-dependent nuclear 
receptor 0.118 













Figure S3 | RNA-seq Ingenuity Pathway Analysis – canonical pathways differentially regulated 
between LORD4 and LORD4C. Differentially regulated canonical pathways between LORD4 and 
LORD4C as revealed with IPA. 
 
